{"d23a23131e4abaf6176686e6897e4193c5c9fcfc": [["BackgroundAt present, we do not know if multiple sclerosis (MS) or disease-modifying therapies (DMT) for MS increase the risk of acquiring COVID-19 or worsen the course (hospitalizations, ICU, death).", [["multiple sclerosis", "DISEASE", 40, 58], ["MS", "DISEASE", 60, 62], ["DMT", "CHEMICAL", 96, 99], ["MS", "DISEASE", 105, 107], ["death", "DISEASE", 193, 198], ["multiple sclerosis (MS)", "PROBLEM", 40, 63], ["disease", "PROBLEM", 67, 74], ["modifying therapies", "TREATMENT", 75, 94], ["MS", "PROBLEM", 105, 107], ["COVID", "TEST", 139, 144], ["sclerosis", "OBSERVATION", 49, 58]]], ["DMT medications have immunosuppressive effects that could hamper mounting an effective immune response to the infection.", [["DMT", "CHEMICAL", 0, 3], ["infection", "DISEASE", 110, 119], ["DMT", "CHEMICAL", 0, 3], ["DMT", "SIMPLE_CHEMICAL", 0, 3], ["DMT medications", "TREATMENT", 0, 15], ["immunosuppressive effects", "TREATMENT", 21, 46], ["the infection", "PROBLEM", 106, 119], ["infection", "OBSERVATION", 110, 119]]], ["1 On the other hand, immunosuppression could offer protection by downregulating hyperinflammation and the cytokine storm associated with severe disease.", [["cytokine", "PROTEIN", 106, 114], ["immunosuppression", "TREATMENT", 21, 38], ["protection", "TREATMENT", 51, 61], ["downregulating hyperinflammation", "PROBLEM", 65, 97], ["the cytokine storm", "PROBLEM", 102, 120], ["severe disease", "PROBLEM", 137, 151], ["cytokine storm", "OBSERVATION", 106, 120], ["severe", "OBSERVATION_MODIFIER", 137, 143], ["disease", "OBSERVATION", 144, 151]]], ["Given the widespread prevalence of COVID-19 in our community, clinicians at the NYU Multiple Sclerosis Comprehensive Care Center (MSCCC) received numerous reports of COVID-19 infection from patients and began systematically collecting symptom data and the clinical course.", [["infection", "DISEASE", 175, 184], ["patients", "ORGANISM", 190, 198], ["patients", "SPECIES", 190, 198], ["COVID-19 infection", "PROBLEM", 166, 184], ["systematically collecting symptom data", "TEST", 209, 247], ["Sclerosis", "OBSERVATION", 93, 102], ["infection", "OBSERVATION", 175, 184]]], ["This timely, real-world observational study on outcomes of COVID-19 in actively treated MS patients could inform clinicians as they counsel MS patients and guide treatment decisions during the pandemic.MethodsDemographic and clinical features were collected on patients currently followed at MSCCC and its 4 affiliated sites in the greater New York area (2 in Long Island, 2 in Brooklyn) with a history of COVID-19 infection from March 16th through April 30, 2020.", [["COVID-19", "CHEMICAL", 59, 67], ["MS", "DISEASE", 88, 90], ["MS", "DISEASE", 140, 142], ["COVID-19 infection", "DISEASE", 406, 424], ["COVID-19", "CHEMICAL", 59, 67], ["patients", "ORGANISM", 91, 99], ["patients", "ORGANISM", 143, 151], ["patients", "ORGANISM", 261, 269], ["patients", "SPECIES", 91, 99], ["patients", "SPECIES", 143, 151], ["patients", "SPECIES", 261, 269], ["observational study", "TEST", 24, 43], ["COVID", "TEST", 59, 64], ["the pandemic", "PROBLEM", 189, 201], ["COVID-19 infection", "PROBLEM", 406, 424], ["greater", "OBSERVATION_MODIFIER", 332, 339], ["New", "OBSERVATION_MODIFIER", 340, 343], ["infection", "OBSERVATION", 415, 424]]], ["All patients who contacted the center with infectious symptoms or were seen during routine teleneurology visits were queried regarding COVID-19 exposure using a standardized instrument.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["infectious symptoms", "PROBLEM", 43, 62], ["a standardized instrument", "TREATMENT", 159, 184]]], ["Inclusion criteria were any patient with MS or related disorders who was diagnosed with COVID-19 by a healthcare provider (based on symptoms, course, radiographic findings consistent with CDC COVID-19 criteria 3 and/or positive COVID-19 PCR when available).", [["MS", "DISEASE", 41, 43], ["patient", "ORGANISM", 28, 35], ["patient", "SPECIES", 28, 35], ["MS", "PROBLEM", 41, 43], ["related disorders", "PROBLEM", 47, 64], ["COVID", "TEST", 88, 93], ["symptoms", "PROBLEM", 132, 140], ["radiographic findings", "TEST", 150, 171], ["CDC COVID", "TEST", 188, 197], ["PCR", "TEST", 237, 240]]], ["For hospitalized patients, in-patient records were reviewed.", [["patients", "ORGANISM", 17, 25], ["patient", "ORGANISM", 30, 37], ["patients", "SPECIES", 17, 25], ["patient", "SPECIES", 30, 37]]], ["NYU School of Medicine Institutional Review Board approval was obtained for the study.MethodsDescriptive statistics were used to summarize the demographic and clinical characteristics of patients.", [["patients", "ORGANISM", 187, 195], ["patients", "SPECIES", 187, 195], ["the study", "TEST", 76, 85]]], ["Categorical variables were summarized as counts and percentages.", [["Categorical variables", "TEST", 0, 21], ["percentages", "TEST", 52, 63]]], ["Differences between hospitalized patients were compared by t-test, \u03c72 test, or Fisher's exact test where appropriate.ResultsA total of 76 patients met inclusion criteria, 72 (93%) with MS, and 4 (7%) with related disorders.", [["MS", "DISEASE", 185, 187], ["patients", "ORGANISM", 33, 41], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 138, 146], ["t-test", "TEST", 59, 65], ["Fisher's exact test", "TEST", 79, 98], ["MS", "TEST", 185, 187], ["related disorders", "PROBLEM", 205, 222]]], ["Disease duration was 15.2\u00b110.7 years (range 1-52).", [["Disease duration", "TEST", 0, 16]]], ["Racial breakdown was: 50 (65.8%) White, 21 (27.6%) Black, 3 (3.9%) Asian, 1 (1.3%) Pacific Islander, and 1 (1.3%) other.", [["Racial breakdown", "PROBLEM", 0, 16], ["White", "TEST", 33, 38], ["Black", "TEST", 51, 56], ["Asian", "TEST", 67, 72], ["Pacific Islander", "TEST", 83, 99]]], ["Hispanic ethnicity was reported by 15 (19.7%).", [["Hispanic ethnicity", "TEST", 0, 18]]], ["Of the 72 MS patients, 55 (76.4%) had a relapsing-remitting subtype and 17 (23.6%) primary-or secondary-progressive subtypes.", [["MS", "DISEASE", 10, 12], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["a relapsing-remitting subtype", "PROBLEM", 38, 67], ["secondary-progressive subtypes", "PROBLEM", 94, 124], ["relapsing", "OBSERVATION_MODIFIER", 40, 49], ["progressive", "OBSERVATION_MODIFIER", 104, 115], ["subtypes", "OBSERVATION", 116, 124]]], ["Diagnoses of four non-MS patients were: neuromyelitis optica spectrum disorder (NMOSD, n=1), chronic-relapsing-inflammatory-optic-neuropathy (CRION, n=1), neurosarcoidosis (n=1), and myelin-oligodendrocyte-glycoprotein-IgG associated disorder (MOGAD, n=1).", [["MS", "DISEASE", 22, 24], ["neuromyelitis optica spectrum disorder", "DISEASE", 40, 78], ["NMOSD", "DISEASE", 80, 85], ["inflammatory-optic-neuropathy", "DISEASE", 111, 140], ["CRION", "DISEASE", 142, 147], ["neurosarcoidosis", "DISEASE", 155, 171], ["MOGAD", "DISEASE", 244, 249], ["patients", "ORGANISM", 25, 33], ["myelin-oligodendrocyte-glycoprotein-IgG", "GENE_OR_GENE_PRODUCT", 183, 222], ["myelin-oligodendrocyte-glycoprotein", "PROTEIN", 183, 218], ["IgG", "PROTEIN", 219, 222], ["patients", "SPECIES", 25, 33], ["neuromyelitis optica spectrum disorder", "PROBLEM", 40, 78], ["NMOSD", "PROBLEM", 80, 85], ["inflammatory-optic-neuropathy", "PROBLEM", 111, 140], ["CRION", "TEST", 142, 147], ["neurosarcoidosis", "PROBLEM", 155, 171], ["myelin", "TEST", 183, 189], ["IgG associated disorder", "PROBLEM", 219, 242], ["non-MS", "OBSERVATION_MODIFIER", 18, 24], ["neuromyelitis optica", "OBSERVATION", 40, 60], ["chronic", "OBSERVATION_MODIFIER", 93, 100], ["relapsing", "OBSERVATION_MODIFIER", 101, 110], ["inflammatory", "OBSERVATION_MODIFIER", 111, 123], ["optic", "ANATOMY", 124, 129], ["neuropathy", "OBSERVATION", 130, 140], ["neurosarcoidosis", "OBSERVATION", 155, 171], ["myelin", "ANATOMY", 183, 189]]], ["65 patients (84%) were on DMT.ResultsCommon symptoms reported included fever (68.4%), cough (68.4%), fatigue (38.2%), shortness of breath (31.6%), and myalgias/arthralgias (26.3%).", [["DMT", "CHEMICAL", 26, 29], ["fever", "DISEASE", 71, 76], ["cough", "DISEASE", 86, 91], ["fatigue", "DISEASE", 101, 108], ["shortness of breath", "DISEASE", 118, 137], ["myalgias", "DISEASE", 151, 159], ["arthralgias", "DISEASE", 160, 171], ["DMT", "CHEMICAL", 26, 29], ["patients", "ORGANISM", 3, 11], ["DMT", "SIMPLE_CHEMICAL", 26, 29], ["patients", "SPECIES", 3, 11], ["ResultsCommon symptoms", "PROBLEM", 30, 52], ["fever", "PROBLEM", 71, 76], ["cough", "PROBLEM", 86, 91], ["fatigue", "PROBLEM", 101, 108], ["shortness of breath", "PROBLEM", 118, 137], ["myalgias", "PROBLEM", 151, 159], ["arthralgias", "PROBLEM", 160, 171]]], ["Other frequent symptoms included anosmia (22%), All rights reserved.", [["anosmia", "DISEASE", 33, 40], ["Other frequent symptoms", "PROBLEM", 0, 23], ["anosmia", "PROBLEM", 33, 40]]], ["No reuse allowed without permission.Results(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.ResultsThe copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.1101/2020.05.12.20094508 doi: medRxiv preprint ageusia (19.7%), and headache (21.1%).", [["headache", "DISEASE", 347, 355], ["medRxiv preprint ageusia", "TREATMENT", 309, 333], ["headache", "PROBLEM", 347, 355], ["med", "ANATOMY", 122, 125]]], ["A subset reported neurologic symptom recrudescence (21.1%) suggestive of relapse.", [["neurologic", "ANATOMY", 18, 28], ["neurologic symptom recrudescence", "DISEASE", 18, 50], ["A subset reported neurologic symptom recrudescence", "PROBLEM", 0, 50], ["relapse", "PROBLEM", 73, 80], ["suggestive of", "UNCERTAINTY", 59, 72], ["relapse", "OBSERVATION", 73, 80]]], ["In some cases, neurologic symptoms preceded viral symptoms by several days.ResultsOf the 84% of patients on DMTs, 44.7% were treated with anti-CD20 therapies (rituximab n =18; ocrelizumab n= 16), 13.5% on Sphingosine-1-phosphate (S1P) modulators (fingolimod n= 8; siponimod n=2), 7.9% (n=6) on glatiramer acetate, 5.3% (n=4) each on natalizumab and dimethyl fumarate and 3.9% (n=3) on beta-interferons.", [["neurologic", "ANATOMY", 15, 25], ["rituximab", "CHEMICAL", 159, 168], ["ocrelizumab", "CHEMICAL", 176, 187], ["Sphingosine-1-phosphate", "CHEMICAL", 205, 228], ["S1P", "CHEMICAL", 230, 233], ["fingolimod", "CHEMICAL", 247, 257], ["glatiramer acetate", "CHEMICAL", 294, 312], ["natalizumab", "CHEMICAL", 333, 344], ["dimethyl fumarate", "CHEMICAL", 349, 366], ["Sphingosine-1-phosphate", "CHEMICAL", 205, 228], ["S1P", "CHEMICAL", 230, 233], ["fingolimod", "CHEMICAL", 247, 257], ["glatiramer acetate", "CHEMICAL", 294, 312], ["dimethyl fumarate", "CHEMICAL", 349, 366], ["patients", "ORGANISM", 96, 104], ["anti-CD20", "SIMPLE_CHEMICAL", 138, 147], ["Sphingosine-1-phosphate", "SIMPLE_CHEMICAL", 205, 228], ["S1P", "SIMPLE_CHEMICAL", 230, 233], ["fingolimod", "SIMPLE_CHEMICAL", 247, 257], ["glatiramer acetate", "SIMPLE_CHEMICAL", 294, 312], ["natalizumab", "SIMPLE_CHEMICAL", 333, 344], ["dimethyl fumarate", "SIMPLE_CHEMICAL", 349, 366], ["beta-interferons", "GENE_OR_GENE_PRODUCT", 385, 401], ["beta", "PROTEIN", 385, 389], ["patients", "SPECIES", 96, 104], ["neurologic symptoms", "PROBLEM", 15, 34], ["viral symptoms", "PROBLEM", 44, 58], ["DMTs", "TEST", 108, 112], ["anti-CD20 therapies", "TREATMENT", 138, 157], ["rituximab n", "TREATMENT", 159, 170], ["ocrelizumab n", "TEST", 176, 189], ["Sphingosine", "TEST", 205, 216], ["phosphate (S1P) modulators", "TREATMENT", 219, 245], ["fingolimod n", "TEST", 247, 259], ["siponimod n", "TEST", 264, 275], ["glatiramer acetate", "TREATMENT", 294, 312], ["natalizumab", "TREATMENT", 333, 344], ["dimethyl fumarate", "TEST", 349, 366], ["beta-interferons", "TREATMENT", 385, 401]]], ["As shown in Table 1 , there were no significant differences between DMT use among those who were and were not hospitalized (p=0.75) or between those specifically treated with anti-CD20 therapies (43% vs 50%, p=0.40).", [["DMT", "CHEMICAL", 68, 71], ["DMT", "CHEMICAL", 68, 71], ["DMT", "SIMPLE_CHEMICAL", 68, 71], ["anti-CD20", "GENE_OR_GENE_PRODUCT", 175, 184], ["anti-CD20 therapies", "TREATMENT", 175, 194], ["no", "UNCERTAINTY", 33, 35], ["significant", "OBSERVATION_MODIFIER", 36, 47]]], ["Table 1 summarizes outcomes by DMT class.ResultsAs shown in Table 2 , of the full sample, 18 (23.7%) were hospitalized.", [["ResultsAs", "TEST", 41, 50]]], ["The hospitalized vs. nonhospitalized patients were more likely to be older (51.9 vs 42.7 years), have progressive MS subtype (38.8% vs 17.2%), be less ambulatory (50% vs. 19% requiring assistance or non-ambulatory, and have comorbid obesity (61.1% vs 20.6%, p=0.002), coronary artery disease (16.7% vs 0%, p=0.01) and/or history of venous thromboembolism (16.7% vs 1.7%, p=0.04).ResultsEight patients (10.5%) had critical illness defined by ICU admission (n=5) and/or death (n=6).", [["coronary artery", "ANATOMY", 268, 283], ["venous", "ANATOMY", 332, 338], ["MS", "DISEASE", 114, 116], ["obesity", "DISEASE", 233, 240], ["coronary artery disease", "DISEASE", 268, 291], ["venous thromboembolism", "DISEASE", 332, 354], ["death", "DISEASE", 468, 473], ["patients", "ORGANISM", 37, 45], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 268, 283], ["venous", "MULTI-TISSUE_STRUCTURE", 332, 338], ["patients", "ORGANISM", 392, 400], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 392, 400], ["progressive MS subtype", "PROBLEM", 102, 124], ["comorbid obesity", "PROBLEM", 224, 240], ["p", "TEST", 258, 259], ["coronary artery disease", "PROBLEM", 268, 291], ["p", "TEST", 306, 307], ["venous thromboembolism", "PROBLEM", 332, 354], ["p", "TEST", 371, 372], ["critical illness", "PROBLEM", 413, 429], ["death", "PROBLEM", 468, 473], ["progressive", "OBSERVATION_MODIFIER", 102, 113], ["coronary artery", "ANATOMY", 268, 283], ["venous", "ANATOMY", 332, 338], ["thromboembolism", "OBSERVATION", 339, 354]]], ["Compared to the entire MS sample, the critically ill patients were older (mean of 57.7\u00b110.5, range 42-71), more likely to have a progressive subtype (50.0%), and less ambulatory (62.5% requiring assistance or non-ambulatory).", [["critically ill", "DISEASE", 38, 52], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["mean", "TEST", 74, 78], ["a progressive subtype", "PROBLEM", 127, 148], ["progressive", "OBSERVATION_MODIFIER", 129, 140], ["subtype", "OBSERVATION_MODIFIER", 141, 148]]], ["Following the pattern observed in those who were hospitalized, the critically ill group had had high rates of comorbid obesity (62.5%), coronary artery disease (25%), and venous thromboembolism (37.5%).", [["coronary artery", "ANATOMY", 136, 151], ["venous", "ANATOMY", 171, 177], ["critically ill", "DISEASE", 67, 81], ["obesity", "DISEASE", 119, 126], ["coronary artery disease", "DISEASE", 136, 159], ["venous thromboembolism", "DISEASE", 171, 193], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 136, 151], ["venous", "PATHOLOGICAL_FORMATION", 171, 177], ["comorbid obesity", "PROBLEM", 110, 126], ["coronary artery disease", "PROBLEM", 136, 159], ["venous thromboembolism", "PROBLEM", 171, 193], ["comorbid obesity", "OBSERVATION", 110, 126], ["coronary artery", "ANATOMY", 136, 151], ["venous", "ANATOMY", 171, 177], ["thromboembolism", "OBSERVATION", 178, 193]]], ["A detailed table of these patients has been compiled and may be available upon request, and/or pending peer review journal acceptance.ResultsNine patients with pediatric-onset MS were identified as the center has a large pediatric MS sample (Table 3) .", [["MS", "DISEASE", 176, 178], ["patients", "ORGANISM", 26, 34], ["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 146, 154], ["large", "OBSERVATION_MODIFIER", 215, 220]]], ["Ages ranged from 13 to 26 years; 8 were female and all had relapsing-remitting MS. Noted comorbidities were obesity (n=3), Type I diabetes (n=1), or both (n=1).", [["MS", "DISEASE", 79, 81], ["obesity", "DISEASE", 108, 115], ["Type I diabetes", "DISEASE", 123, 138], ["remitting MS", "PROBLEM", 69, 81], ["Noted comorbidities", "PROBLEM", 83, 102], ["obesity", "PROBLEM", 108, 115], ["Type I diabetes", "PROBLEM", 123, 138], ["obesity", "OBSERVATION", 108, 115], ["diabetes", "OBSERVATION", 130, 138]]], ["Two of the nine were hospitalized requiring supplemental oxygen.", [["oxygen", "CHEMICAL", 57, 63], ["oxygen", "CHEMICAL", 57, 63], ["oxygen", "SIMPLE_CHEMICAL", 57, 63], ["supplemental oxygen", "TREATMENT", 44, 63]]], ["None required invasive ventilation.", [["invasive ventilation", "TREATMENT", 14, 34], ["invasive ventilation", "OBSERVATION", 14, 34]]], ["Eight patients were either fully recovered or recovering at censoring date.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14]]], ["One remains hospitalized.DiscussionPatients with MS and related disorders often seek guidance regarding the impact of the disease and medication on their risk of COVID-19 infection.", [["MS", "DISEASE", 49, 51], ["infection", "DISEASE", 171, 180], ["COVID-19", "ORGANISM", 162, 170], ["MS and related disorders", "PROBLEM", 49, 73], ["the disease", "PROBLEM", 118, 129], ["medication", "TREATMENT", 134, 144], ["COVID-19 infection", "PROBLEM", 162, 180], ["hospitalized", "OBSERVATION", 12, 24], ["disease", "OBSERVATION", 122, 129], ["infection", "OBSERVATION", 171, 180]]], ["This observational study provides some insights regarding COVID-19 disease course and outcomes in actively treated patients with MS and related disorders.DiscussionThe rate of hospitalization in our patients (24%) and mortality (7.9%) are in-line with the data of other published MS patient database 4 and for the general population of patients with COVID-19.", [["MS", "DISEASE", 129, 131], ["patients", "ORGANISM", 115, 123], ["patients", "ORGANISM", 199, 207], ["patient", "ORGANISM", 283, 290], ["patients", "ORGANISM", 336, 344], ["patients", "SPECIES", 115, 123], ["patients", "SPECIES", 199, 207], ["patient", "SPECIES", 283, 290], ["patients", "SPECIES", 336, 344], ["This observational study", "TEST", 0, 24], ["COVID-19 disease course", "TREATMENT", 58, 81], ["MS", "PROBLEM", 129, 131], ["related disorders", "PROBLEM", 136, 153], ["COVID", "TEST", 350, 355]]], ["5 Similar risk factors were identified and included older age, male sex, and higher number of comorbidities identified including obesity, diabetes, hypertension, and coronary artery disease [6] [7] [8] .", [["coronary artery", "ANATOMY", 166, 181], ["obesity", "DISEASE", 129, 136], ["diabetes", "DISEASE", 138, 146], ["hypertension", "DISEASE", 148, 160], ["coronary artery disease", "DISEASE", 166, 189], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 166, 181], ["obesity", "PROBLEM", 129, 136], ["diabetes", "PROBLEM", 138, 146], ["hypertension", "PROBLEM", 148, 160], ["coronary artery disease", "PROBLEM", 166, 189], ["obesity", "OBSERVATION", 129, 136], ["diabetes", "OBSERVATION", 138, 146], ["hypertension", "OBSERVATION", 148, 160], ["coronary artery", "ANATOMY", 166, 181]]], ["MS-specific features associated with more severe COVID-19 included non-ambulatory status and progressive disease course.", [["more severe COVID", "PROBLEM", 37, 54], ["non-ambulatory status", "PROBLEM", 67, 88], ["progressive disease course", "PROBLEM", 93, 119], ["progressive", "OBSERVATION_MODIFIER", 93, 104], ["disease", "OBSERVATION", 105, 112]]], ["Given the small sample size, we could not determine whether these patients were at higher risk given their advanced age and other comorbidities, or whether worse disability in and of itself represents an additional risk factor for complications.", [["disability", "DISEASE", 162, 172], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["the small sample size", "PROBLEM", 6, 27], ["other comorbidities", "PROBLEM", 124, 143], ["complications", "PROBLEM", 231, 244], ["small", "OBSERVATION_MODIFIER", 10, 15], ["sample", "OBSERVATION_MODIFIER", 16, 22], ["size", "OBSERVATION_MODIFIER", 23, 27]]], ["No reuse allowed without permission.Discussion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.1101/2020.05.12.20094508 doi: medRxiv preprintDiscussionWe did not observe an association between DMT class and COVID-19 outcome in univariate comparisons, however, our sample size is small and these preliminary findings should be interpreted with caution.", [["medRxiv", "TREATMENT", 315, 322], ["COVID", "TEST", 397, 402], ["med", "ANATOMY", 125, 128], ["size", "OBSERVATION_MODIFIER", 461, 465], ["small", "OBSERVATION_MODIFIER", 469, 474]]], ["There is a relatively high proportion of COVID-19 infected patients on anti-CD20 therapies (44.7%) compared to our MSCCC population in which 33.1% of patients take anti-CD20 therapies.", [["COVID-19 infected", "DISEASE", 41, 58], ["COVID-19", "ORGANISM", 41, 49], ["patients", "ORGANISM", 59, 67], ["anti-CD20", "GENE_OR_GENE_PRODUCT", 71, 80], ["MSCCC", "CANCER", 115, 120], ["patients", "ORGANISM", 150, 158], ["anti-CD20", "GENE_OR_GENE_PRODUCT", 164, 173], ["patients", "SPECIES", 59, 67], ["patients", "SPECIES", 150, 158], ["COVID", "TEST", 41, 46], ["anti-CD20 therapies", "TREATMENT", 71, 90], ["anti-CD20 therapies", "TREATMENT", 164, 183], ["relatively", "OBSERVATION_MODIFIER", 11, 21], ["high", "OBSERVATION_MODIFIER", 22, 26], ["infected", "OBSERVATION_MODIFIER", 50, 58]]], ["This observation can be an artifact of data collection (such patients are more likely to have regular visits during this period) or might represent an increased susceptibility to COVID-19 infection, as has been noted with psoriasis patients on other biologic therapies 9 and non-COVID-19 infections in MS patients on anti-CD20 therapies in general.", [["infection", "DISEASE", 188, 197], ["psoriasis", "DISEASE", 222, 231], ["infections", "DISEASE", 288, 298], ["MS", "DISEASE", 302, 304], ["patients", "ORGANISM", 61, 69], ["COVID-19", "ORGANISM", 179, 187], ["patients", "ORGANISM", 232, 240], ["non-COVID-19", "ORGANISM", 275, 287], ["patients", "ORGANISM", 305, 313], ["anti-CD20", "SIMPLE_CHEMICAL", 317, 326], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 232, 240], ["patients", "SPECIES", 305, 313], ["COVID-19", "SPECIES", 179, 187], ["an artifact of data collection", "PROBLEM", 24, 54], ["an increased susceptibility to COVID-19 infection", "PROBLEM", 148, 197], ["psoriasis", "PROBLEM", 222, 231], ["other biologic therapies", "TREATMENT", 244, 268], ["non-COVID-19 infections in MS", "PROBLEM", 275, 304], ["anti-CD20 therapies", "TREATMENT", 317, 336], ["might represent", "UNCERTAINTY", 132, 147], ["increased", "OBSERVATION_MODIFIER", 151, 160], ["susceptibility", "OBSERVATION", 161, 175], ["infection", "OBSERVATION", 188, 197], ["psoriasis", "OBSERVATION", 222, 231], ["infections", "OBSERVATION", 288, 298]]], ["1 As a note of caution in the care of MS patients, a subgroup of individuals reported worsening of preexisting neurologic symptoms before or at onset of COVID-19 symptoms.", [["neurologic", "ANATOMY", 111, 121], ["MS", "DISEASE", 38, 40], ["neurologic symptoms", "DISEASE", 111, 130], ["patients", "ORGANISM", 41, 49], ["individuals", "ORGANISM", 65, 76], ["patients", "SPECIES", 41, 49], ["preexisting neurologic symptoms", "PROBLEM", 99, 130], ["COVID-19 symptoms", "PROBLEM", 153, 170], ["worsening", "OBSERVATION_MODIFIER", 86, 95]]], ["It is important to consider COVID-19 in the differential of worsening neurological symptoms and to be cautious about the indiscriminate use of steroids.DiscussionOur study has several limitations.", [["neurological", "ANATOMY", 70, 82], ["steroids", "CHEMICAL", 143, 151], ["COVID-19", "CHEMICAL", 28, 36], ["steroids", "CHEMICAL", 143, 151], ["steroids", "SIMPLE_CHEMICAL", 143, 151], ["COVID", "TEST", 28, 33], ["worsening neurological symptoms", "PROBLEM", 60, 91], ["steroids", "TREATMENT", 143, 151], ["DiscussionOur study", "TEST", 152, 171]]], ["Patients were identified during routine teleneurology visits, if they notified the office, or if hospitalized.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["This likely led to an over-representation of more symptomatic individuals.", [["more symptomatic individuals", "PROBLEM", 45, 73]]], ["Although we used a systematic questionnaire to collect relevant data, we could not verify this data independently unless the patient was seen by NYU Langone-affiliated physician or hospital.", [["patient", "ORGANISM", 125, 132], ["patient", "SPECIES", 125, 132]]], ["Compounding this problem was lack of access to COVID-19 testing in our area.", [["COVID-19", "CHEMICAL", 47, 55], ["COVID", "TEST", 47, 52]]], ["Less than half of our patients (48.7%) underwent SARS-COV2 PCR testing.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["SARS-COV2 PCR testing", "TEST", 49, 70]]], ["As shown in Table 4 , subgroup analysis showed that this group was not different from the overall sample with respect to demographic or MSrelated features.DiscussionOur early experience with COVID-19 at NYU Langone MSCCC could inform clinicians taking care of MS patients during the pandemic.", [["MS", "DISEASE", 260, 262], ["patients", "ORGANISM", 263, 271], ["patients", "SPECIES", 263, 271], ["subgroup analysis", "TEST", 22, 39], ["COVID", "TREATMENT", 191, 196]]], ["Our findings suggest that individuals with MS who experience COVID-19 have similar disease course, outcomes, and risk factors for complications as the general population.", [["MS", "DISEASE", 43, 45], ["MS", "PROBLEM", 43, 45], ["COVID", "TEST", 61, 66], ["complications", "PROBLEM", 130, 143], ["the general population", "PROBLEM", 147, 169]]], ["Rigorous, population-based studies are needed to confirm our preliminary findings and better define the risk of COVID-19 infection with respect to individual DMTs.", [["infection", "DISEASE", 121, 130], ["based studies", "TEST", 21, 34], ["COVID-19 infection", "PROBLEM", 112, 130], ["infection", "OBSERVATION", 121, 130]]], ["No reuse allowed without permission.Discussion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.1101/2020.05.12.20094508 doi: medRxiv preprint Legend: Anti-CD20: ocrelizumab, rituximab; S1P inhibitors: fingolimod, siponimod; Interferons: interferon beta-1a, interferon beta-1b; IVIG intravenous immunoglobulins.", [["intravenous", "ANATOMY", 472, 483], ["ocrelizumab", "CHEMICAL", 351, 362], ["rituximab", "CHEMICAL", 364, 373], ["S1P", "CHEMICAL", 375, 378], ["fingolimod", "CHEMICAL", 391, 401], ["siponimod", "CHEMICAL", 403, 412], ["interferon beta-1a, interferon beta-1b", "CHEMICAL", 427, 465], ["ocrelizumab", "CHEMICAL", 351, 362], ["fingolimod", "CHEMICAL", 391, 401], ["siponimod", "CHEMICAL", 403, 412], ["CD20", "GENE_OR_GENE_PRODUCT", 345, 349], ["ocrelizumab", "SIMPLE_CHEMICAL", 351, 362], ["rituximab", "SIMPLE_CHEMICAL", 364, 373], ["S1P inhibitors", "SIMPLE_CHEMICAL", 375, 389], ["fingolimod", "SIMPLE_CHEMICAL", 391, 401], ["siponimod", "SIMPLE_CHEMICAL", 403, 412], ["interferon beta-1a", "GENE_OR_GENE_PRODUCT", 427, 445], ["interferon beta-1b", "GENE_OR_GENE_PRODUCT", 447, 465], ["IVIG", "SIMPLE_CHEMICAL", 467, 471], ["intravenous immunoglobulins", "SIMPLE_CHEMICAL", 472, 499], ["CD20", "PROTEIN", 345, 349], ["Interferons", "PROTEIN", 414, 425], ["interferon beta-1a", "PROTEIN", 427, 445], ["interferon beta-1b", "PROTEIN", 447, 465], ["IVIG intravenous immunoglobulins", "PROTEIN", 467, 499], ["Anti-CD20", "TREATMENT", 340, 349], ["ocrelizumab", "TREATMENT", 351, 362], ["rituximab", "TREATMENT", 364, 373], ["S1P inhibitors", "TREATMENT", 375, 389], ["fingolimod", "TREATMENT", 391, 401], ["siponimod", "TREATMENT", 403, 412], ["Interferons", "TREATMENT", 414, 425], ["interferon beta", "TREATMENT", 427, 442], ["interferon beta", "TREATMENT", 447, 462], ["IVIG intravenous immunoglobulins", "TREATMENT", 467, 499], ["med", "ANATOMY", 125, 128]]], ["One 58-year-old female with history of hypertension on leflunomide had a mild course.DiscussionAll rights reserved.", [["hypertension", "DISEASE", 39, 51], ["leflunomide", "CHEMICAL", 55, 66], ["leflunomide", "CHEMICAL", 55, 66], ["female", "ORGANISM", 16, 22], ["leflunomide", "SIMPLE_CHEMICAL", 55, 66], ["hypertension", "PROBLEM", 39, 51], ["leflunomide", "TREATMENT", 55, 66], ["a mild course", "PROBLEM", 71, 84], ["hypertension", "OBSERVATION", 39, 51], ["leflunomide", "OBSERVATION", 55, 66], ["mild", "OBSERVATION_MODIFIER", 73, 77], ["course", "OBSERVATION_MODIFIER", 78, 84]]], ["No reuse allowed without permission.Discussion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.1101/2020.05.12.20094508 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.1101/2020.05.12.20094508 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.COVID-19 OutcomesDeath, n (%) 6 (7.9%) 5 (13.5%) Recovered, n (%) 56 (73.7%) 25 (67.6%) All rights reserved.", [["Death", "DISEASE", 770, 775], ["COVID", "TEST", 753, 758], ["OutcomesDeath", "TEST", 762, 775], ["med", "ANATOMY", 125, 128], ["med", "ANATOMY", 411, 414], ["med", "ANATOMY", 697, 700]]], ["No reuse allowed without permission.COVID-19 Outcomes(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.COVID-19 OutcomesThe copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.1101/2020.05.12.20094508 doi: medRxiv preprint", [["COVID", "TEST", 188, 193], ["The copyright holder", "TREATMENT", 205, 225], ["medRxiv", "TREATMENT", 329, 336], ["med", "ANATOMY", 132, 135]]]], "PMC7336103": [["IntroductionThe fast-growing outbreak of the 2019 novel coronavirus (COVID-19), which originated from Wuhan in central China, reached multiple continents in merely a month.", [["coronavirus", "DISEASE", 56, 67], ["COVID-19", "CHEMICAL", 69, 77], ["coronavirus", "ORGANISM", 56, 67], ["COVID-19", "ORGANISM", 69, 77], ["coronavirus", "SPECIES", 56, 67], ["COVID", "TEST", 69, 74], ["central China", "ANATOMY", 111, 124]]], ["Cross person-to-person transmission of this new virus can result in severe and fatal respiratory disease like acute respiratory distress syndrome (ARDS) in humans [1].", [["respiratory", "ANATOMY", 85, 96], ["respiratory disease", "DISEASE", 85, 104], ["acute respiratory distress syndrome", "DISEASE", 110, 145], ["ARDS", "DISEASE", 147, 151], ["humans", "ORGANISM", 156, 162], ["person", "SPECIES", 6, 12], ["person", "SPECIES", 16, 22], ["humans", "SPECIES", 156, 162], ["humans", "SPECIES", 156, 162], ["this new virus", "PROBLEM", 39, 53], ["severe and fatal respiratory disease", "PROBLEM", 68, 104], ["acute respiratory distress syndrome", "PROBLEM", 110, 145], ["ARDS", "PROBLEM", 147, 151], ["severe", "OBSERVATION_MODIFIER", 68, 74], ["fatal", "OBSERVATION_MODIFIER", 79, 84], ["respiratory disease", "OBSERVATION", 85, 104], ["acute", "OBSERVATION_MODIFIER", 110, 115], ["respiratory distress", "OBSERVATION", 116, 136]]], ["With the gradual recognition of COVID-19 pneumonia, professional consensus, guidelines and criteria were steadily established with the aim of preventing transmission and facilitating diagnosis and treatment.IntroductionAlthough COVID-19 pneumonia was considered as a low lethal disease, recognition of disease progression was an important decision point concerning intensive therapies [1, 2].", [["pneumonia", "DISEASE", 41, 50], ["pneumonia", "DISEASE", 237, 246], ["COVID", "TEST", 32, 37], ["pneumonia", "PROBLEM", 41, 50], ["treatment", "TREATMENT", 197, 206], ["COVID", "TEST", 228, 233], ["pneumonia", "PROBLEM", 237, 246], ["a low lethal disease", "PROBLEM", 265, 285], ["disease progression", "PROBLEM", 302, 321], ["intensive therapies", "TREATMENT", 365, 384], ["pneumonia", "OBSERVATION", 41, 50], ["pneumonia", "OBSERVATION", 237, 246], ["low lethal", "OBSERVATION_MODIFIER", 267, 277]]], ["Accordingly, chest CT has been preferentially used as a stable marker of COVID-19 pneumonia, but clinical experiences have revealed the decrease of its availability in critical cases.", [["chest", "ANATOMY", 13, 18], ["pneumonia", "DISEASE", 82, 91], ["chest CT", "TEST", 13, 21], ["COVID-19 pneumonia", "PROBLEM", 73, 91], ["chest", "ANATOMY", 13, 18], ["stable", "OBSERVATION_MODIFIER", 56, 62], ["pneumonia", "OBSERVATION", 82, 91], ["decrease", "OBSERVATION_MODIFIER", 136, 144]]], ["Therefore, a more sensitive and specific disease-progression marker of COVID-19 pneumonia has been required.IntroductionLactate dehydrogenase (LDH) is an enzyme implicated in the conversion of lactate to pyruvate in the cells of most body tissues and increased following tissue breakdown.", [["cells", "ANATOMY", 220, 225], ["body tissues", "ANATOMY", 234, 246], ["tissue", "ANATOMY", 271, 277], ["pneumonia", "DISEASE", 80, 89], ["IntroductionLactate", "CHEMICAL", 108, 127], ["lactate", "CHEMICAL", 193, 200], ["pyruvate", "CHEMICAL", 204, 212], ["IntroductionLactate", "CHEMICAL", 108, 127], ["lactate", "CHEMICAL", 193, 200], ["pyruvate", "CHEMICAL", 204, 212], ["IntroductionLactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 108, 141], ["LDH", "GENE_OR_GENE_PRODUCT", 143, 146], ["lactate", "SIMPLE_CHEMICAL", 193, 200], ["pyruvate", "SIMPLE_CHEMICAL", 204, 212], ["cells", "CELL", 220, 225], ["body tissues", "TISSUE", 234, 246], ["tissue", "TISSUE", 271, 277], ["IntroductionLactate dehydrogenase", "PROTEIN", 108, 141], ["LDH", "PROTEIN", 143, 146], ["COVID-19", "SPECIES", 71, 79], ["a more sensitive and specific disease", "PROBLEM", 11, 48], ["COVID", "TEST", 71, 76], ["pneumonia", "PROBLEM", 80, 89], ["IntroductionLactate dehydrogenase (LDH)", "TEST", 108, 147], ["an enzyme", "TEST", 151, 160], ["lactate", "TEST", 193, 200], ["tissue breakdown", "PROBLEM", 271, 287], ["pneumonia", "OBSERVATION", 80, 89], ["most body", "ANATOMY_MODIFIER", 229, 238], ["tissues", "ANATOMY", 239, 246], ["increased", "OBSERVATION_MODIFIER", 251, 260], ["following tissue", "OBSERVATION_MODIFIER", 261, 277], ["breakdown", "OBSERVATION_MODIFIER", 278, 287]]], ["Consequently, elevated serum LDH is present in numerous clinical conditions, such as hemolysis, cancer, severe infections and sepsis, liver diseases, hematologic malignancies, and many others.", [["serum", "ANATOMY", 23, 28], ["cancer", "ANATOMY", 96, 102], ["liver", "ANATOMY", 134, 139], ["hematologic malignancies", "ANATOMY", 150, 174], ["hemolysis", "DISEASE", 85, 94], ["cancer", "DISEASE", 96, 102], ["infections", "DISEASE", 111, 121], ["sepsis", "DISEASE", 126, 132], ["liver diseases", "DISEASE", 134, 148], ["hematologic malignancies", "DISEASE", 150, 174], ["serum", "ORGANISM_SUBSTANCE", 23, 28], ["LDH", "GENE_OR_GENE_PRODUCT", 29, 32], ["cancer", "CANCER", 96, 102], ["liver", "ORGAN", 134, 139], ["hematologic malignancies", "CANCER", 150, 174], ["serum LDH", "PROTEIN", 23, 32], ["elevated serum LDH", "PROBLEM", 14, 32], ["hemolysis", "PROBLEM", 85, 94], ["cancer", "PROBLEM", 96, 102], ["severe infections", "PROBLEM", 104, 121], ["sepsis", "PROBLEM", 126, 132], ["liver diseases", "PROBLEM", 134, 148], ["hematologic malignancies", "PROBLEM", 150, 174], ["elevated", "OBSERVATION_MODIFIER", 14, 22], ["serum LDH", "OBSERVATION_MODIFIER", 23, 32], ["hemolysis", "OBSERVATION", 85, 94], ["cancer", "OBSERVATION", 96, 102], ["severe", "OBSERVATION_MODIFIER", 104, 110], ["infections", "OBSERVATION", 111, 121], ["sepsis", "OBSERVATION", 126, 132], ["liver", "ANATOMY", 134, 139], ["diseases", "OBSERVATION", 140, 148], ["hematologic malignancies", "OBSERVATION", 150, 174]]], ["Nowadays, there was much evidence suggesting that the serum LDH levels serve as a non-specific indicator of cellular death in many diseases [3, 4].", [["serum", "ANATOMY", 54, 59], ["cellular", "ANATOMY", 108, 116], ["death", "DISEASE", 117, 122], ["serum", "ORGANISM_SUBSTANCE", 54, 59], ["LDH", "GENE_OR_GENE_PRODUCT", 60, 63], ["cellular", "CELL", 108, 116], ["LDH", "PROTEIN", 60, 63], ["the serum LDH levels", "TEST", 50, 70], ["cellular death", "PROBLEM", 108, 122], ["many diseases", "PROBLEM", 126, 139], ["much evidence suggesting", "UNCERTAINTY", 20, 44], ["cellular death", "OBSERVATION", 108, 122]]], ["However, the current information about dynamic change of LDH in COVID-19 pneumonia was very still.IntroductionHere, we hypothesized that certain LDH change might be correlated to the time course of COVID-19 pneumonia.", [["pneumonia", "DISEASE", 73, 82], ["pneumonia", "DISEASE", 207, 216], ["LDH", "GENE_OR_GENE_PRODUCT", 57, 60], ["COVID-19", "ORGANISM", 64, 72], ["LDH", "GENE_OR_GENE_PRODUCT", 145, 148], ["LDH", "TEST", 57, 60], ["COVID", "TEST", 64, 69], ["pneumonia", "PROBLEM", 73, 82], ["certain LDH change", "PROBLEM", 137, 155], ["COVID", "TEST", 198, 203], ["pneumonia", "PROBLEM", 207, 216], ["pneumonia", "OBSERVATION", 73, 82], ["pneumonia", "OBSERVATION", 207, 216]]], ["We therefore measured LDH levels and related them to disease\u2019s severity and status.", [["LDH", "GENE_OR_GENE_PRODUCT", 22, 25], ["LDH", "PROTEIN", 22, 25], ["LDH levels", "TEST", 22, 32]]], ["It was aimed to establish serum LDH as a potential marker for monitoring treatment response in COVID-19 pneumonia.Patients ::: Patients and methodsAll 87 patients were admitted to The Fifth Hospital of Suzhou and diagnosed with COVID-19 pneumonia from Jan 10 to Feb 16, 2020.", [["serum", "ANATOMY", 26, 31], ["pneumonia", "DISEASE", 104, 113], ["pneumonia", "DISEASE", 237, 246], ["serum", "ORGANISM_SUBSTANCE", 26, 31], ["LDH", "GENE_OR_GENE_PRODUCT", 32, 35], ["Patients", "ORGANISM", 114, 122], ["Patients", "ORGANISM", 127, 135], ["patients", "ORGANISM", 154, 162], ["serum LDH", "PROTEIN", 26, 35], ["Patients", "SPECIES", 114, 122], ["Patients", "SPECIES", 127, 135], ["patients", "SPECIES", 154, 162], ["COVID-19", "SPECIES", 95, 103], ["serum LDH", "TEST", 26, 35], ["monitoring treatment response", "TEST", 62, 91], ["COVID", "TEST", 95, 100], ["pneumonia", "PROBLEM", 104, 113], ["COVID", "TEST", 228, 233], ["pneumonia", "PROBLEM", 237, 246], ["pneumonia", "OBSERVATION", 104, 113], ["pneumonia", "OBSERVATION", 237, 246]]], ["Diagnosis of COVID-19 infection in patients was made by positive test for viral RNA of respiratory secretions obtained by bronchoalveolar lavage, sputum, nasopharyngeal swab, or oropharyngeal swab.", [["respiratory secretions", "ANATOMY", 87, 109], ["bronchoalveolar lavage", "ANATOMY", 122, 144], ["sputum", "ANATOMY", 146, 152], ["nasopharyngeal swab", "ANATOMY", 154, 173], ["oropharyngeal swab", "ANATOMY", 178, 196], ["COVID-19", "CHEMICAL", 13, 21], ["infection", "DISEASE", 22, 31], ["COVID-19", "ORGANISM", 13, 21], ["patients", "ORGANISM", 35, 43], ["bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 122, 144], ["sputum", "ORGANISM_SUBSTANCE", 146, 152], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 154, 173], ["oropharyngeal", "ORGANISM_SUBDIVISION", 178, 191], ["swab", "ORGANISM_SUBSTANCE", 192, 196], ["viral RNA", "RNA", 74, 83], ["patients", "SPECIES", 35, 43], ["COVID-19 infection", "PROBLEM", 13, 31], ["viral RNA of respiratory secretions", "PROBLEM", 74, 109], ["bronchoalveolar lavage", "TEST", 122, 144], ["sputum", "TEST", 146, 152], ["nasopharyngeal swab", "TEST", 154, 173], ["oropharyngeal swab", "TEST", 178, 196], ["infection", "OBSERVATION", 22, 31], ["respiratory", "ANATOMY", 87, 98], ["secretions", "OBSERVATION", 99, 109], ["nasopharyngeal", "ANATOMY", 154, 168], ["oropharyngeal", "ANATOMY", 178, 191]]], ["Demographic information, clinical characteristics (included medical history, severity and comorbidities) and chest CT scan results of each patient were obtained from the electronical medical record system of The Fifth hospital of Suzhou.", [["patient", "ORGANISM", 139, 146], ["patient", "SPECIES", 139, 146], ["chest CT scan", "TEST", 109, 122], ["chest", "ANATOMY", 109, 114]]], ["Severity of COVID-19 was defined according to the diagnostic and treatment guideline for COVID-19 pneumonia issued by Chinese National Health Committee (Version 1\u20136).", [["pneumonia", "DISEASE", 98, 107], ["COVID", "TEST", 12, 17], ["COVID", "TEST", 89, 94], ["pneumonia", "PROBLEM", 98, 107], ["pneumonia", "OBSERVATION", 98, 107]]], ["The study was approved by the Ethics Committee of our Institute of The Fifth People\u2019s Hospital of Suzhou (2020\u2013005).Treatment and evaluation ::: Patients and methodsClinical treatment and assessments were carried out by the diagnostic and treatment guideline for COVID-19 pneumonia issued by Chinese National Health Committee (Version 1\u20136).", [["pneumonia", "DISEASE", 272, 281], ["Patients", "ORGANISM", 145, 153], ["People", "SPECIES", 77, 83], ["Patients", "SPECIES", 145, 153], ["The study", "TEST", 0, 9], ["evaluation", "TEST", 130, 140], ["Clinical treatment", "TREATMENT", 165, 183], ["assessments", "TEST", 188, 199], ["COVID", "TEST", 263, 268], ["pneumonia", "PROBLEM", 272, 281], ["pneumonia", "OBSERVATION", 272, 281]]], ["As multiple pulmonary CT scans provided reliable data, it was preferentially used as a gold standard of disease status.Serial determinations of LDH levels ::: Patients and methodsThe serum LDH was determined by VITROS\u00ae dry chemistry analyzer (Johnson, range from 313 to 618 U/L) [5, 6].", [["pulmonary", "ANATOMY", 12, 21], ["serum", "ANATOMY", 183, 188], ["pulmonary", "ORGAN", 12, 21], ["LDH", "GENE_OR_GENE_PRODUCT", 144, 147], ["Patients", "ORGANISM", 159, 167], ["serum", "ORGANISM_SUBSTANCE", 183, 188], ["LDH", "GENE_OR_GENE_PRODUCT", 189, 192], ["LDH", "PROTEIN", 144, 147], ["serum LDH", "PROTEIN", 183, 192], ["Patients", "SPECIES", 159, 167], ["multiple pulmonary CT scans", "TEST", 3, 30], ["Serial determinations of LDH levels", "TEST", 119, 154], ["The serum LDH", "TEST", 179, 192], ["VITROS", "TEST", 211, 217], ["pulmonary", "ANATOMY", 12, 21]]], ["All operations are performed in strict accordance with the operating instructions.", [["All operations", "TREATMENT", 0, 14]]], ["The serum LDH levels were investigated at diagnosis and at routine follow-up visits.", [["serum", "ANATOMY", 4, 9], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["LDH", "GENE_OR_GENE_PRODUCT", 10, 13], ["LDH", "PROTEIN", 10, 13], ["The serum LDH levels", "TEST", 0, 20]]], ["The serial value of LDH was selected around the data of chest CT scan (\u2212 1 ~ + 1 day).Definition ::: Patients and methodsThe time to LDH normalization referred to the time interval from increased LDH to normalized LDH.", [["chest", "ANATOMY", 56, 61], ["LDH", "GENE_OR_GENE_PRODUCT", 20, 23], ["Patients", "ORGANISM", 101, 109], ["LDH", "SIMPLE_CHEMICAL", 133, 136], ["LDH", "SIMPLE_CHEMICAL", 196, 199], ["LDH", "GENE_OR_GENE_PRODUCT", 214, 217], ["LDH", "PROTEIN", 20, 23], ["LDH", "PROTEIN", 133, 136], ["LDH", "PROTEIN", 196, 199], ["LDH", "PROTEIN", 214, 217], ["Patients", "SPECIES", 101, 109], ["The serial value of LDH", "TEST", 0, 23], ["chest CT scan", "TEST", 56, 69], ["LDH normalization", "TEST", 133, 150], ["increased LDH", "PROBLEM", 186, 199], ["LDH", "TEST", 214, 217], ["chest", "ANATOMY", 56, 61], ["increased", "OBSERVATION_MODIFIER", 186, 195], ["LDH", "OBSERVATION", 196, 199]]], ["This CT image scoring system was an adaptation of a method previously used to describe idiopathic pulmonary fibrosis and severe acute respiratory syndrome (SARS) [7].", [["pulmonary", "ANATOMY", 98, 107], ["idiopathic pulmonary fibrosis", "DISEASE", 87, 116], ["acute respiratory syndrome", "DISEASE", 128, 154], ["SARS", "DISEASE", 156, 160], ["pulmonary", "ORGAN", 98, 107], ["This CT image scoring system", "TEST", 0, 28], ["a method", "TREATMENT", 50, 58], ["idiopathic pulmonary fibrosis", "PROBLEM", 87, 116], ["severe acute respiratory syndrome", "PROBLEM", 121, 154], ["idiopathic", "OBSERVATION_MODIFIER", 87, 97], ["pulmonary", "ANATOMY", 98, 107], ["fibrosis", "OBSERVATION", 108, 116], ["severe", "OBSERVATION_MODIFIER", 121, 127], ["acute", "OBSERVATION_MODIFIER", 128, 133], ["respiratory syndrome", "OBSERVATION", 134, 154]]], ["CT score was assigned to each lung and each lobe, based on the size of the infected area.", [["lung", "ANATOMY", 30, 34], ["lobe", "ANATOMY", 44, 48], ["area", "ANATOMY", 84, 88], ["lung", "ORGAN", 30, 34], ["lobe", "ORGAN", 44, 48], ["CT score", "TEST", 0, 8], ["the infected area", "PROBLEM", 71, 88], ["lung", "ANATOMY", 30, 34], ["lobe", "ANATOMY_MODIFIER", 44, 48], ["size", "OBSERVATION_MODIFIER", 63, 67], ["infected", "OBSERVATION", 75, 83]]], ["The score ranged from 0 to 5, with score 0 for no infected area, 1 for less than 5%, 2 for 6\u201325%, 3 for 26\u201350%, 4 for 51\u201375%, and 5 for more than 75%.", [["The score", "TEST", 0, 9], ["infected area", "PROBLEM", 50, 63], ["infected", "OBSERVATION", 50, 58]]], ["The peak progress on CT (PPC) was defined as the highest score of CT image, remarkable absorption on CT (RAC) was defined as reduced CT image score by 50% compared to PPC.", [["CT (PPC", "TEST", 21, 28], ["CT image", "TEST", 66, 74], ["CT", "TEST", 101, 103], ["reduced CT image score", "TEST", 125, 147], ["PPC", "TEST", 167, 170], ["peak", "OBSERVATION_MODIFIER", 4, 8]]], ["The time to radiographic absorption (TRA) was established as the time interval from PPC to time point of beginning reduction in CT image score.Statistical analysis ::: Patients and methodsThe normality of all data was tested by Kolmogorov-Smirnov test.", [["Patients", "ORGANISM", 168, 176], ["Patients", "SPECIES", 168, 176], ["PPC", "TREATMENT", 84, 87], ["CT image score", "TEST", 128, 142], ["reduction", "OBSERVATION_MODIFIER", 115, 124]]], ["The levels of LDH were compared between non-severe patients and severe patients using t test.", [["LDH", "GENE_OR_GENE_PRODUCT", 14, 17], ["patients", "ORGANISM", 51, 59], ["patients", "ORGANISM", 71, 79], ["LDH", "PROTEIN", 14, 17], ["patients", "SPECIES", 51, 59], ["patients", "SPECIES", 71, 79], ["The levels of LDH", "TEST", 0, 17], ["t test", "TEST", 86, 92], ["LDH", "ANATOMY", 14, 17], ["severe", "OBSERVATION_MODIFIER", 64, 70]]], ["The values of LDH selected from the data of admission, PPC, and RAC were compared using paired-samples T test.", [["LDH", "GENE_OR_GENE_PRODUCT", 14, 17], ["LDH", "PROTEIN", 14, 17], ["The values", "TEST", 0, 10], ["LDH", "TEST", 14, 17], ["PPC", "TEST", 55, 58], ["paired-samples T test", "TEST", 88, 109]]], ["The predictive ability of decrease or increase in LDH to corresponding radiographic absorption or progression was evaluated by X2 tests.", [["LDH", "SIMPLE_CHEMICAL", 50, 53], ["LDH", "PROTEIN", 50, 53], ["increase in LDH to corresponding radiographic absorption", "PROBLEM", 38, 94], ["X2 tests", "TEST", 127, 135], ["decrease", "OBSERVATION_MODIFIER", 26, 34], ["increase", "OBSERVATION_MODIFIER", 38, 46]]], ["Receiver operating characteristic (ROC) curves were calculated in order to select the cut-off level of an increase or decrease in serum LDH indicating progress or improvement of adjacent chest scan.", [["serum", "ANATOMY", 130, 135], ["chest", "ANATOMY", 187, 192], ["serum", "ORGANISM_SUBSTANCE", 130, 135], ["LDH", "GENE_OR_GENE_PRODUCT", 136, 139], ["chest", "ORGAN", 187, 192], ["an increase", "PROBLEM", 103, 114], ["serum LDH", "TEST", 130, 139], ["adjacent chest scan", "TEST", 178, 197], ["increase", "OBSERVATION_MODIFIER", 106, 114], ["decrease", "OBSERVATION_MODIFIER", 118, 126], ["serum LDH", "OBSERVATION", 130, 139], ["chest", "ANATOMY", 187, 192]]], ["The correlation of the time to LDH normalization and the TRA was analyzed by Pearson correlation.", [["LDH", "GENE_OR_GENE_PRODUCT", 31, 34], ["LDH", "PROTEIN", 31, 34], ["LDH normalization", "TEST", 31, 48]]], ["All tests were two-sided with a P-value of less than 0.05 being considered statistically significant.Demographics and clinical characteristics ::: ResultsAmong those patients (Table 1), 47 were male and 40 were female.", [["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 166, 174], ["All tests", "TEST", 0, 9], ["a P-value", "TEST", 30, 39]]], ["The patients were categorized into 77 non-severe and 10 severe cases on admission.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["non-severe and 10 severe cases", "PROBLEM", 38, 68]]], ["Underlying comorbidity was found in 28 (32.2%) patients, including hypertension (6, 6.9%), diabetes (5, 5.7%), and chronic airway diseases patients (5, 5.7%).", [["airway", "ANATOMY", 123, 129], ["hypertension", "DISEASE", 67, 79], ["diabetes", "DISEASE", 91, 99], ["chronic airway diseases", "DISEASE", 115, 138], ["patients", "ORGANISM", 47, 55], ["airway", "MULTI-TISSUE_STRUCTURE", 123, 129], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 139, 147], ["Underlying comorbidity", "PROBLEM", 0, 22], ["hypertension", "PROBLEM", 67, 79], ["diabetes", "PROBLEM", 91, 99], ["chronic airway diseases", "PROBLEM", 115, 138], ["comorbidity", "OBSERVATION", 11, 22], ["hypertension", "OBSERVATION", 67, 79], ["chronic", "OBSERVATION_MODIFIER", 115, 122], ["airway", "ANATOMY", 123, 129], ["diseases", "OBSERVATION", 130, 138]]]], "cb4f5f35816826a7e3970f11e6948d58e2101adc": [["During initial evaluation of a patient coming from the community with pneumonia, the identification of possible risk factors for multidrug-resistant organisms or unusual pathogens is crucial [1] [2] [3] .", [["pneumonia", "DISEASE", 70, 79], ["patient", "ORGANISM", 31, 38], ["patient", "SPECIES", 31, 38], ["initial evaluation", "TEST", 7, 25], ["pneumonia", "PROBLEM", 70, 79], ["risk factors", "PROBLEM", 112, 124], ["multidrug-resistant organisms", "PROBLEM", 129, 158], ["unusual pathogens", "PROBLEM", 162, 179], ["pneumonia", "OBSERVATION", 70, 79]]], ["Because a microbiological identification is found in about 30% of hospitalized patients with pneumonia coming from the community, and usually requires 24-48 hours to be available, most of patients are treated empirically [4] .", [["pneumonia", "DISEASE", 93, 102], ["patients", "ORGANISM", 79, 87], ["patients", "ORGANISM", 188, 196], ["patients", "SPECIES", 79, 87], ["patients", "SPECIES", 188, 196], ["a microbiological identification", "TEST", 8, 40], ["pneumonia", "PROBLEM", 93, 102], ["pneumonia", "OBSERVATION", 93, 102]]], ["Delay in initiation of appropriate empiric antibiotic therapy is a known risk factor for worse clinical outcomes [5] [6] [7] ; therefore, it is relevant to promptly recognize patients at risk for specific pathogens, specially multidrug-resistant or atypical microbes [1] [2] [3] .", [["patients", "ORGANISM", 175, 183], ["[1] [2] [3]", "SIMPLE_CHEMICAL", 267, 278], ["patients", "SPECIES", 175, 183], ["appropriate empiric antibiotic therapy", "TREATMENT", 23, 61], ["worse clinical outcomes", "PROBLEM", 89, 112], ["specific pathogens", "PROBLEM", 196, 214], ["specially multidrug-resistant or atypical microbes", "PROBLEM", 216, 266]]]], "PMC7236151": [["DisclosureAG has been a consultant and/or advisor to or has received honoraria from Ache\u00e9, Daiichi-Sankyo, Torrent, Cristalia, and Janssen.", [["DisclosureAG", "CHEMICAL", 0, 12], ["honoraria", "ORGANISM", 69, 78]]]], "b80277c38f948b359d4cebc8b83ec7ed8273a61c": [["INTRODUCTIONOn January 21, 2020, the United States reported its first case of the novel coronavirus disease 2019 (COVID- 19) .", [["coronavirus disease", "DISEASE", 88, 107], ["the novel coronavirus disease", "PROBLEM", 78, 107], ["COVID", "TEST", 114, 119], ["coronavirus disease", "OBSERVATION", 88, 107]]], ["1 As of April 3, 2020, the United States leads the world in confirmed cases with over 278 thousand people affected, 2,3 and over 30 states have adopted directives to keep people at home to \"flatten the curve.\" 4 As the number of coronavirus cases continues to climb, healthcare systems have begun to feel the strain on resources.", [["coronavirus", "DISEASE", 229, 240], ["people", "ORGANISM", 99, 105], ["people", "ORGANISM", 171, 177], ["coronavirus", "ORGANISM", 229, 240], ["people", "SPECIES", 99, 105], ["people", "SPECIES", 171, 177], ["coronavirus cases", "PROBLEM", 229, 246]]], ["On March 24, 2020, the Center for Disease Control and Prevention 5 recognized that different states may have varying degrees of risk but nonetheless recommended that all U.S. hospitals prepare for a surge of patients with COVID-19 requiring acute and critical care.", [["patients", "ORGANISM", 208, 216], ["patients", "SPECIES", 208, 216], ["Disease Control", "TREATMENT", 34, 49], ["COVID", "TREATMENT", 222, 227], ["acute and critical care", "TREATMENT", 241, 264]]], ["Preparations included changing practices to prevent the spread of disease and to protect the safety of healthcare workers (HCWs).", [["changing practices", "TREATMENT", 22, 40], ["disease", "PROBLEM", 66, 73]]], ["In response to an evolving body of information from this early stage of the pandemic, some hospitals and professional societies 6 modified departmental policies and physician-hospital coverage plans to minimize risk, 7 viral exposure, and personal protective equipment (PPE) depletion.INTRODUCTIONTeaching hospitals face the unique responsibility of balancing current public health goals with resident education.", [["personal protective equipment (PPE) depletion", "TREATMENT", 239, 284]]], ["8, 9 Specific to otolaryngology-head and neck surgery (OHNS), 10 many procedures such as endoscopy; tracheotomy; and sinus, skull base, and upper airway surgery can aerosolize respiratory droplets.", [["head", "ANATOMY", 32, 36], ["neck", "ANATOMY", 41, 45], ["sinus", "ANATOMY", 117, 122], ["skull", "ANATOMY", 124, 129], ["airway", "ANATOMY", 146, 152], ["respiratory droplets", "ANATOMY", 176, 196], ["head", "ORGANISM_SUBDIVISION", 32, 36], ["neck", "ORGAN", 41, 45], ["sinus", "MULTI-TISSUE_STRUCTURE", 117, 122], ["skull", "ORGAN", 124, 129], ["airway", "MULTI-TISSUE_STRUCTURE", 146, 152], ["head and neck surgery", "TREATMENT", 32, 53], ["endoscopy", "TEST", 89, 98], ["tracheotomy", "TREATMENT", 100, 111], ["sinus, skull base", "TEST", 117, 134], ["upper airway surgery", "TREATMENT", 140, 160], ["respiratory droplets", "PROBLEM", 176, 196], ["head", "ANATOMY", 32, 36], ["neck", "ANATOMY", 41, 45], ["surgery", "OBSERVATION", 46, 53], ["tracheotomy", "OBSERVATION", 100, 111], ["sinus", "ANATOMY", 117, 122], ["skull", "ANATOMY", 124, 129], ["base", "ANATOMY_MODIFIER", 130, 134], ["upper", "ANATOMY_MODIFIER", 140, 145], ["airway", "ANATOMY", 146, 152], ["respiratory droplets", "OBSERVATION", 176, 196]]], ["The high viral loads in the nasal 11 and oropharyngeal mucosa, along with our current understanding of the route of severe acute respiratory syndrome (SARS) transmission 12 and anecdotal reports of disease transmission during aerosolizing procedures, place otolaryngologists at a higher risk for contracting COVID-19.", [["nasal 11", "ANATOMY", 28, 36], ["oropharyngeal mucosa", "ANATOMY", 41, 61], ["acute respiratory syndrome", "DISEASE", 123, 149], ["SARS", "DISEASE", 151, 155], ["COVID-19", "CHEMICAL", 308, 316], ["nasal 11", "MULTI-TISSUE_STRUCTURE", 28, 36], ["oropharyngeal mucosa", "MULTI-TISSUE_STRUCTURE", 41, 61], ["The high viral loads in the nasal 11 and oropharyngeal mucosa", "PROBLEM", 0, 61], ["severe acute respiratory syndrome", "PROBLEM", 116, 149], ["disease transmission", "PROBLEM", 198, 218], ["aerosolizing procedures", "TREATMENT", 226, 249], ["contracting COVID", "TEST", 296, 313], ["high", "OBSERVATION_MODIFIER", 4, 8], ["viral loads", "OBSERVATION", 9, 20], ["nasal", "ANATOMY", 28, 33], ["oropharyngeal mucosa", "ANATOMY", 41, 61], ["severe", "OBSERVATION_MODIFIER", 116, 122], ["acute", "OBSERVATION_MODIFIER", 123, 128], ["respiratory syndrome", "OBSERVATION", 129, 149]]], ["Along with other HCWs directly treating COVID-19 patients, OHNS residents may experience considerable anxiety regarding their personal safety, transmission of the infection, and education.", [["COVID", "DISEASE", 40, 45], ["anxiety", "DISEASE", 102, 109], ["infection", "DISEASE", 163, 172], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["considerable anxiety", "PROBLEM", 89, 109], ["the infection", "PROBLEM", 159, 172], ["infection", "OBSERVATION", 163, 172]]], ["Prior studies of HCWs during the 2002-2003 outbreak of SARS 13 showed long-term psychosocial effects among HCWs who cared for SARS patients.", [["SARS", "DISEASE", 55, 59], ["SARS", "DISEASE", 126, 130], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139]]], ["14, 15 Recent recommendations from the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) and Society of University Otolaryngologists (SUO) necessitated changes to resident clinical responsibilities, rotation schedules, and PPE guidelines during this pandemic.", [["Head and Neck Surgery", "TREATMENT", 74, 95], ["rotation schedules", "TREATMENT", 216, 234], ["PPE guidelines", "TREATMENT", 240, 254], ["this pandemic", "PROBLEM", 262, 275], ["Head", "ANATOMY", 74, 78], ["Neck", "ANATOMY", 83, 87]]], ["The AAO-HNS released a position statement on March 23, 2020, advising otolaryngologists to limit care to time-sensitive problems and use appropriate PPE.", [["appropriate PPE", "TREATMENT", 137, 152]]], ["16 The following day, the SUO Council released recommendations to reduce trainee risk of contracting COVID-19 through minimizing unnecessary exposure to patients as well as social distancing among resident team members.", [["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 153, 161], ["contracting COVID", "TREATMENT", 89, 106]]], ["17 With these guiding principles, varying departmental policies were created in response to COVID-19 during March 2020 because current and projected numbers of cases and resource shortages varied broadly across the country.INTRODUCTIONTo our knowledge, there are no published studies examining practice patterns among residents of any specialty during the initial phase of the COVID-19 pandemic.", [["COVID", "TEST", 92, 97], ["published studies", "TEST", 266, 283], ["the COVID", "TEST", 373, 382], ["pandemic", "PROBLEM", 386, 394]]], ["Thus, we conducted a cross-sectional analysis to evaluate U.S. OHNS residents' practice patterns and perceptions or concerns during the early stages of this pandemic.", [["a cross-sectional analysis", "TEST", 19, 45], ["this pandemic", "PROBLEM", 152, 165]]], ["An understanding of institutional guidelines and differences may help inform programs' policies and identify areas of resident-specific concerns during the COVID-19 pandemic.Study DesignThis study was approved by the institutional review board at the University of California, San Francisco.", [["the COVID", "TEST", 152, 161], ["pandemic", "PROBLEM", 165, 173], ["Study DesignThis study", "TEST", 174, 196]]], ["Residents in PGY1 through PGY3 were defined as junior residents, whereas PGY4 and PGY5 trainees were defined as senior residents.", [["PGY1", "DNA", 13, 17]]], ["No response was excluded.Resident Practice Patterns, PPE, and Perceptions Regarding COVID-19Respondents were asked when (if applicable) any policy changes had been enacted within their city/county, hospital, and department.", [["response", "OBSERVATION", 3, 11], ["was excluded", "UNCERTAINTY", 12, 24]]], ["Departmental policy changes assessed included those affecting rotation schedules, clinical responsibilities, and aerosol-generating procedures.Resident Practice Patterns, PPE, and Perceptions Regarding COVID-19Each study participant was queried on the specific PPE policies for various clinical scenarios.", [["participant", "SPECIES", 221, 232], ["rotation schedules", "TREATMENT", 62, 80], ["aerosol-generating procedures", "TREATMENT", 113, 142]]], ["COVID-19 status was dichotomized into COVID-19-positive or person under investigation (PUI) versus COVID-19-negative or those without symptoms.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 38, 46], ["COVID-19", "GENE_OR_GENE_PRODUCT", 99, 107], ["COVID", "PROTEIN", 0, 5], ["person", "SPECIES", 59, 65], ["COVID", "TEST", 0, 5], ["COVID", "TEST", 38, 43], ["PUI", "TEST", 87, 90], ["COVID", "TEST", 99, 104], ["symptoms", "PROBLEM", 134, 142]]], ["Lastly, participants were asked about their concerns, satisfaction with their department response, and perceived level of risk for residents and attendings for contracting COVID-19.", [["participants", "SPECIES", 8, 20], ["contracting COVID", "TEST", 160, 177]]], ["These Likert-scale responses were scored from 1 to 5.Statistical AnalysisResponses were collated in Microsoft Excel, version 14.5.3 (Microsoft Corp., Redmond, WA) and Stata (Stata 14.0 College Station, TX).", [["These Likert-scale responses", "TEST", 0, 28], ["version", "TEST", 117, 124]]], ["Data were analyzed by chisquared or t tests as appropriate.", [["t tests", "TEST", 36, 43]]], ["Kaplan-Meier curves were used to analyze the time to policy change for programs by high versus low numbers COVID-19 infections in their states.", [["infections", "DISEASE", 116, 126]]], ["The states considered to have high numbers of COVID-19 infections were the 10 states with the greatest numbers of COVID-19 cases on the date the survey was released and included California, Florida, Georgia, Illinois, Louisiana, Massachusetts, Michigan, New Jersey, New York, and Washington.", [["infections", "DISEASE", 55, 65], ["high numbers of COVID-19 infections", "PROBLEM", 30, 65], ["COVID", "TEST", 114, 119]]], ["For data regarding institutional policy changes, if multiple participants within the same institution provided differing responses, the most common answer provided by respondents was utilized.", [["participants", "SPECIES", 61, 73]]], ["If there was no majority, then the most conservative answer suggesting a change in policy was used for analysis.", [["analysis", "TEST", 103, 111]]], ["We evaluated the association between resident satisfaction and timeliness of enacted policy changes, which was dichotomized into early versus later responders by the average date of policy change for programs included in this study.RESULTSWe obtained complete survey responses from 82 residents across 51 of 81 institutions contacted.", [["this study", "TEST", 221, 231]]], ["This yielded a program response rate of 63% and represents 43% of all U.S. OHNS residency programs ( Table I ).", [["a program response rate", "TEST", 13, 36]]], ["Most programs (94%) required resident coverage for at least two hospital sites.", [["resident coverage", "TREATMENT", 29, 46]]], ["All geographic regions were represented, and 67% of states with an OHNS residency program (28 of 42) were included.", [["geographic", "OBSERVATION_MODIFIER", 4, 14]]], ["All programs reported policy changes for local businesses, and almost all hospital systems (82%) had postponed elective surgeries and nonurgent clinic visits.", [["postponed elective surgeries", "TREATMENT", 101, 129]]], ["A timeline of OHNS residency programs' policy changes relative to nationwide events is depicted in Figure 1 respectively).", [["OHNS residency programs", "TREATMENT", 14, 37]]], ["Nineteen programs (37%) attempted to mitigate exposure by creating resident cohort groups.", [["Nineteen programs", "TREATMENT", 0, 17]]], ["Of these 19 programs, 12 created resident cohort schedules that alternated on a weekly basis.", [["cohort schedules", "TREATMENT", 42, 58]]], ["The majority of programs made changes to performance of aerosolizing procedures by halting decongestant/anesthetic spray use (65%) and restricting tracheotomy tube changes to urgent scenarios (61%).", [["aerosolizing procedures", "TREATMENT", 56, 79], ["halting decongestant/anesthetic spray", "TREATMENT", 83, 120], ["restricting tracheotomy tube changes", "TREATMENT", 135, 171], ["urgent scenarios", "TREATMENT", 175, 191], ["tracheotomy tube", "OBSERVATION", 147, 163]]], ["For nasolaryngoscopy, 18% of programs required an attending or fellow to perform the procedure, and 10% required attending approval before residents proceeded.RESULTSPPE usage policies were also assessed (Fig. 2) .", [["nasolaryngoscopy", "TREATMENT", 4, 20], ["the procedure", "TREATMENT", 81, 94]]], ["For asymptomatic or COVID-19-negative patients, the majority of residents reported use of surgical masks for history and physical exams (80%), and an N95 or powered airpurifying respirator (PAPR) for aerosol-generating procedures (85% and 91%, respectively).", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["COVID", "TEST", 20, 25], ["surgical masks", "TREATMENT", 90, 104], ["physical exams", "TEST", 121, 135], ["an N95", "TREATMENT", 147, 153], ["powered airpurifying respirator", "TREATMENT", 157, 188], ["aerosol-generating procedures", "TREATMENT", 200, 229]]], ["In contrast, among COVID-19-positive patients or PUIs, N95 or PAPR use was almost universal.RESULTSResident perception of risk of contracting COVID-19 was queried (Fig. 3) .", [["COVID-19", "CHEMICAL", 142, 150], ["COVID-19", "GENE_OR_GENE_PRODUCT", 19, 27], ["patients", "ORGANISM", 37, 45], ["PAPR", "PROTEIN", 62, 66], ["patients", "SPECIES", 37, 45], ["COVID", "TEST", 19, 24], ["PUIs", "PROBLEM", 49, 53], ["contracting COVID", "TEST", 130, 147]]], ["There was a significant difference between the average Likert-scale scores between juniors (3.85 AE 0.98) and seniors (3.03 AE 1.05; P < .05), with 50% of senior residents reporting equivalent risk among residents.", [["juniors", "TEST", 83, 90], ["seniors", "TEST", 110, 117], ["P", "TEST", 133, 134], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["difference", "OBSERVATION_MODIFIER", 24, 34]]], ["Furthermore, the majority of residents Applying pledgets in nose prior to endoscopy 43% (22) Nasolaryngoscopy performed by attending or fellow only 18% (9) Require approval by attending or senior resident 10% (5) Attending call/rotation changes Attendings covering (or covering more) primary call 10% (5) Attendings covering fewer hospital sites 14% (7) Resident call/rotation changes Senior residents now covering (or covering more) primary call 33% (17) Residents covering fewer hospital sites 8% (4) Cohorted residents* 37% (19) Residents alternating at hospitals weekly 29% (15) There was a statistically significant difference in average scores between junior and senior residents when asked to rate risk level between junior and senior residents (P < .05).", [["nose", "ORGAN", 60, 64], ["endoscopy", "TEST", 74, 83], ["significant", "OBSERVATION_MODIFIER", 609, 620], ["difference", "OBSERVATION", 621, 631]]], ["The majority of residents rated residents at a higher risk level than attendings for contracting COVID-19.", [["contracting COVID", "TEST", 85, 102]]], ["COVID-19 = coronavirus 2019. departmental response, and 88% of residents felt \"extremely comfortable\" or \"somewhat comfortable\" with communicating their concerns.", [["COVID", "TEST", 0, 5], ["coronavirus", "PROBLEM", 11, 22]]], ["A minority of residents were dissatisfied with their program response (16%) and uncomfortable communicating their concerns to their department (7%).", [["uncomfortable", "PROBLEM", 80, 93]]], ["Satisfaction level was strongly correlated with comfort in communicating their concerns (r = 0.72, P < .00001) and inversely correlated with resident perception of increased risk of contracting COVID-19 relative to attendings (r = \u22120.52, P < .00001).", [["contracting COVID", "TEST", 182, 199], ["increased", "OBSERVATION_MODIFIER", 164, 173]]], ["Furthermore, residents at programs with departmental policy changes by March 17, 2020 (the average date of department policy change among programs), had higher average satisfaction scores than residents at programs that implemented changes at a later date (4.23 AE 0.94 vs. 3.30 AE 1.56, P = .002).DISCUSSIONThis is the first study to assess the response of OHNS residency programs to a pandemic and resident perceptions of these changes.", [["P", "TEST", 288, 289], ["the first study", "TEST", 316, 331]]], ["Less common adjunctive measures included shared primary call burden by attendings and senior residents.DISCUSSIONThe majority of residency programs also made changes to the practice of aerosol-generating procedures, such as nasolaryngoscopy, that were congruent with recommendations by the AAO-HNS.", [["aerosol-generating procedures", "TREATMENT", 185, 214], ["nasolaryngoscopy", "TREATMENT", 224, 240]]], ["18, 19 A majority of programs (63%) eliminated nasal sprays prior to endoscopy.", [["nasal", "ANATOMY", 47, 52], ["nasal sprays", "TREATMENT", 47, 59], ["endoscopy", "TEST", 69, 78]]], ["Alternatively, 43% of programs started using pledgets to achieve topical anesthesia or decongestion for endoscopies, which may have value in curbing the sneeze reflex and subsequent aerosolization of droplets.", [["pledgets", "TREATMENT", 45, 53], ["topical anesthesia", "TREATMENT", 65, 83], ["decongestion", "TREATMENT", 87, 99], ["endoscopies", "TREATMENT", 104, 115], ["subsequent aerosolization of droplets", "TREATMENT", 171, 208]]], ["Furthermore, the vast majority of residents started using filtering respirators for aerosol-generating procedures regardless of patient COVID-19 status or symptoms.", [["patient", "ORGANISM", 128, 135], ["patient", "SPECIES", 128, 135], ["filtering respirators", "TREATMENT", 58, 79], ["aerosol-generating procedures", "TREATMENT", 84, 113], ["patient COVID", "TEST", 128, 141], ["symptoms", "PROBLEM", 155, 163]]], ["In a minority of programs, flexible laryngoscopy was performed by only attendings or fellows.", [["flexible laryngoscopy", "TEST", 27, 48]]], ["These policies are consistent with recently published anesthesiology guidelines 20 which noted that sometimes the most appropriate airway managers are senior-level physicians.", [["airway", "ANATOMY", 131, 137], ["airway", "MULTI-TISSUE_STRUCTURE", 131, 137], ["consistent with", "UNCERTAINTY", 19, 34]]], ["Another potential practice change, not assessed in this study, involves laryngoscopy equipment options.", [["this study", "TEST", 51, 61], ["laryngoscopy equipment options", "TREATMENT", 72, 102]]], ["An OHNS department in China 21 recommended using the smallest-diameter flexible laryngoscopes available.", [["the smallest-diameter flexible laryngoscopes", "TREATMENT", 49, 93]]], ["Meanwhile, our institution has transitioned to disposable flexible video laryngoscopes to further minimize risk of disease transmission during transport and sterile processing of reusable endoscopes.DISCUSSIONThe changes to tracheotomy care seen in this study echoed similar themes from the AAO-HNS position statement regarding tracheotomy recommendations during the COVID-19 pandemic.", [["disposable flexible video laryngoscopes", "TREATMENT", 47, 86], ["disease transmission", "PROBLEM", 115, 135], ["sterile processing of reusable endoscopes", "TREATMENT", 157, 198], ["tracheotomy care", "TREATMENT", 224, 240], ["this study", "TEST", 249, 259], ["tracheotomy", "TREATMENT", 328, 339], ["the COVID", "TEST", 363, 372], ["pandemic", "PROBLEM", 376, 384], ["disease", "OBSERVATION", 115, 122], ["tracheotomy", "OBSERVATION", 224, 235]]], ["22 Most programs reported a reduction in the frequency of tracheotomy tube changes to prioritize the safety of HCWs.", [["tube", "TISSUE", 70, 74], ["tracheotomy tube changes", "TREATMENT", 58, 82], ["reduction", "OBSERVATION_MODIFIER", 28, 37], ["tracheotomy tube", "OBSERVATION", 58, 74]]], ["In addition, for COVID-19positive patients, the AAO-HNS recommended performing tracheotomy no sooner than 2 to 3 weeks after intubation and utilizing heat moisture exchange devices when the patient no longer requires mechanical ventilation, regardless of COVID status.", [["patients", "ORGANISM", 34, 42], ["patient", "ORGANISM", 190, 197], ["patients", "SPECIES", 34, 42], ["patient", "SPECIES", 190, 197], ["COVID", "TEST", 17, 22], ["tracheotomy", "TREATMENT", 79, 90], ["intubation", "TREATMENT", 125, 135], ["heat moisture exchange devices", "TREATMENT", 150, 180], ["mechanical ventilation", "TREATMENT", 217, 239], ["COVID status", "PROBLEM", 255, 267]]], ["We suspect specific institutional guidelines regarding tracheotomy procedures and routine care will evolve in response to this position statement.DISCUSSIONIt is notable that two-thirds of the residents who were surveyed perceived their risk of contracting COVID-19 as higher than that of their attendings, and this increased perception of risk correlated with reduced resident satisfaction.", [["tracheotomy procedures", "TREATMENT", 55, 77], ["routine care", "TREATMENT", 82, 94], ["contracting COVID", "TEST", 245, 262]]], ["Prior studies suggest that risk perceptions among HCWs may have psychosocial implications.", [["Prior studies", "TEST", 0, 13]]], ["In a study of over 10 thousand Singapore HCWs who worked during the 2002 SARS outbreak, 76% perceived a great personal risk of contracting SARS.", [["SARS", "DISEASE", 73, 77], ["SARS", "DISEASE", 139, 143], ["contracting SARS", "PROBLEM", 127, 143], ["contracting SARS", "OBSERVATION", 127, 143]]], ["14 HCWs at SARS-affected institutions expressed significantly higher levels of anxiety than their counterparts at unaffected institutions, 14 which had ramifications on long-term psychological stress and burnout.", [["SARS", "DISEASE", 11, 15], ["anxiety", "DISEASE", 79, 86], ["burnout", "DISEASE", 204, 211], ["anxiety", "PROBLEM", 79, 86]]], ["15 A longer duration of perceived risk of contracting SARS also correlated adversely with burnout, posttraumatic stress, and maladaptive coping mechanisms.DISCUSSIONOur survey results show that, in addition to creating risk-mitigating policies, OHNS programs have taken measures to manage risk with greater faculty oversight.", [["SARS", "DISEASE", 54, 58], ["burnout", "DISEASE", 90, 97], ["posttraumatic stress", "DISEASE", 99, 119], ["contracting SARS", "PROBLEM", 42, 58], ["posttraumatic stress", "PROBLEM", 99, 119], ["maladaptive coping mechanisms", "PROBLEM", 125, 154], ["OHNS programs", "TREATMENT", 245, 258]]], ["For example, residents at some programs discussed flexible laryngoscopy with attendings before performing the procedure or attendings performed it themselves.", [["flexible laryngoscopy", "TEST", 50, 71], ["the procedure", "TREATMENT", 106, 119]]], ["Such efforts serve as examples of increased teamwork and communication, which have been shown to reduce perceived risk in a study of HCWs during the 2014 to 2016 Ebola outbreak.", [["Ebola", "DISEASE", 162, 167], ["a study", "TEST", 122, 129]]], ["23 Communication within OHNS hospital teams may also serve as a form of social support, which has been shown to be protective against HCW anxiety and stress during the COVID-19 pandemic in Wuhan, China.", [["anxiety", "DISEASE", 138, 145], ["social support", "TREATMENT", 72, 86], ["HCW anxiety", "PROBLEM", 134, 145], ["stress", "PROBLEM", 150, 156], ["the COVID", "TEST", 164, 173]]], ["24 Taken together, enhanced communication and a supportive network within OHNS departments are vital to survive the high-stress clinical situations associated with the COVID-19 pandemic.DISCUSSIONAlthough concerns about personal anxiety and burnout were least prevalent in our survey, over half of survey respondents were at least moderately concerned about burnout for themselves or for coresidents.", [["personal anxiety", "DISEASE", 220, 236], ["burnout", "DISEASE", 241, 248], ["burnout", "DISEASE", 358, 365], ["the COVID", "TEST", 164, 173], ["personal anxiety", "PROBLEM", 220, 236]]], ["25 Elements that improve meaning in work include direct patient care, intellectual engagement, respect, and community.", [["patient", "ORGANISM", 56, 63], ["patient", "SPECIES", 56, 63], ["direct patient care", "TREATMENT", 49, 68]]], ["Clinical practice during the present COVID-19 pandemic presents residents with unique opportunities for meaningful and necessary work in direct patient care.", [["patient", "ORGANISM", 144, 151], ["patient", "SPECIES", 144, 151], ["direct patient care", "TREATMENT", 137, 156]]], ["For instance, the creation of three daily, multi-institutional, OHNS-specific, virtual teaching forums 26- with accessible educational opportunities during a time of social isolation.", [["social isolation", "TREATMENT", 166, 182]]], ["Looking ahead, open communication and an integrated team approach within and between OHNS departments will be essential to provide efficient and thoughtful care to patients and providers alike in the months to come.", [["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 164, 172]]], ["There were limitations to this cross-sectional survey study.", [["this cross-sectional survey study", "TEST", 26, 59]]], ["This may have been further amplified if different programs implemented changes at different rates based on local COVID-19 infection rates.", [["infection", "DISEASE", 122, 131], ["local COVID", "TEST", 107, 118], ["infection rates", "PROBLEM", 122, 137], ["infection", "OBSERVATION", 122, 131]]], ["We tried to minimize this limitation by capturing survey responses within a short time interval of 6 days to reflect programs' initial planning phases for the pandemic.", [["the pandemic", "PROBLEM", 155, 167]]], ["Furthermore, selfreflective risk level comparisons are subject to bias, and the elective nature of the survey may allow for selection bias.", [["selection bias", "TEST", 124, 138]]], ["Further follow-up surveys of OHNS residents will be essential to characterize practice patterns, perceptions, and stressors for burnout during the course of the COVID-19 pandemic.", [["burnout", "DISEASE", 128, 135], ["burnout", "PROBLEM", 128, 135], ["the COVID", "TEST", 157, 166], ["pandemic", "PROBLEM", 170, 178]]], ["We believe these efforts are valuable and time-sensitive, particularly as we potentially face multiple waves of the COVID-19 pandemic.CONCLUSIONThe field of OHNS has been responsive to the COVID-19 pandemic across all geographic regions in the United States.", [["OHNS", "CHEMICAL", 157, 161], ["OHNS", "CANCER", 157, 161], ["the COVID", "TEST", 112, 121], ["pandemic", "PROBLEM", 125, 133], ["the COVID", "TEST", 185, 194]]], ["Common clinical practice and procedural changes included reducing resident staffing of the operating rooms, limiting nonurgent clinics and consults, creating separate team cohorts, and reducing risks associated with aerosol-generating procedures.", [["aerosol-generating procedures", "TREATMENT", 216, 245]]], ["OHNS residents are most concerned about PPE shortages and transmitting COVID-19 to others.", [["COVID-19", "CHEMICAL", 71, 79], ["PPE shortages", "PROBLEM", 40, 53], ["transmitting COVID", "TEST", 58, 76]]], ["Overall, the majority of residents were satisfied with their department's response to COVID-19.", [["COVID-19", "CHEMICAL", 86, 94], ["COVID-19", "DNA", 86, 94], ["COVID", "TEST", 86, 91]]], ["Residents' satisfaction correlated with their level of comfort in discussing concerns with their attendings and inversely correlated with perceptions of increased risk of contracting COVID-19 relative to their attendings.", [["contracting COVID", "PROBLEM", 171, 188]]], ["As our field moves past the initial phase of the COVID-19 pandemic, OHNS residency programs should continue to evolve practice changes in response to resource and clinical needs as well as engage residents in open communication in order to effectively address sources of anxiety related to this healthcare crisis.", [["anxiety", "DISEASE", 271, 278], ["open communication", "TREATMENT", 209, 227], ["anxiety", "PROBLEM", 271, 278], ["this healthcare crisis", "PROBLEM", 290, 312]]]], "d95e3ed1bd0305406b52487d66310ad26cd5b9d3": [["EDITOR'S LETTERCoronavirus disease 2019 (COVID-19) caused by \"Severe acute respiratory syndrome coronavirus 2\" (SARS-CoV-2) was first reported in China.", [["COVID-19", "CHEMICAL", 41, 49], ["acute respiratory syndrome coronavirus", "DISEASE", 69, 107], ["SARS", "DISEASE", 112, 116], ["SARS-CoV-2", "ORGANISM", 112, 122], ["Severe acute respiratory syndrome coronavirus", "SPECIES", 62, 107], ["SARS-CoV-2", "SPECIES", 112, 122], ["LETTERCoronavirus disease", "PROBLEM", 9, 34], ["COVID", "TEST", 41, 46], ["Severe acute respiratory syndrome coronavirus", "PROBLEM", 62, 107], ["Severe", "OBSERVATION_MODIFIER", 62, 68], ["acute", "OBSERVATION_MODIFIER", 69, 74], ["respiratory syndrome", "OBSERVATION", 75, 95]]], ["[1] \ue062is is the third extremely pathogenic human coronavirus which has emerged recently after severe acute respiratory syndrome (SARS) coronavirus and Middle East respiratory syndrome (MERS) coronavirus.", [["human coronavirus", "DISEASE", 42, 59], ["acute respiratory syndrome (SARS) coronavirus", "DISEASE", 100, 145], ["Middle East respiratory syndrome (MERS) coronavirus", "DISEASE", 150, 201], ["human", "ORGANISM", 42, 47], ["Middle East respiratory", "ORGANISM", 150, 173], ["MERS) coronavirus", "ORGANISM", 184, 201], ["human", "SPECIES", 42, 47], ["coronavirus", "SPECIES", 48, 59], ["coronavirus", "SPECIES", 134, 145], ["human coronavirus", "SPECIES", 42, 59], ["Middle East respiratory syndrome (MERS) coronavirus", "SPECIES", 150, 201], ["the third extremely pathogenic human coronavirus", "PROBLEM", 11, 59], ["severe acute respiratory syndrome", "PROBLEM", 93, 126], ["SARS) coronavirus", "PROBLEM", 128, 145], ["Middle East respiratory syndrome", "PROBLEM", 150, 182], ["coronavirus", "PROBLEM", 190, 201], ["human coronavirus", "OBSERVATION", 42, 59], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["acute", "OBSERVATION_MODIFIER", 100, 105], ["respiratory syndrome", "OBSERVATION", 106, 126], ["Middle", "ANATOMY_MODIFIER", 150, 156], ["respiratory syndrome", "OBSERVATION", 162, 182]]], ["SARS-CoV-2 is mainly transmitted by person-to-person contact in community and health-care settings.", [["SARS", "DISEASE", 0, 4], ["person", "SPECIES", 36, 42], ["person", "SPECIES", 46, 52], ["SARS-CoV", "SPECIES", 0, 8]]], ["[2] \ue062is pattern of spread demands large-scale and proactive measures to avoid further widespread dissemination.", [["spread demands", "PROBLEM", 19, 33], ["proactive measures", "TREATMENT", 50, 68], ["further widespread dissemination", "PROBLEM", 78, 110], ["widespread", "OBSERVATION_MODIFIER", 86, 96], ["dissemination", "OBSERVATION", 97, 110]]], ["SARS-CoV-2 survives on contaminated dry surfaces and fomites, which facilitate hand to mucous membranes (of the mouth, nose, and eyes) spread.", [["fomites", "ANATOMY", 53, 60], ["hand", "ANATOMY", 79, 83], ["mucous membranes", "ANATOMY", 87, 103], ["mouth", "ANATOMY", 112, 117], ["nose", "ANATOMY", 119, 123], ["eyes", "ANATOMY", 129, 133], ["SARS", "DISEASE", 0, 4], ["hand", "ORGANISM_SUBDIVISION", 79, 83], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 87, 103], ["mouth", "ORGANISM_SUBDIVISION", 112, 117], ["nose", "ORGANISM_SUBDIVISION", 119, 123], ["eyes", "ORGAN", 129, 133], ["SARS", "PROBLEM", 0, 4], ["contaminated dry surfaces", "TREATMENT", 23, 48], ["mucous membranes", "ANATOMY", 87, 103], ["mouth", "ANATOMY", 112, 117], ["nose", "ANATOMY", 119, 123], ["eyes", "ANATOMY", 129, 133]]], ["[3, 4] \ue062is emphasizes the significance of in-depth knowledge about the perseverance of coronavirus on inanimate surfaces.", [["[3, 4] \ue062is", "SIMPLE_CHEMICAL", 0, 10], ["coronavirus", "ORGANISM", 87, 98], ["coronavirus", "PROBLEM", 87, 98], ["coronavirus", "OBSERVATION", 87, 98]]], ["[5] Various fixatives and biocidal agents are widely used in health-care settings including cytopathology laboratories which may impact (and help negate) the spread of this virus.", [["biocidal agents", "SIMPLE_CHEMICAL", 26, 41], ["Various fixatives", "TREATMENT", 4, 21], ["biocidal agents", "TREATMENT", 26, 41], ["cytopathology laboratories", "TEST", 92, 118], ["this virus", "PROBLEM", 168, 178]]], ["[6, 7] \ue062e current review summarizes the available relevant data on this topic about cytopathology laboratory protocols and suggests precautions based on this data. \ue062ese recommendations may change as new information comes to light.", [["cytopathology laboratory protocols", "TEST", 84, 118], ["precautions", "TREATMENT", 132, 143], ["this data", "TEST", 153, 162]]], ["Each institution and laboratory has to adapt and adjust depending on local regulatory limitations. \ue062e recommendations suggested at the end of the review discussion should be considered with these things in mind.EDITOR'S LETTERAt present, the diagnosis of COVID 19 is mostly being accomplished by performing real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) for SARS-CoV-2 on respiratory specimens such as nasopharyngeal swabs.", [["respiratory specimens", "ANATOMY", 393, 414], ["nasopharyngeal swabs", "ANATOMY", 423, 443], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 379, 389], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 423, 443], ["reverse transcriptase", "PROTEIN", 317, 338], ["SARS-CoV", "SPECIES", 379, 387], ["polymerase chain reaction", "PROBLEM", 339, 364], ["rRT", "TEST", 366, 369], ["PCR", "TEST", 370, 373], ["SARS", "PROBLEM", 379, 383], ["CoV", "TEST", 384, 387], ["respiratory specimens", "TEST", 393, 414], ["nasopharyngeal swabs", "TREATMENT", 423, 443], ["nasopharyngeal", "ANATOMY", 423, 437]]], ["[8] \ue062e primary mode of spread, which has led to the global pandemic, is the respiratory route.", [["respiratory", "ANATOMY", 76, 87], ["global", "OBSERVATION_MODIFIER", 52, 58], ["pandemic", "OBSERVATION", 59, 67]]], ["A report studying different types of clinical specimens from patients (most cases 1-3 days after hospital admission) detected a positive PCR test in about 1% (n = 307) of blood samples, suggesting the systemic nature of the disease in at least a portion of the cases.", [["specimens", "ANATOMY", 46, 55], ["blood samples", "ANATOMY", 171, 184], ["specimens", "CANCER", 46, 55], ["patients", "ORGANISM", 61, 69], ["blood samples", "ORGANISM_SUBSTANCE", 171, 184], ["patients", "SPECIES", 61, 69], ["clinical specimens", "TEST", 37, 55], ["a positive PCR test", "PROBLEM", 126, 145], ["blood samples", "TEST", 171, 184], ["the disease", "PROBLEM", 220, 231], ["systemic", "OBSERVATION_MODIFIER", 201, 209], ["disease", "OBSERVATION", 224, 231]]], ["[9] \ue062is study also reported positive results in 29% (n = 153) of fecal samples.", [["fecal samples", "ANATOMY", 65, 78], ["fecal samples", "CANCER", 65, 78], ["\ue062is study", "TEST", 4, 13], ["fecal samples", "TEST", 65, 78], ["fecal", "ANATOMY", 65, 70]]], ["[9] Although tests based on PCR have been reported positive in non-respiratory specimens, it does equate with infectivity and so the non-respiratory route of viral transmission is possible but is not proven at this stage.EDITOR'S LETTERAs mentioned previously, the molecular test to detect SARS-CoV-2 is based on rRT-PCR. \ue062is test amplifies viral RNA in a patient's specimen for the detection of SARS-CoV-2 genetic material.", [["non-respiratory specimens", "ANATOMY", 63, 88], ["specimen", "ANATOMY", 366, 374], ["SARS", "DISEASE", 290, 294], ["SARS", "DISEASE", 396, 400], ["SARS-CoV-2", "ORGANISM", 290, 300], ["patient", "ORGANISM", 356, 363], ["rRT", "DNA", 313, 316], ["viral RNA", "RNA", 341, 350], ["patient", "SPECIES", 356, 363], ["SARS-CoV", "SPECIES", 290, 298], ["SARS-CoV", "SPECIES", 396, 404], ["tests", "TEST", 13, 18], ["PCR", "TEST", 28, 31], ["non-respiratory specimens", "TEST", 63, 88], ["infectivity", "PROBLEM", 110, 121], ["viral transmission", "PROBLEM", 158, 176], ["the molecular test", "TEST", 261, 279], ["SARS", "TEST", 290, 294], ["CoV", "TEST", 295, 298], ["rRT", "TEST", 313, 316], ["\ue062is test", "TEST", 322, 330], ["viral RNA", "PROBLEM", 341, 350], ["a patient's specimen", "TEST", 354, 374], ["the detection", "TEST", 379, 392], ["SARS", "PROBLEM", 396, 400], ["CoV", "TEST", 401, 404]]], ["[10] False negatives are possible due to multiple variables including simple technical errors, inadequate collection, improper handling, and shipping.", [["False negatives", "TEST", 5, 20], ["multiple variables", "PROBLEM", 41, 59], ["simple technical errors", "PROBLEM", 70, 93], ["inadequate collection", "PROBLEM", 95, 116], ["improper handling", "PROBLEM", 118, 135], ["simple", "OBSERVATION_MODIFIER", 70, 76], ["technical errors", "OBSERVATION", 77, 93], ["inadequate", "OBSERVATION_MODIFIER", 95, 105], ["collection", "OBSERVATION", 106, 116], ["improper handling", "OBSERVATION", 118, 135]]], ["[11] One study comparing rRT-PCR with computerized tomography (CT), reports that the sensitivity of the test is only 70%.", [["One study", "TEST", 5, 14], ["rRT", "TEST", 25, 28], ["PCR", "TEST", 29, 32], ["computerized tomography (CT", "TEST", 38, 65], ["the test", "TEST", 100, 108]]], ["[12] Further compounding the issue, the sensitivity may be lower in some symptomatic cases due to a smaller viral load, [13] but usually the viral load is higher in the early stages of the disease.", [["the sensitivity", "TEST", 36, 51], ["a smaller viral load", "PROBLEM", 98, 118], ["the viral load", "TEST", 137, 151], ["the disease", "PROBLEM", 185, 196], ["smaller", "OBSERVATION_MODIFIER", 100, 107], ["viral load", "OBSERVATION", 108, 118], ["viral load", "OBSERVATION", 141, 151], ["higher", "OBSERVATION_MODIFIER", 155, 161], ["early stages", "OBSERVATION_MODIFIER", 169, 181], ["disease", "OBSERVATION", 189, 196]]], ["However, newer tests suggest higher sensitivity with the potential of false positives due to very high sensitivity and possible cross contaminations during the pandemic with the widespread presence of virus (at the level of collection of sample and later during the technical procedure).EDITOR'S LETTERAs a result, even if the specimen in the cytopathology laboratory is not expected to be positive or even if the molecular test is negative for SARS-CoV-2, all of the specimens should be considered potentially positive.", [["specimen", "ANATOMY", 327, 335], ["specimens", "ANATOMY", 468, 477], ["SARS", "DISEASE", 445, 449], ["SARS-CoV-2", "ORGANISM", 445, 455], ["specimens", "CANCER", 468, 477], ["SARS-CoV", "SPECIES", 445, 453], ["newer tests", "TEST", 9, 20], ["higher sensitivity", "PROBLEM", 29, 47], ["false positives", "PROBLEM", 70, 85], ["very high sensitivity", "PROBLEM", 93, 114], ["cross contaminations", "PROBLEM", 128, 148], ["the pandemic", "PROBLEM", 156, 168], ["virus", "PROBLEM", 201, 206], ["the technical procedure", "TREATMENT", 262, 285], ["the specimen", "TEST", 323, 335], ["the cytopathology laboratory", "TEST", 339, 367], ["the molecular test", "TEST", 410, 428], ["SARS", "PROBLEM", 445, 449], ["CoV", "TEST", 450, 453], ["the specimens", "TEST", 464, 477], ["virus", "OBSERVATION", 201, 206]]], ["It is therefore mandatory to practice all the universal/standard precautions with basic protective measures while handling any biological specimen irrespective of SARS-CoV-2 status [Tables 1 -3] .", [["specimen", "ANATOMY", 138, 146], ["universal/standard precautions", "TREATMENT", 46, 76], ["basic protective measures", "TREATMENT", 82, 107], ["SARS", "TEST", 163, 167]]], ["[14] [15] [16] All cytology personnel should follow the basic protective measures against SARS-CoV-2 recommended by the World Health Organization (WHO) [ Table 2 ].", [["SARS", "DISEASE", 90, 94], ["[14] [15] [16", "SIMPLE_CHEMICAL", 0, 13], ["All cytology", "TEST", 15, 27], ["SARS", "PROBLEM", 90, 94]]], ["[16] Although, appropriate disinfectants and precautions related to cytopathological/histological fixation and processing of samples during the current COVID 19 pandemic are not known, information can likely be extrapolated from other recent coronaviruses (e.g., SARS and MERS).", [["samples", "ANATOMY", 125, 132], ["SARS", "DISEASE", 263, 267], ["coronaviruses", "ORGANISM", 242, 255], ["appropriate disinfectants", "TREATMENT", 15, 40], ["precautions", "TREATMENT", 45, 56], ["cytopathological/histological fixation", "TREATMENT", 68, 106], ["other recent coronaviruses", "PROBLEM", 229, 255], ["SARS", "PROBLEM", 263, 267], ["histological fixation", "OBSERVATION", 85, 106], ["coronaviruses", "OBSERVATION", 242, 255]]], ["Similar Table 3 : Summary of the Interim Laboratory Biosafety Guidelines from the CDC for the specimens suspected for or positive for SARS-CoV-2.", [["specimens", "ANATOMY", 94, 103], ["SARS", "DISEASE", 134, 138], ["SARS-CoV", "SPECIES", 134, 142], ["the CDC", "TEST", 78, 85], ["the specimens", "TEST", 90, 103], ["SARS", "PROBLEM", 134, 138], ["CoV", "TEST", 139, 142]]], ["Follow standard precautions when handling clinical specimens, all of which may contain potentially infectious materials mentioned in Table 1 .", [["specimens", "ANATOMY", 51, 60], ["handling clinical specimens", "TEST", 33, 60], ["infectious", "OBSERVATION", 99, 109]]], ["Any technique which may generate aerosols or droplets (e.g., squirting [instead of gently delivering as tiny drops] of the specimen through a needle, vertexing) should be avoided, but is required to be practiced then it should be executed in a certified Class II Biological Safety Cabinet (BSC).", [["specimen", "ANATOMY", 123, 131], ["Any technique", "TREATMENT", 0, 13], ["gently delivering as tiny drops", "TREATMENT", 83, 114], ["a needle, vertexing)", "TREATMENT", 140, 160]]], ["Similarly, for centrifugation suitable physical containment should be practiced with securely capped specimen tubes.", [["centrifugation suitable physical containment", "TREATMENT", 15, 59], ["securely capped specimen tubes", "TREATMENT", 85, 115], ["specimen tubes", "OBSERVATION", 101, 115]]], ["Ideally, such procedures should also be performed in a Class II Biological Safety Cabinet.", [["such procedures", "TREATMENT", 9, 24]]], ["Clean and disinfect the equipment(s) and work surfaces after specimens are processed using appropriate disinfectants which are used for disinfecting other respiratory pathogens, such as other human coronaviruses and seasonal influenza viruses.", [["specimens", "ANATOMY", 61, 70], ["influenza viruses", "DISEASE", 225, 242], ["human", "ORGANISM", 192, 197], ["seasonal influenza viruses", "ORGANISM", 216, 242], ["human", "SPECIES", 192, 197], ["human coronaviruses", "SPECIES", 192, 211], ["appropriate disinfectants", "TREATMENT", 91, 116], ["disinfecting other respiratory pathogens", "PROBLEM", 136, 176], ["other human coronaviruses", "PROBLEM", 186, 211], ["seasonal influenza viruses", "PROBLEM", 216, 242], ["disinfect", "OBSERVATION", 10, 19], ["influenza viruses", "OBSERVATION", 225, 242]]], ["Practice standard procedures applied for other respiratory pathogens, such as other human coronaviruses and seasonal influenza viruses.", [["influenza viruses", "DISEASE", 117, 134], ["human", "ORGANISM", 84, 89], ["seasonal influenza viruses", "ORGANISM", 108, 134], ["human", "SPECIES", 84, 89], ["human coronaviruses", "SPECIES", 84, 103], ["Practice standard procedures", "TREATMENT", 0, 28], ["other respiratory pathogens", "PROBLEM", 41, 68], ["other human coronaviruses", "PROBLEM", 78, 103], ["seasonal influenza viruses", "PROBLEM", 108, 134], ["respiratory", "ANATOMY", 47, 58], ["pathogens", "OBSERVATION", 59, 68], ["influenza viruses", "OBSERVATION", 117, 134]]], ["If the diagnostic testing specimens are processed outside of a BSL-2 laboratory, [33] such as preparation of cytology direct smears, rinsing of FNAB aspirates for cell block, the Standard Precautions (similar to those mentioned under Table 1 ) should be practiced as a barrier between the specimen and personnel.", [["specimens", "ANATOMY", 26, 35], ["FNAB aspirates", "ANATOMY", 144, 158], ["cell", "ANATOMY", 163, 167], ["specimen", "ANATOMY", 289, 297], ["specimens", "CANCER", 26, 35], ["cell", "CELL", 163, 167], ["the diagnostic testing specimens", "TEST", 3, 35], ["a BSL", "TEST", 61, 66], ["cytology direct smears", "TEST", 109, 131], ["FNAB aspirates", "TEST", 144, 158], ["cell block", "TREATMENT", 163, 173], ["the Standard Precautions", "TREATMENT", 175, 199]]], ["Preparation and fixing of cytology smears should be performed under certified a Class II [35] Biological Safety Cabinet.", [["cytology smears", "TEST", 26, 41]]], ["Table 1 : Standard precautions -Summary modified for cytopathology laboratory specimens based on the CDC guidelines.", [["specimens", "ANATOMY", 78, 87], ["cytopathology laboratory specimens", "TEST", 53, 87]]], ["[14, 15] 1.", [["[14, 15] 1", "SIMPLE_CHEMICAL", 0, 10]]], ["Ensure that the technologist use personal protective equipment (PPE) such as medical mask, gloves, eye protection, and a long-sleeved gown.", [["eye", "ANATOMY", 99, 102], ["eye", "ORGANISM_SUBDIVISION", 99, 102], ["personal protective equipment (PPE)", "TREATMENT", 33, 68], ["medical mask", "TREATMENT", 77, 89], ["gloves", "TREATMENT", 91, 97], ["eye protection", "TREATMENT", 99, 113], ["a long-sleeved gown", "TREATMENT", 119, 138], ["eye", "ANATOMY", 99, 102]]], ["If the specimen with potential of aerosol-generation, such as squirting of aspirates from fine-needle aspiration biopsy procedure is being processed, the personnel should wear at least the protective mask such as NIOSH certified N95, an EU standard FFP2, or the equivalent.", [["specimen", "ANATOMY", 7, 15], ["aspirates", "ANATOMY", 75, 84], ["aerosol-generation", "TREATMENT", 34, 52], ["aspirates", "TEST", 75, 84], ["fine-needle aspiration biopsy procedure", "TREATMENT", 90, 129], ["the protective mask", "TREATMENT", 185, 204]]], ["All personnel involved in handling and transporting the specimens should be trained for safely handling the process, including spill decontamination methods.", [["specimens", "ANATOMY", 56, 65], ["spill decontamination methods", "TREATMENT", 127, 156]]], ["Transport the primary specimen container with the patient's label in a leak-proof secondary containers, such as sealable plastic biohazard specimen bag with properly filled laboratory requisition.", [["specimen", "ANATOMY", 22, 30], ["patient", "ORGANISM", 50, 57], ["patient", "SPECIES", 50, 57], ["a leak-proof secondary containers", "TREATMENT", 69, 102], ["sealable plastic biohazard specimen bag", "TREATMENT", 112, 151]]], ["Adhere to all biosafety practices including transport precautions (6c) depending on the pathophysiology of the organism being considered.", [["all biosafety practices", "TREATMENT", 10, 33], ["transport precautions", "TREATMENT", 44, 65], ["the organism", "PROBLEM", 107, 119]]], ["Preferably transport fresh, unfixed specimens by hand, and DO NOT ship the specimen with pneumatic-tube systems.", [["specimens", "ANATOMY", 36, 45], ["hand", "ANATOMY", 49, 53], ["specimen", "ANATOMY", 75, 83], ["hand", "ORGANISM_SUBDIVISION", 49, 53], ["tube", "TISSUE", 99, 103], ["pneumatic-tube systems", "TREATMENT", 89, 111], ["tube systems", "OBSERVATION", 99, 111]]], ["Each specimen must be clearly labeled with at least two patient identifiers including full name and date of birth with other details with specific warnings as applicable (e.g., suspected or confirmed SARS-CoV-2 virus) on the form.", [["specimen", "ANATOMY", 5, 13], ["patient", "ORGANISM", 56, 63], ["SARS-CoV-2 virus", "ORGANISM", 200, 216], ["patient", "SPECIES", 56, 63], ["CoV-2 virus", "SPECIES", 205, 216], ["SARS-CoV-2 virus", "SPECIES", 200, 216], ["SARS", "PROBLEM", 200, 204]]], ["Wash your hands frequently with soap and water counting up to 20 (approx.", [["soap and water", "TREATMENT", 32, 46]]], ["Maintain social distancing and maintain at least 1 m (3 ft) distance between yourself and anyone to avoid droplet/ microparticle infection due to coughing, sneezing, and even talking.", [["infection", "DISEASE", 129, 138], ["coughing", "DISEASE", 146, 154], ["sneezing", "DISEASE", 156, 164], ["droplet/ microparticle infection", "PROBLEM", 106, 138], ["coughing", "PROBLEM", 146, 154], ["sneezing", "PROBLEM", 156, 164], ["infection", "OBSERVATION", 129, 138]]], ["Avoid touching face (eyes, nose, and mouth) is the most important component as final personal protection.", [["face", "ANATOMY", 15, 19], ["eyes", "ANATOMY", 21, 25], ["nose", "ANATOMY", 27, 31], ["mouth", "ANATOMY", 37, 42], ["eyes", "ORGAN", 21, 25], ["nose", "ORGANISM_SUBDIVISION", 27, 31], ["mouth", "ORGANISM_SUBDIVISION", 37, 42], ["touching face (eyes, nose, and mouth", "PROBLEM", 6, 42], ["eyes", "ANATOMY", 21, 25], ["nose", "ANATOMY", 27, 31], ["mouth", "ANATOMY", 37, 42]]], ["Studies showed that rate of unknowingly touching the face is up to 15-23/h.", [["Studies", "TEST", 0, 7], ["face", "ANATOMY", 53, 57]]], ["[38, 39] \ue062e most probable mode of getting infection is from many inanimate surfaces [ Table 4 ]. d.", [["infection", "DISEASE", 42, 51], ["getting infection", "PROBLEM", 34, 51], ["infection", "OBSERVATION", 42, 51]]], ["If you are sick with fever, cough, or difficulty breathing, seek medical advice early and stay informed to follow updated advice by your health-care provider and official resources. protocols should be effective to disinfect and inactivate SARS-CoV-2.", [["fever", "DISEASE", 21, 26], ["cough", "DISEASE", 28, 33], ["SARS", "DISEASE", 240, 244], ["SARS-CoV-2", "ORGANISM", 240, 250], ["SARS-CoV", "SPECIES", 240, 248], ["sick", "PROBLEM", 11, 15], ["fever", "PROBLEM", 21, 26], ["cough", "PROBLEM", 28, 33], ["difficulty breathing", "PROBLEM", 38, 58], ["protocols", "TREATMENT", 182, 191]]], ["[17] \ue062us, once the processing is complete as cytopathologic preparation and after formalin fixation and paraffin embedding for cell-blocks, SARS-CoV-2 if present in the specimen should be inactive.", [["cell", "ANATOMY", 127, 131], ["specimen", "ANATOMY", 169, 177], ["formalin", "CHEMICAL", 82, 90], ["paraffin", "CHEMICAL", 104, 112], ["cell", "CELL", 127, 131], ["SARS-CoV-2", "ORGANISM", 140, 150], ["specimen", "CANCER", 169, 177], ["cytopathologic preparation", "TREATMENT", 45, 71], ["formalin fixation", "TREATMENT", 82, 99], ["paraffin embedding", "TREATMENT", 104, 122], ["cell-blocks", "TREATMENT", 127, 138], ["SARS", "PROBLEM", 140, 144], ["CoV", "TEST", 145, 148]]], ["[17] A study reported that aerosol and fomite transmission of SARS-CoV-2 is possible because the pathogen continues to be infectious for hours in aerosols and for days on surfaces.", [["SARS", "DISEASE", 62, 66], ["SARS-CoV-2", "ORGANISM", 62, 72], ["SARS-CoV", "SPECIES", 62, 70], ["A study", "TEST", 5, 12], ["aerosol", "TREATMENT", 27, 34], ["SARS", "PROBLEM", 62, 66], ["CoV", "TEST", 67, 70], ["the pathogen", "PROBLEM", 93, 105], ["infectious", "OBSERVATION", 122, 132]]], ["[18] \ue062e findings are comparable to those observed with SARS-CoV-1 [19] providing useful information for the current mitigation efforts during this pandemic. \ue062e study observed that SARS-CoV-2 survives for up to 24 h on cardboard and plastic/stainless-steel surfaces up to 2-3 days.", [["SARS", "DISEASE", 180, 184], ["stainless-steel", "CHEMICAL", 240, 255], ["SARS-CoV-2", "ORGANISM", 180, 190], ["SARS-CoV", "SPECIES", 55, 63], ["SARS-CoV", "TEST", 55, 63], ["\ue062e study", "TEST", 157, 165], ["SARS", "PROBLEM", 180, 184], ["plastic/stainless-steel surfaces", "TREATMENT", 232, 264]]], ["[18] [19] [20] Many ostensibly clean surfaces and devices within a pathology department (including but not limited to doorknobs, tables and chairs, countertops, desks, keyboards, phones, microscopes, glass slides, slide trays/boards, on-site adequacy carts, door handles, light switches, toilets, faucets, and sinks) may be contaminated with the virus and should be considered potential fomites.", [["fomites", "CANCER", 387, 394], ["slide trays/boards", "TREATMENT", 214, 232], ["light switches", "TREATMENT", 272, 286], ["the virus", "PROBLEM", 342, 351], ["clean", "OBSERVATION", 31, 36]]], ["[21] \ue062e duration for which SARS-CoV-2-like viruses have been reported to persist on various surfaces is listed in Table 4 .", [["SARS", "DISEASE", 27, 31], ["SARS-CoV-2-like viruses", "ORGANISM", 27, 50], ["SARS", "PROBLEM", 27, 31], ["CoV", "TEST", 32, 35], ["like viruses", "PROBLEM", 38, 50], ["viruses", "OBSERVATION", 43, 50]]], ["[22] Virus infectivity is defined as the ability of the virus to enter and colonize the host to replicate and reproduce itself with the potential to establish itself as an infection resulting in disease.", [["infection", "DISEASE", 172, 181], ["[22] Virus", "ORGANISM", 0, 10], ["Virus infectivity", "PROBLEM", 5, 22], ["the virus", "PROBLEM", 52, 61], ["an infection", "PROBLEM", 169, 181], ["disease", "PROBLEM", 195, 202], ["infection", "OBSERVATION", 172, 181]]], ["[22] A previously suggested benchmark, a log10 viral reduction factor of more than 3, is considered as virucidal effectivity against viruses including coronaviruses on surfaces.", [["coronaviruses", "ORGANISM", 151, 164], ["log10 viral reduction factor", "PROTEIN", 41, 69], ["a log10 viral reduction factor", "TREATMENT", 39, 69], ["viruses", "PROBLEM", 133, 140], ["coronaviruses", "PROBLEM", 151, 164]]], ["[23] Formalin and ethanol used in low concentration (usually used as a preservative) decrease the viral infectivity to more than 3 log10.", [["Formalin", "CHEMICAL", 5, 13], ["ethanol", "CHEMICAL", 18, 25], ["[23] Formalin", "CHEMICAL", 0, 13], ["ethanol", "CHEMICAL", 18, 25], ["[23] Formalin", "SIMPLE_CHEMICAL", 0, 13], ["ethanol", "SIMPLE_CHEMICAL", 18, 25], ["Formalin", "TREATMENT", 5, 13], ["ethanol", "TREATMENT", 18, 25], ["a preservative)", "TREATMENT", 69, 84], ["the viral infectivity", "PROBLEM", 94, 115], ["viral infectivity", "OBSERVATION", 98, 115]]], ["[22] \ue062e effect of time and concentrations of various fixatives and biocidal agents on SARS and a few other viruses are summarized in Table 5 . \ue062e table shows that for ethanol, 95% ethanol with SARS-CoV (Isolate FFM-1) for 30 s reduces the viral infectivity to more than 5.5 log10; 85% ethanol with SARS-CoV (Isolate FFM-1) for 30 s reduces the viral infectivity to more than 5.5 log10; [24] 80% ethanol with SARS-CoV (Isolate FFM-1) for 30 s reduces the viral infectivity to more than 4.3 log10; [24] 80% ethanol with MERS-CoV (Strain EMC) for 30 s reduces the viral infectivity to more than >4.0 log10; [25] 78% ethanol with SARS-CoV (Isolate FFM-1) for 30 s reduces Table 6 : Summary of measures recommended for routine cytopathology division (in addition to the basic protective measures summarized in Table 2 ) during SARS-CoV-2 pandemic.Measure(s) recommendedTo minimize the risk of exposure with rapid dissemination of the virus, the \"on-site adequacy evaluation services\" may be suspended during COVID 19 pandemic related suspension of elective procedures.** However, if FNAB has to be performed without on-site adequacy evaluation:Measure(s) recommendedAir-drying both the direct smears spread between slides allows staining the smears with Diff-Quik and Pap stain (as saline-rehydrated alcohol-fixed airdried smears).", [["SARS", "DISEASE", 86, 90], ["ethanol", "CHEMICAL", 167, 174], ["ethanol", "CHEMICAL", 180, 187], ["SARS", "DISEASE", 193, 197], ["ethanol", "CHEMICAL", 285, 292], ["SARS", "DISEASE", 298, 302], ["ethanol", "CHEMICAL", 395, 402], ["SARS", "DISEASE", 408, 412], ["ethanol", "CHEMICAL", 505, 512], ["MERS-CoV", "CHEMICAL", 518, 526], ["ethanol", "CHEMICAL", 613, 620], ["SARS", "DISEASE", 626, 630], ["SARS-CoV-2 pandemic", "DISEASE", 822, 841], ["alcohol", "CHEMICAL", 1295, 1302], ["ethanol", "CHEMICAL", 167, 174], ["ethanol", "CHEMICAL", 180, 187], ["ethanol", "CHEMICAL", 285, 292], ["ethanol", "CHEMICAL", 395, 402], ["ethanol", "CHEMICAL", 505, 512], ["ethanol", "CHEMICAL", 613, 620], ["alcohol", "CHEMICAL", 1295, 1302], ["ethanol", "SIMPLE_CHEMICAL", 167, 174], ["ethanol", "SIMPLE_CHEMICAL", 180, 187], ["SARS-CoV", "SIMPLE_CHEMICAL", 193, 201], ["ethanol", "SIMPLE_CHEMICAL", 285, 292], ["SARS-CoV", "ORGANISM", 298, 306], ["ethanol", "SIMPLE_CHEMICAL", 395, 402], ["SARS-CoV", "SIMPLE_CHEMICAL", 408, 416], ["ethanol", "SIMPLE_CHEMICAL", 505, 512], ["MERS-CoV", "SIMPLE_CHEMICAL", 518, 526], ["ethanol", "SIMPLE_CHEMICAL", 613, 620], ["SARS-CoV", "SIMPLE_CHEMICAL", 626, 634], ["SARS-CoV-2", "ORGANISM", 822, 832], ["saline", "SIMPLE_CHEMICAL", 1277, 1283], ["alcohol", "SIMPLE_CHEMICAL", 1295, 1302], ["SARS-CoV", "SPECIES", 193, 201], ["SARS-CoV", "SPECIES", 298, 306], ["SARS-CoV", "SPECIES", 408, 416], ["MERS-CoV", "SPECIES", 518, 526], ["SARS-CoV", "SPECIES", 626, 634], ["various fixatives", "TREATMENT", 45, 62], ["biocidal agents", "TREATMENT", 67, 82], ["SARS", "PROBLEM", 86, 90], ["ethanol", "TREATMENT", 167, 174], ["CoV (Isolate FFM", "TREATMENT", 198, 214], ["the viral infectivity", "PROBLEM", 235, 256], ["SARS", "TEST", 298, 302], ["CoV (Isolate FFM", "TREATMENT", 303, 319], ["the viral infectivity", "PROBLEM", 340, 361], ["CoV (Isolate FFM", "TREATMENT", 413, 429], ["the viral infectivity", "PROBLEM", 450, 471], ["CoV (Strain EMC)", "TREATMENT", 523, 539], ["the viral infectivity", "PROBLEM", 557, 578], ["CoV (Isolate FFM", "TREATMENT", 631, 647], ["the basic protective measures", "TREATMENT", 761, 790], ["pandemic", "PROBLEM", 833, 841], ["the virus", "PROBLEM", 925, 934], ["elective procedures", "TREATMENT", 1043, 1062], ["FNAB", "TEST", 1078, 1082], ["adequacy evaluation", "TEST", 1119, 1138], ["the direct smears", "TEST", 1177, 1194], ["the smears", "TEST", 1233, 1243], ["Diff", "TEST", 1249, 1253], ["Pap stain", "TEST", 1263, 1272], ["saline", "TEST", 1277, 1283], ["drying", "OBSERVATION_MODIFIER", 1165, 1171]]], ["[40] \ue062e saline used for rehydration should be discarded as biological waste similar to other biological specimens. \ue062e air-dried smears are easy to be transported to Cytoprep lab in slide containers, which should be sanitized/disinfected by rinsing in 95% for 2-5 min, if the slide containers are reused. *Modify as per local regulatory issues and geopolitical limitations based on general information reviewed in this editorial.Cell-blockthe viral infectivity to more than 5.0 log10; [26] 70% ethanol with MHV (Strains MHV-2 and MHV-N) for 10 min reduces the viral infectivity to more than >3.9 log10; [27] and 70% ethanol with CCV (Strain I-71) for 10 min reduces the viral infectivity to more than >3.3 log10.", [["specimens", "ANATOMY", 104, 113], ["Cell", "ANATOMY", 428, 432], ["ethanol", "CHEMICAL", 493, 500], ["ethanol", "CHEMICAL", 615, 622], ["ethanol", "CHEMICAL", 493, 500], ["ethanol", "CHEMICAL", 615, 622], ["[40] \ue062e saline", "SIMPLE_CHEMICAL", 0, 14], ["Cell", "CELL", 428, 432], ["ethanol", "SIMPLE_CHEMICAL", 493, 500], ["MHV", "ORGANISM", 506, 509], ["MHV-2", "ORGANISM", 519, 524], ["MHV-N", "ORGANISM", 529, 534], ["ethanol", "SIMPLE_CHEMICAL", 615, 622], ["MHV", "SPECIES", 506, 509], ["CCV", "SPECIES", 628, 631], ["\ue062e saline", "TREATMENT", 5, 14], ["rehydration", "TREATMENT", 24, 35], ["other biological specimens", "TEST", 87, 113], ["the slide containers", "TREATMENT", 271, 291], ["Cell", "TEST", 428, 432], ["viral infectivity", "PROBLEM", 442, 459], ["MHV (Strains MHV", "TREATMENT", 506, 522], ["the viral infectivity", "PROBLEM", 555, 576], ["CCV (Strain I", "TEST", 628, 641], ["the viral infectivity", "PROBLEM", 665, 686], ["viral infectivity", "OBSERVATION", 442, 459], ["viral infectivity", "OBSERVATION", 559, 576], ["viral infectivity", "OBSERVATION", 669, 686]]], ["[27] Similarly for formalin, 1% formaldehyde with SARS-CoV (Isolate FFM-1) for 2 min reduces the viral infectivity to more than >3.0 log10; [26] 0.7% formaldehyde with SARS-CoV (Isolate FFM-1) for 2 min reduces the viral infectivity to more than >3.0 log10; [26] 0.7% formaldehyde with MHV for 10 min reduces the viral infectivity to more than >3.5 log10; [27] 0.7% formaldehyde with CCV (Strain I-71) for 10 min reduces the viral infectivity to more than >3.7 log10; [27] and 0.009% formaldehyde with CCV for 24 h reduces the viral infectivity to more than >4.0 log10 [28] [ Table 5 ].Cell-blockAbout 95% ethanol reduces the viral infectivity to more than 5.5 in 30 s and formaldehyde even in the concentration of 1% decreased the viral infectivity to more than 3 in 2 min [ Table 5 ].", [["Cell", "ANATOMY", 586, 590], ["formalin", "CHEMICAL", 19, 27], ["formaldehyde", "CHEMICAL", 32, 44], ["SARS", "DISEASE", 50, 54], ["formaldehyde", "CHEMICAL", 150, 162], ["SARS", "DISEASE", 168, 172], ["formaldehyde", "CHEMICAL", 268, 280], ["formaldehyde", "CHEMICAL", 366, 378], ["formaldehyde", "CHEMICAL", 484, 496], ["ethanol", "CHEMICAL", 606, 613], ["formaldehyde", "CHEMICAL", 673, 685], ["formalin", "CHEMICAL", 19, 27], ["formaldehyde", "CHEMICAL", 32, 44], ["formaldehyde", "CHEMICAL", 150, 162], ["formaldehyde", "CHEMICAL", 268, 280], ["formaldehyde", "CHEMICAL", 366, 378], ["formaldehyde", "CHEMICAL", 484, 496], ["ethanol", "CHEMICAL", 606, 613], ["formaldehyde", "CHEMICAL", 673, 685], ["formalin", "SIMPLE_CHEMICAL", 19, 27], ["formaldehyde", "SIMPLE_CHEMICAL", 32, 44], ["SARS-CoV", "SIMPLE_CHEMICAL", 50, 58], ["formaldehyde", "SIMPLE_CHEMICAL", 150, 162], ["SARS-CoV", "SIMPLE_CHEMICAL", 168, 176], ["formaldehyde", "SIMPLE_CHEMICAL", 268, 280], ["MHV", "ORGANISM", 286, 289], ["formaldehyde", "SIMPLE_CHEMICAL", 366, 378], ["CCV", "ORGANISM", 384, 387], ["formaldehyde", "SIMPLE_CHEMICAL", 484, 496], ["Cell", "CELL", 586, 590], ["ethanol", "SIMPLE_CHEMICAL", 606, 613], ["formaldehyde", "SIMPLE_CHEMICAL", 673, 685], ["SARS-CoV", "SPECIES", 50, 58], ["SARS-CoV", "SPECIES", 168, 176], ["MHV", "SPECIES", 286, 289], ["CCV", "SPECIES", 502, 505], ["formalin", "TEST", 19, 27], ["SARS", "TEST", 50, 54], ["CoV (Isolate FFM", "TREATMENT", 55, 71], ["the viral infectivity", "PROBLEM", 93, 114], ["SARS", "TEST", 168, 172], ["CoV (Isolate FFM", "TREATMENT", 173, 189], ["the viral infectivity", "PROBLEM", 211, 232], ["MHV", "TREATMENT", 286, 289], ["the viral infectivity", "PROBLEM", 309, 330], ["CCV (Strain I", "TEST", 384, 397], ["the viral infectivity", "PROBLEM", 421, 442], ["the viral infectivity", "PROBLEM", 523, 544], ["Cell", "TEST", 586, 590], ["blockAbout", "TEST", 591, 601], ["the viral infectivity", "PROBLEM", 622, 643], ["formaldehyde", "TREATMENT", 673, 685], ["the viral infectivity", "PROBLEM", 728, 749], ["viral infectivity", "OBSERVATION", 425, 442], ["viral infectivity", "OBSERVATION", 626, 643], ["viral infectivity", "OBSERVATION", 732, 749]]], ["[22] Various reagents such as ethanol and 10% formalin (3.7% formaldehyde) usually used in cytopathology processing at initial stages as fixative have virucidal activity.", [["ethanol", "CHEMICAL", 30, 37], ["formalin", "CHEMICAL", 46, 54], ["formaldehyde", "CHEMICAL", 61, 73], ["ethanol", "CHEMICAL", 30, 37], ["formalin", "CHEMICAL", 46, 54], ["formaldehyde", "CHEMICAL", 61, 73], ["ethanol", "SIMPLE_CHEMICAL", 30, 37], ["formalin", "SIMPLE_CHEMICAL", 46, 54], ["formaldehyde", "SIMPLE_CHEMICAL", 61, 73], ["Various reagents", "TREATMENT", 5, 21], ["ethanol and 10% formalin", "TREATMENT", 30, 54], ["virucidal activity", "OBSERVATION", 151, 169]]], ["[22] Based on the aforementioned, SARS-CoV-2 in any specimen processed with routine fixatives in cytopathology should be inactivated [ Table 5 ].", [["specimen", "ANATOMY", 52, 60], ["SARS", "DISEASE", 34, 38], ["SARS", "TEST", 34, 38], ["CoV", "TEST", 39, 42], ["routine fixatives", "TREATMENT", 76, 93]]], ["[22, 29] \ue062e data presented thus far suggest that the susceptibility to infection follows the bell curve, with an increase in the severity of the disease with the higher mortality in members of the population over 50 years.", [["infection", "DISEASE", 71, 80], ["the susceptibility to infection", "PROBLEM", 49, 80], ["the bell curve", "TEST", 89, 103], ["the disease", "PROBLEM", 141, 152], ["infection", "OBSERVATION", 71, 80], ["increase", "OBSERVATION_MODIFIER", 113, 121], ["severity", "OBSERVATION_MODIFIER", 129, 137], ["disease", "OBSERVATION", 145, 152], ["higher", "OBSERVATION_MODIFIER", 162, 168]]], ["[30, 31] \ue062is observation should be considered while organizing cytology laboratory services, namely, the potential effect on the personnel associated with various cytology services in regard to their potential for SARS-CoV-2 exposure.Cell-blockA summary of recommendations for procedure specific protocols in routine cytopathology is enumerated in Table 6 . \ue062ese guidelines are recommended in addition to the WHO basic protective measures at a personal level [ Table 2 ].", [["Cell", "ANATOMY", 234, 238], ["SARS", "DISEASE", 214, 218], ["CoV-2", "ORGANISM", 219, 224], ["Cell", "CELL", 234, 238], ["\ue062is observation", "TEST", 9, 24], ["SARS", "PROBLEM", 214, 218], ["CoV", "PROBLEM", 219, 222], ["procedure specific protocols", "TREATMENT", 277, 305], ["routine cytopathology", "TEST", 309, 330]]], ["[16] \ue062e virus survives on various plastic/metal surfaces, cardboards, disposable gowns, and paper surfaces for a significant amount of time [ Table 5 ].", [["various plastic/metal surfaces", "TREATMENT", 26, 56], ["disposable gowns", "TREATMENT", 70, 86]]], ["[18, 19, 21, 22, 38] To avoid dissemination of the virus, it is recommended that on-site adequacy services should be canceled or postponed during the pandemic.", [["dissemination of the virus", "PROBLEM", 30, 56], ["virus", "OBSERVATION", 51, 56]]], ["In case a particular procedure is deemed necessary to be performed, the on-site personnel should follow the guidelines generated based on the information discussed in this review and summarized in Table 6 .", [["a particular procedure", "TREATMENT", 8, 30]]]], "4efbcea3f72b9d042d6955d927db1526c32e78dd": [["Hypertension, renin-angiotensin-aldosterone system inhibition, and COVID-19Few could have imagined that hypertension and its treatment with inhibitors of the renin-angiotensinaldosterone system (RAAS) would become a hot topic during the global COVID-19 pandemic.", [["Hypertension", "DISEASE", 0, 12], ["renin-angiotensin-aldosterone", "CHEMICAL", 14, 43], ["hypertension", "DISEASE", 104, 116], ["aldosterone", "CHEMICAL", 32, 43], ["renin-angiotensin-aldosterone", "GENE_OR_GENE_PRODUCT", 14, 43], ["renin", "GENE_OR_GENE_PRODUCT", 158, 163], ["angiotensinaldosterone", "GENE_OR_GENE_PRODUCT", 164, 186], ["renin", "PROTEIN", 158, 163], ["Hypertension", "PROBLEM", 0, 12], ["renin-angiotensin-aldosterone system inhibition", "TREATMENT", 14, 61], ["COVID", "TREATMENT", 67, 72], ["hypertension", "PROBLEM", 104, 116], ["its treatment", "TREATMENT", 121, 134], ["inhibitors", "TREATMENT", 140, 150], ["the renin-angiotensinaldosterone system", "TREATMENT", 154, 193], ["the global COVID", "TEST", 233, 249], ["pandemic", "PROBLEM", 253, 261], ["hypertension", "OBSERVATION", 104, 116]]], ["Two factors have contributed to this: first, the observation that hypertension is one of the most common comorbidities associated with severe cases of COVID-19 in patients who have been admitted to hospital and their risk of death; 1 and second, that like the severe acute respiratory syndrome coronavirus (SARS-CoV), SARS-CoV-2 infects cells via specific binding to angiotensin-converting enzyme 2 (ACE2), which is ubiquitously expressed in the lung and other tissues.", [["cells", "ANATOMY", 337, 342], ["lung", "ANATOMY", 446, 450], ["tissues", "ANATOMY", 461, 468], ["hypertension", "DISEASE", 66, 78], ["COVID-19", "CHEMICAL", 151, 159], ["death", "DISEASE", 225, 230], ["acute respiratory syndrome coronavirus", "DISEASE", 267, 305], ["SARS", "DISEASE", 307, 311], ["SARS", "DISEASE", 318, 322], ["angiotensin", "CHEMICAL", 367, 378], ["COVID-19", "CHEMICAL", 151, 159], ["patients", "ORGANISM", 163, 171], ["SARS-CoV", "ORGANISM", 307, 315], ["SARS-CoV-2", "ORGANISM", 318, 328], ["cells", "CELL", 337, 342], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 367, 398], ["ACE2", "GENE_OR_GENE_PRODUCT", 400, 404], ["lung", "ORGAN", 446, 450], ["tissues", "TISSUE", 461, 468], ["angiotensin-converting enzyme 2", "PROTEIN", 367, 398], ["ACE2", "PROTEIN", 400, 404], ["patients", "SPECIES", 163, 171], ["severe acute respiratory syndrome coronavirus", "SPECIES", 260, 305], ["SARS-CoV", "SPECIES", 307, 315], ["SARS-CoV", "SPECIES", 318, 326], ["hypertension", "PROBLEM", 66, 78], ["death", "PROBLEM", 225, 230], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 256, 305], ["SARS", "PROBLEM", 318, 322], ["CoV-2 infects cells", "PROBLEM", 323, 342], ["angiotensin", "TEST", 367, 378], ["hypertension", "OBSERVATION", 66, 78], ["severe", "OBSERVATION_MODIFIER", 260, 266], ["acute", "OBSERVATION_MODIFIER", 267, 272], ["respiratory syndrome coronavirus", "OBSERVATION", 273, 305], ["lung", "ANATOMY", 446, 450], ["other tissues", "ANATOMY", 455, 468]]], ["2 These factors have fuelled speculation that use of RAAS inhibitors, particularly ACE inhibitors or angiotensin-receptor blockers, could lead to increased expression of ACE2 in the respiratory tract, thereby increasing the risk of both becoming infected and developing severe life-threatening complications due to COVID-19.", [["respiratory tract", "ANATOMY", 182, 199], ["angiotensin", "CHEMICAL", 101, 112], ["COVID-19", "CHEMICAL", 315, 323], ["RAAS", "GENE_OR_GENE_PRODUCT", 53, 57], ["ACE", "GENE_OR_GENE_PRODUCT", 83, 86], ["angiotensin-receptor blockers", "GENE_OR_GENE_PRODUCT", 101, 130], ["ACE2", "GENE_OR_GENE_PRODUCT", 170, 174], ["respiratory tract", "ORGANISM_SUBDIVISION", 182, 199], ["ACE2", "PROTEIN", 170, 174], ["RAAS inhibitors", "TREATMENT", 53, 68], ["ACE inhibitors", "TREATMENT", 83, 97], ["angiotensin-receptor blockers", "TREATMENT", 101, 130], ["increased expression of ACE2 in the respiratory tract", "PROBLEM", 146, 199], ["infected", "PROBLEM", 246, 254], ["severe life-threatening complications", "PROBLEM", 270, 307], ["COVID", "TEST", 315, 320], ["respiratory tract", "ANATOMY", 182, 199], ["infected", "OBSERVATION", 246, 254], ["severe", "OBSERVATION_MODIFIER", 270, 276]]], ["The fact that no evidence supports any aspect of this speculation mattered little as the hypothesis gained traction, initially via social media and subsequently via the medical press.", [["no evidence supports", "UNCERTAINTY", 14, 34]]], ["3 Anxiety among patients and physicians has been profound because ACE inhibitors and angiotensinreceptor blockers are the foundation of drug treatment for hypertension, heart disease, and chronic kidney disease, and are among the most widely prescribed drugs globally.", [["heart", "ANATOMY", 169, 174], ["kidney", "ANATOMY", 196, 202], ["Anxiety", "DISEASE", 2, 9], ["hypertension", "DISEASE", 155, 167], ["heart disease", "DISEASE", 169, 182], ["chronic kidney disease", "DISEASE", 188, 210], ["patients", "ORGANISM", 16, 24], ["ACE", "GENE_OR_GENE_PRODUCT", 66, 69], ["angiotensinreceptor blockers", "SIMPLE_CHEMICAL", 85, 113], ["heart", "ORGAN", 169, 174], ["kidney", "ORGAN", 196, 202], ["patients", "SPECIES", 16, 24], ["ACE inhibitors", "TREATMENT", 66, 80], ["angiotensinreceptor blockers", "TREATMENT", 85, 113], ["drug treatment", "TREATMENT", 136, 150], ["hypertension", "PROBLEM", 155, 167], ["heart disease", "PROBLEM", 169, 182], ["chronic kidney disease", "PROBLEM", 188, 210], ["heart", "ANATOMY", 169, 174], ["disease", "OBSERVATION", 175, 182], ["chronic", "OBSERVATION_MODIFIER", 188, 195], ["kidney", "ANATOMY", 196, 202], ["disease", "OBSERVATION", 203, 210]]], ["Patients have subsequently been withdrawing and substituting these treatments, prompting international cardiovascular and hypertension specialist societies to issue statements of reassurance, while acknowledging the lack of high-quality data to refute the increasing alarm.", [["cardiovascular", "ANATOMY", 103, 117], ["hypertension", "DISEASE", 122, 134], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["these treatments", "TREATMENT", 61, 77], ["international cardiovascular and hypertension specialist", "TREATMENT", 89, 145], ["reassurance", "TREATMENT", 179, 190], ["the increasing alarm", "PROBLEM", 252, 272]]], ["This debate, fuelled by speculation, has at last become enriched by data, with the publication of several observational cohort studies.", [["several observational cohort studies", "TEST", 98, 134]]], ["[4] [5] [6] [7] [8] [9] [10] In The Lancet, Francisco de Abajo and colleagues 4 present data from a casepopulation pharmacoepidemiological study of 1139 adult patients (cases) who had been admitted to hospital in Madrid, Spain, due to COVID-19 during March, 2020, who were each carefully matched with ten population controls with data from 2018, to give a total of 11 390 matched controls.", [["[4] [5] [6] [7] [8] [9] [10", "SIMPLE_CHEMICAL", 0, 27], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 159, 167], ["a casepopulation pharmacoepidemiological study", "TEST", 98, 144], ["COVID", "TEST", 235, 240]]], ["The main outcome measure was admission to hospital of patients with PCR-confirmed COVID-19, comparing the current use of RAAS inhibitors with other antihypertensive drugs.", [["patients", "ORGANISM", 54, 62], ["RAAS", "GENE_OR_GENE_PRODUCT", 121, 125], ["patients", "SPECIES", 54, 62], ["PCR", "TEST", 68, 71], ["COVID", "TEST", 82, 87], ["RAAS inhibitors", "TREATMENT", 121, 136], ["other antihypertensive drugs", "TREATMENT", 142, 170], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["The RAAS inhibitors were predominantly ACE inhibitors and angiotensinreceptor blockers, with few individuals currently using aldosterone antagonists or renin inhibitors.", [["aldosterone", "CHEMICAL", 125, 136], ["aldosterone", "CHEMICAL", 125, 136], ["RAAS", "GENE_OR_GENE_PRODUCT", 4, 8], ["ACE", "GENE_OR_GENE_PRODUCT", 39, 42], ["angiotensinreceptor blockers", "SIMPLE_CHEMICAL", 58, 86], ["aldosterone antagonists", "GENE_OR_GENE_PRODUCT", 125, 148], ["renin", "GENE_OR_GENE_PRODUCT", 152, 157], ["renin", "PROTEIN", 152, 157], ["The RAAS inhibitors", "TREATMENT", 0, 19], ["predominantly ACE inhibitors", "TREATMENT", 25, 53], ["angiotensinreceptor blockers", "TREATMENT", 58, 86], ["aldosterone antagonists", "TREATMENT", 125, 148], ["renin inhibitors", "TREATMENT", 152, 168]]], ["Compared with the use of other antihypertensive drugs, current use of RAAS inhibitors was not associated with increased risk of COVID-19 requiring admission to hospital (odds ratio [OR] 0\u00b794, 95% CI 0\u00b777-1\u00b715, adjusted for potential confounding factors), or increased risk of severe complications from COVID-19 needing intensive care or leading to a fatal outcome (1\u00b708, 0\u00b780-1\u00b747).", [["RAAS", "GENE_OR_GENE_PRODUCT", 70, 74], ["other antihypertensive drugs", "TREATMENT", 25, 53], ["RAAS inhibitors", "TREATMENT", 70, 85], ["COVID", "TEST", 128, 133], ["CI", "TEST", 196, 198], ["severe complications", "PROBLEM", 276, 296], ["COVID", "TEST", 302, 307], ["intensive care", "TREATMENT", 319, 333], ["severe", "OBSERVATION_MODIFIER", 276, 282], ["complications", "OBSERVATION", 283, 296]]], ["These findings were uninfluenced by age, sex, or background cardiovascular risk.", [["cardiovascular", "ANATOMY", 60, 74], ["background cardiovascular risk", "PROBLEM", 49, 79]]], ["Moreover, excluding aldosterone antagonists and renin inhibitors and focusing only on ACE inhibitors or angiotensin-receptor blockers made no difference to these conclusions.Hypertension, renin-angiotensin-aldosterone system inhibition, and COVID-19Potential differences exist between ACE inhibitors and angiotensin-receptor blockers in the context of risk associated with COVID-19.", [["aldosterone", "CHEMICAL", 20, 31], ["angiotensin", "CHEMICAL", 104, 115], ["Hypertension", "DISEASE", 174, 186], ["aldosterone", "CHEMICAL", 206, 217], ["angiotensin", "CHEMICAL", 304, 315], ["aldosterone", "CHEMICAL", 20, 31], ["aldosterone", "CHEMICAL", 206, 217], ["COVID-19", "CHEMICAL", 373, 381], ["aldosterone antagonists", "GENE_OR_GENE_PRODUCT", 20, 43], ["renin", "GENE_OR_GENE_PRODUCT", 48, 53], ["ACE", "GENE_OR_GENE_PRODUCT", 86, 89], ["angiotensin-receptor blockers", "SIMPLE_CHEMICAL", 104, 133], ["renin-angiotensin-aldosterone", "GENE_OR_GENE_PRODUCT", 188, 217], ["COVID-19Potential", "SIMPLE_CHEMICAL", 241, 258], ["ACE", "GENE_OR_GENE_PRODUCT", 285, 288], ["angiotensin-receptor blockers", "SIMPLE_CHEMICAL", 304, 333], ["aldosterone antagonists", "TREATMENT", 20, 43], ["renin inhibitors", "TREATMENT", 48, 64], ["ACE inhibitors", "TREATMENT", 86, 100], ["angiotensin", "TREATMENT", 104, 115], ["receptor blockers", "TREATMENT", 116, 133], ["Hypertension", "PROBLEM", 174, 186], ["renin-angiotensin", "TREATMENT", 188, 205], ["aldosterone system inhibition", "TREATMENT", 206, 235], ["COVID", "TREATMENT", 241, 246], ["ACE inhibitors", "TREATMENT", 285, 299], ["angiotensin", "TREATMENT", 304, 315], ["receptor blockers", "TREATMENT", 316, 333], ["COVID", "TEST", 373, 378]]], ["In the study by de Abajo and colleagues, no difference was found between ACE inhibitors and angiotensin-receptor blockers for the main outcome, which was most notable when comparing monotherapy with these drugs (adjusted OR for ACE inhibitor monotherapy was 0\u00b783 [95% CI 0\u00b762-1\u00b712] and for angiotensin-receptor blocker monotherapy was 0\u00b787 [0\u00b760-1\u00b728]).", [["angiotensin", "CHEMICAL", 92, 103], ["ACE inhibitor", "CHEMICAL", 228, 241], ["angiotensin-receptor blocker", "CHEMICAL", 290, 318], ["ACE", "GENE_OR_GENE_PRODUCT", 73, 76], ["angiotensin-receptor blockers", "SIMPLE_CHEMICAL", 92, 121], ["ACE", "GENE_OR_GENE_PRODUCT", 228, 231], ["angiotensin-receptor blocker", "SIMPLE_CHEMICAL", 290, 318], ["the study", "TEST", 3, 12], ["ACE inhibitors", "TREATMENT", 73, 87], ["angiotensin-receptor blockers", "TREATMENT", 92, 121], ["these drugs", "TREATMENT", 199, 210], ["ACE inhibitor monotherapy", "TREATMENT", 228, 253], ["CI", "TEST", 268, 270], ["angiotensin-receptor blocker monotherapy", "TREATMENT", 290, 330]]], ["4 This finding is also consistent with most other recent observational studies.", [["observational studies", "TEST", 57, 78], ["consistent with", "UNCERTAINTY", 23, 38]]], ["[5] [6] [7] The exception among these studies was one study 8 using observational data from 169 hospitals in Asia, Europe, and North America that reported possible enhanced benefit of ACE inhibitors compared with angiotensin-receptor blockers on mortality, but the authors rightly cautioned against overinterpretation of these data because of potential unmeasured confounding.", [["angiotensin", "CHEMICAL", 213, 224], ["ACE", "GENE_OR_GENE_PRODUCT", 184, 187], ["angiotensin-receptor blockers", "SIMPLE_CHEMICAL", 213, 242], ["these studies", "TEST", 32, 45], ["one study", "TEST", 50, 59], ["observational data", "TEST", 68, 86], ["ACE inhibitors", "TREATMENT", 184, 198], ["angiotensin-receptor blockers", "TREATMENT", 213, 242]]], ["Diabetes is a common comorbidity associated with poorer outcomes in patients with COVID-19 and these patients often have hypertension and are prescribed RAAS inhibitors.", [["Diabetes", "DISEASE", 0, 8], ["hypertension", "DISEASE", 121, 133], ["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 101, 109], ["Diabetes", "PROBLEM", 0, 8], ["a common comorbidity", "PROBLEM", 12, 32], ["COVID", "TEST", 82, 87], ["hypertension", "PROBLEM", 121, 133], ["RAAS inhibitors", "TREATMENT", 153, 168], ["hypertension", "OBSERVATION", 121, 133]]], ["Thus, an interesting and potentially clinically important finding in the study by de Abajo and colleagues is that the use of RAAS inhibitors compared with other antihypertensive drugs almost halved the risk of adverse outcomes in patients with COVID-19 who had diabetes (adjusted OR 0\u00b753, 95% CI 0\u00b734-0\u00b780).", [["diabetes", "DISEASE", 261, 269], ["RAAS", "GENE_OR_GENE_PRODUCT", 125, 129], ["patients", "ORGANISM", 230, 238], ["patients", "SPECIES", 230, 238], ["the study", "TEST", 69, 78], ["RAAS inhibitors", "TREATMENT", 125, 140], ["other antihypertensive drugs", "TREATMENT", 155, 183], ["diabetes", "PROBLEM", 261, 269], ["CI", "TEST", 293, 295]]], ["4 Other studies have also suggested that use of RAAS inhibitors might confer protective effects against complications and death in patients with COVID-19 versus other antihypertensive drugs, although these studies were not restricted to patients with diabetes.", [["death", "DISEASE", 122, 127], ["COVID-19", "CHEMICAL", 145, 153], ["diabetes", "DISEASE", 251, 259], ["COVID-19", "CHEMICAL", 145, 153], ["RAAS", "GENE_OR_GENE_PRODUCT", 48, 52], ["patients", "ORGANISM", 131, 139], ["patients", "ORGANISM", 237, 245], ["patients", "SPECIES", 131, 139], ["patients", "SPECIES", 237, 245], ["Other studies", "TEST", 2, 15], ["RAAS inhibitors", "TREATMENT", 48, 63], ["complications", "PROBLEM", 104, 117], ["death", "PROBLEM", 122, 127], ["COVID", "TEST", 145, 150], ["other antihypertensive drugs", "TREATMENT", 161, 189], ["these studies", "TEST", 200, 213], ["diabetes", "PROBLEM", 251, 259]]], ["9, 10 A notable feature of the emerging data is the excess risk of admission to hospital, admission to intensive care units, and fatal outcomes in patients who are given any kind of antihypertensive drug versus non-users.", [["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155], ["antihypertensive drug", "TREATMENT", 182, 203], ["notable", "OBSERVATION_MODIFIER", 8, 15]]], ["4 Although this potential association of antihypertensive treatment and increased risk of severe COVID-19 has caused alarm, generally people are accepting that it most likely reflects the use of these drugs for patients who are older and who invariably have multiple comorbidities, and despite rigorous attempts to adjust for comorbidities in observational studies, fully adjusting for confounding by indication is not possible.Hypertension, renin-angiotensin-aldosterone system inhibition, and COVID-19The limitations of the study by de Abajo and colleagues 4 apply to all of the observational studies we have discussed here, which are not randomised controlled trials, and despite multiple statistical adjustments are invariably subject to confounding, either unmeasured or unknown.", [["COVID", "DISEASE", 97, 102], ["Hypertension", "DISEASE", 428, 440], ["aldosterone", "CHEMICAL", 460, 471], ["COVID-19", "CHEMICAL", 97, 105], ["aldosterone", "CHEMICAL", 460, 471], ["people", "ORGANISM", 134, 140], ["patients", "ORGANISM", 211, 219], ["renin-angiotensin-aldosterone", "GENE_OR_GENE_PRODUCT", 442, 471], ["people", "SPECIES", 134, 140], ["patients", "SPECIES", 211, 219], ["antihypertensive treatment", "TREATMENT", 41, 67], ["severe COVID", "PROBLEM", 90, 102], ["alarm", "PROBLEM", 117, 122], ["these drugs", "TREATMENT", 195, 206], ["multiple comorbidities", "PROBLEM", 258, 280], ["comorbidities", "PROBLEM", 326, 339], ["observational studies", "TEST", 343, 364], ["Hypertension", "PROBLEM", 428, 440], ["renin-angiotensin-aldosterone system inhibition", "TREATMENT", 442, 489], ["COVID", "TEST", 495, 500], ["the study", "TEST", 522, 531], ["the observational studies", "TEST", 577, 602], ["severe", "OBSERVATION_MODIFIER", 90, 96]]], ["Controlling for whether patients were compliant with their RAAS inhibitor treatment, either before or after becoming infected with SARS-CoV-2, is also not possible.", [["SARS", "DISEASE", 131, 135], ["patients", "ORGANISM", 24, 32], ["SARS-CoV-2", "ORGANISM", 131, 141], ["patients", "SPECIES", 24, 32], ["SARS-CoV", "SPECIES", 131, 139], ["their RAAS inhibitor treatment", "TREATMENT", 53, 83], ["SARS", "PROBLEM", 131, 135], ["infected", "OBSERVATION", 117, 125], ["not possible", "UNCERTAINTY", 151, 163]]], ["Nevertheless, the aforementioned studies, 4-10 each with its own important nuances, all reached similar overarching conclusions from which a reasonable interpretation is that no evidence exists to support the speculation that RAAS inhibitors increase the risk of COVID-19.", [["COVID-19", "CHEMICAL", 263, 271], ["RAAS", "GENE_OR_GENE_PRODUCT", 226, 230], ["the aforementioned studies", "TEST", 14, 40], ["RAAS inhibitors", "TREATMENT", 226, 241], ["COVID", "TEST", 263, 268], ["no evidence exists", "UNCERTAINTY", 175, 193]]], ["Nor does evidence exist to suggest that, once infected, the risk of admission to hospital due to COVID-19, progression to more severe complications, or death is increased with RAAS inhibitor use compared with treatment with other antihypertensive drugs.", [["death", "DISEASE", 152, 157], ["COVID", "TEST", 97, 102], ["more severe complications", "PROBLEM", 122, 147], ["death", "PROBLEM", 152, 157], ["RAAS inhibitor", "TREATMENT", 176, 190], ["treatment", "TREATMENT", 209, 218], ["other antihypertensive drugs", "TREATMENT", 224, 252], ["severe", "OBSERVATION_MODIFIER", 127, 133], ["complications", "OBSERVATION", 134, 147], ["increased", "OBSERVATION_MODIFIER", 161, 170]]], ["Findings from some studies even suggest that treatment with RAAS inhibitors might reduce risk of severe complications or death due to COVID-19, 9, 10 but this potentially important finding needs confirmation in randomised controlled trials.Hypertension, renin-angiotensin-aldosterone system inhibition, and COVID-19For the moment, we should applaud the remarkable achievement of investigators globally, in the face of considerable adversity, for rapidly generating scientific data that should diminish the speculation about the safety of RAAS inhibitors during this global COVID-19 pandemic and provide a degree of reassurance to patients and their doctors.", [["death", "DISEASE", 121, 126], ["Hypertension", "DISEASE", 240, 252], ["aldosterone", "CHEMICAL", 272, 283], ["RAAS", "GENE_OR_GENE_PRODUCT", 60, 64], ["renin-angiotensin-aldosterone", "GENE_OR_GENE_PRODUCT", 254, 283], ["RAAS", "GENE_OR_GENE_PRODUCT", 538, 542], ["patients", "ORGANISM", 630, 638], ["patients", "SPECIES", 630, 638], ["some studies", "TEST", 14, 26], ["RAAS inhibitors", "TREATMENT", 60, 75], ["severe complications", "PROBLEM", 97, 117], ["death", "PROBLEM", 121, 126], ["COVID", "TEST", 134, 139], ["randomised controlled trials", "TREATMENT", 211, 239], ["Hypertension", "PROBLEM", 240, 252], ["renin-angiotensin-aldosterone system inhibition", "TREATMENT", 254, 301], ["COVID", "TEST", 307, 312], ["RAAS inhibitors", "TREATMENT", 538, 553], ["this global COVID", "TEST", 561, 578], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["complications", "OBSERVATION", 104, 117]]]], "3b2d14d09efcf36462304a894a721423ee6cfd72": [["IntroductionIn 2020, the coronavirus pandemic has rapidly spread around the globe, threatening health and economical systems.", [["coronavirus pandemic", "DISEASE", 25, 45], ["coronavirus", "ORGANISM", 25, 36], ["coronavirus", "SPECIES", 25, 36], ["IntroductionIn", "TREATMENT", 0, 14], ["the coronavirus pandemic", "PROBLEM", 21, 45], ["coronavirus pandemic", "OBSERVATION", 25, 45], ["rapidly", "OBSERVATION_MODIFIER", 50, 57], ["spread", "OBSERVATION_MODIFIER", 58, 64], ["globe", "ANATOMY", 76, 81]]], ["At first, many governments attempted to minimize exposure to the virus by limiting cross-border arrivals.", [["the virus", "PROBLEM", 61, 70]]], ["However, the rapid person-to-person transmission rate of the virus 1,2 required that more severe measures be taken to plummet infection frequencies.IntroductionGovernments that used lockdown to enforce social distancing varied in their policy, timing, and duration, in particular relative to the mortality rate in their country.", [["infection", "DISEASE", 126, 135], ["person", "SPECIES", 19, 25], ["person", "SPECIES", 29, 35], ["the virus", "PROBLEM", 57, 66], ["plummet infection frequencies", "PROBLEM", 118, 147], ["infection", "OBSERVATION", 126, 135]]], ["For example, Italy enforced a severe, nationwide, lockdown on March 10, when over 35,000 confirmed cases and almost 3,000 deaths had already been recorded.", [["deaths", "DISEASE", 122, 128], ["severe", "OBSERVATION_MODIFIER", 30, 36]]], ["In other countries, lockdown policies were embraced at earlier stages in attempt to prevent severe outbreaks.", [["severe outbreaks", "PROBLEM", 92, 108], ["severe", "OBSERVATION_MODIFIER", 92, 98], ["outbreaks", "OBSERVATION", 99, 108]]], ["Israel, for instance, reached the strict lockdown on March 19 with a relatively low number of 648 confirmed cases and no deaths to that day.", [["deaths", "DISEASE", 121, 127]]], ["In contrast, several countries, such as Sweden and Japan, advocated social distancing but did not enforce a lockdown as a means of coronavirus spread prevention.IntroductionHow can social distancing be quantified?", [["coronavirus", "DISEASE", 131, 142], ["coronavirus", "ORGANISM", 131, 142], ["coronavirus", "SPECIES", 131, 142], ["coronavirus spread prevention", "TREATMENT", 131, 160]]], ["One could measure governmental regulations such as the permitted walking distance from the residence, limitations on mass gatherings, school closures, and whether people were allowed to attend their workplaces.", [["people", "ORGANISM", 163, 169], ["people", "SPECIES", 163, 169]]], ["This score was used to predict future infections depending on the intervention level.IntroductionWhile this model may be useful when governmental decisions are made, it does not reflect whether social distancing has been implemented de facto 4 .", [["infections", "DISEASE", 38, 48], ["This score", "TEST", 0, 10], ["future infections", "PROBLEM", 31, 48], ["infections", "OBSERVATION", 38, 48]]], ["Soures et al. used data collected from navigation applications on mobile cellphones together with past infection rates to predict future infection rates 5 .", [["infection", "DISEASE", 103, 112], ["infection", "DISEASE", 137, 146], ["navigation applications", "TREATMENT", 39, 62], ["mobile cellphones", "TREATMENT", 66, 83], ["past infection rates", "PROBLEM", 98, 118], ["infection rates", "PROBLEM", 137, 152], ["infection", "OBSERVATION", 103, 112]]], ["These predictions were based on a neural-network model, in which the connection between mobility data and infection rates is hard to interpret, and thus, practically, cannot be converted into tangible measures for the arms race against the disease.", [["neural", "ANATOMY", 34, 40], ["infection", "DISEASE", 106, 115], ["mobility data", "TEST", 88, 101], ["infection rates", "PROBLEM", 106, 121], ["the disease", "PROBLEM", 236, 247], ["disease", "OBSERVATION", 240, 247]]], ["It is currently unknown which aspects of the lockdown (e.g., duration, strictness, timing from onset of death cases) affect mortality rates.", [["death", "DISEASE", 104, 109], ["mortality rates", "TEST", 124, 139]]], ["Understanding the linkage between lockdown dynamics and COVID-19 death incidents is highly important for balancing between health, welfare, and economy.IntroductionHere we develop parametric models that quantify trends related to mobility and mortality and fit them to all OECD countries.", [["death", "DISEASE", 65, 70], ["parametric models", "TEST", 180, 197]]], ["Using these models, we demonstrate that the timing in which the social distancing was initiated by itself explains 62% of the COVID-19 related deaths across OECD .", [["deaths", "DISEASE", 143, 149]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)IntroductionThe copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.11.20128520 doi: medRxiv preprint countries, excluding Japan (that was previously reported as an exception with respect to the spread of the disease, e.g., by Iwasaki and Grubaugh 6 ).", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 208, 228], ["the disease", "PROBLEM", 453, 464], ["med", "ANATOMY", 99, 102], ["disease", "OBSERVATION", 457, 464]]], ["In contrast, the severity of the lockdown and its duration are not as informative for explaining mortality rates.", [["mortality rates", "TEST", 97, 112]]], ["Our analysis thus suggests that a moderate lockdown, rather than a very strict one as imposed by most countries, should be sufficient to curb COVID-19 related mortality, as long as action is taken in the appropriate time frame.ResultsFollowing the COVID-19 outbreak, Apple Inc. published daily reports regarding people movement, collected from usage of maps on mobile cellphones 7 .", [["people", "ORGANISM", 312, 318], ["people", "SPECIES", 312, 318], ["Our analysis", "TEST", 0, 12], ["a moderate lockdown", "PROBLEM", 32, 51], ["the COVID", "TEST", 244, 253], ["moderate", "OBSERVATION_MODIFIER", 34, 42], ["lockdown", "OBSERVATION", 43, 51]]], ["We used these mobility data, denoted as ( ), to quantify the actual commencement of the lockdown as a function of time in different OECD countries.", [["these mobility data", "TEST", 8, 27]]], ["We collected daily death incidents across time and overlaid them on the mobility data.", [["death", "DISEASE", 19, 24], ["the mobility data", "TEST", 68, 85]]], ["We observed that the trend of daily deaths stabilized and subsequently decreased several days after a sharp mobility drop (Fig. 1a for the United Kingdom as an example and Supplementary Fig. S1 for all OECD countries). ( ) is given as percentages relative to that recorded on January 13, that serves as the baseline; (b) An illustration of the mobility model and its free parameters: -mobility difference between routine and lockdown; -drop steepness; -drop midpoint; -mobility level during lockdown; -release day; -recovery rate, see Methods for more details.Mobility analysisThe mobility in a single country during the observed time period of the COVID-19 pandemic can generally be divided into four phases: (1) a stable phase of high mobility (with fluctuations on .", [["deaths", "DISEASE", 36, 42], ["a sharp mobility drop", "PROBLEM", 100, 121], ["Supplementary Fig", "TREATMENT", 172, 189], ["the mobility model", "TEST", 340, 358], ["its free parameters", "TEST", 363, 382], ["mobility difference", "PROBLEM", 385, 404], ["routine and lockdown", "TEST", 413, 433], ["drop steepness", "PROBLEM", 436, 450], ["drop midpoint", "PROBLEM", 453, 466], ["mobility level", "PROBLEM", 469, 483], ["Mobility analysis", "TEST", 560, 577], ["the COVID", "TEST", 645, 654], ["mobility", "OBSERVATION_MODIFIER", 581, 589], ["stable", "OBSERVATION_MODIFIER", 716, 722], ["high mobility", "OBSERVATION_MODIFIER", 732, 745]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Mobility analysisThe copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.11.20128520 doi: medRxiv preprint weekends); (2) a sharp drop (suggesting social distancing has actually started); (3) a period of low mobility; and (4) a gradual incline towards a normal routine (Fig. 1) .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["Mobility analysis", "TEST", 196, 213], ["The copyright holder", "TREATMENT", 213, 233], ["a sharp drop", "PROBLEM", 370, 382], ["low mobility", "PROBLEM", 452, 464], ["a gradual incline", "PROBLEM", 474, 491], ["med", "ANATOMY", 99, 102], ["low mobility", "OBSERVATION_MODIFIER", 452, 464]]], ["Phases (1)-(3) reflect a (mirrored) logistic function and phase (4) is approximately linear.", [["Phases", "TEST", 0, 6], ["linear", "OBSERVATION_MODIFIER", 85, 91]]], ["We modeled this overall trend by assembling a logistic function and a linear one as a function of time ( , given in days):Mobility analysisThe six free parameters of this model are illustrated in Fig. 1b .", [["Mobility analysis", "TEST", 122, 139], ["free", "OBSERVATION_MODIFIER", 147, 151], ["illustrated", "OBSERVATION", 181, 192], ["Fig", "OBSERVATION_MODIFIER", 196, 199]]], ["Nevertheless, the mobility in Italy declined in a relatively gradual manner with respect to other examined countries, as the drop duration lasted 20 days.", [["mobility", "OBSERVATION_MODIFIER", 18, 26]]], ["The extent of mobility reduction in Germany (59%) was relatively low compared to other countries in which a lockdown was issued, and a gradual return to normal routine was initiated right after the lowest mobility level was reached.", [["mobility reduction", "PROBLEM", 14, 32], ["the lowest mobility level", "TEST", 194, 219], ["extent", "OBSERVATION_MODIFIER", 4, 10], ["mobility", "OBSERVATION_MODIFIER", 14, 22], ["reduction", "OBSERVATION_MODIFIER", 23, 32], ["low", "OBSERVATION_MODIFIER", 65, 68]]], ["Even though a lockdown was not regulated in Sweden, the data and model show that social distancing indeed happened, as a drop of 29% was observed followed by a moderate return back to routine (lockdown release rate of 0.57).Mobility analysis.", [["routine (lockdown release rate", "TREATMENT", 184, 214], ["Mobility analysis", "TEST", 224, 241]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.11.20128520 doi: medRxiv preprintCOVID-19 mortalityThe accumulated number of COVID-19 deaths across time, ( ), was fitted using a logistic function, \u0302( ), to the data (see Methods).", [["CC", "CHEMICAL", 0, 2], ["deaths", "DISEASE", 389, 395], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["medRxiv preprintCOVID", "TREATMENT", 320, 341], ["COVID", "TEST", 380, 385], ["med", "ANATOMY", 99, 102], ["accumulated", "OBSERVATION_MODIFIER", 358, 369], ["number", "OBSERVATION_MODIFIER", 370, 376]]], ["The average Pearson correlation between the observed mortality data and the fitted function, across all countries, was (all ; Supplementary Table S3;Association between mobility and mortality dataWe computed the response time of each country, , defined as the difference between the social distancing start time and the day when ten first deaths were recorded.", [["deaths", "DISEASE", 339, 345]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["Italy, Japan, Spain, and the United States), indicating that social distancing started after ten COVID-19 deaths were documented (Fig. 4, Supplementary Fig. S2 ).", [["deaths", "DISEASE", 106, 112], ["S2", "PROTEIN", 157, 159]]], ["We observed a significant correlation between and the log COVID-19 Mortality Probability (Pearson ,(which was not certified by peer review)).", [["the log COVID", "TEST", 50, 63]]], ["Previous reports have discussed the abnormally low mortality rate in Japan 6 , thus, we computed the correlation excluding Japan and obtained a substantial increase in correlation ( , ).", [["the abnormally low mortality rate", "PROBLEM", 32, 65], ["increase", "OBSERVATION_MODIFIER", 156, 164]]], ["Neither the lockdown strictness nor the lockdown duration were significantly correlated with log COVID-19 Mortality Probability (Supplementary Table S5 ). .", [["log COVID", "TEST", 93, 102]]], ["The dashed vertical blue lines represent the day ten deaths were documented. represents the time difference between the orange and the blue vertical lines, defined as the response time ( is negative for Israel and positive for Japan).", [["deaths", "DISEASE", 53, 59], ["vertical blue lines", "CELL", 11, 30], ["blue vertical lines", "CELL", 135, 154], ["dashed vertical blue lines", "CELL_LINE", 4, 30], ["blue vertical lines", "CELL_LINE", 135, 154], ["The dashed vertical blue lines", "TREATMENT", 0, 30], ["the blue vertical lines", "TREATMENT", 131, 154], ["vertical", "OBSERVATION_MODIFIER", 11, 19], ["blue lines", "OBSERVATION", 20, 30], ["blue", "OBSERVATION", 135, 139], ["vertical lines", "OBSERVATION", 140, 154]]], ["The graphs for all OECD countries are given in Supplementary Fig. S2 .(which was not certified by peer review).", [["all OECD countries", "TREATMENT", 15, 33]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.11.20128520 doi: medRxiv preprint Figure 4 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["A semi-logarithmic scatter plot of the COVID-19 Mortality Probability and .", [["A semi-logarithmic scatter plot", "TEST", 0, 31], ["the COVID", "TEST", 35, 44]]], ["The x axis represents , the difference between the social distancing start time and the day in which the ten first deaths were recorded for the respective country (intuitively, the response time).", [["deaths", "DISEASE", 115, 121], ["x axis", "OBSERVATION_MODIFIER", 4, 10]]], ["The y axis represents the COVID-19 Mortality Probability in a logarithmic scale.", [["the COVID", "TEST", 22, 31], ["a logarithmic scale", "TREATMENT", 60, 79]]], ["Dot sizes are proportional to population sizes.", [["sizes", "OBSERVATION_MODIFIER", 4, 9], ["proportional", "OBSERVATION_MODIFIER", 14, 26], ["population", "OBSERVATION_MODIFIER", 30, 40], ["sizes", "OBSERVATION_MODIFIER", 41, 46]]], ["The dashed line corresponds to the fitted regression, excluding Japan.", [["The dashed line", "TREATMENT", 0, 15], ["dashed line", "OBSERVATION", 4, 15]]], ["The high correlation between and the log COVID-19 Mortality Probability yielded a crucial implication, as it allowed inferring the time required for this probability to double.", [["the log COVID", "TEST", 33, 46], ["high", "OBSERVATION_MODIFIER", 4, 8]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.11.20128520 doi: medRxiv preprint Next, we aimed to compute the time offset between mobility reduction and the decline in mortality growth rate.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["mobility reduction", "TREATMENT", 387, 405], ["the decline", "PROBLEM", 410, 421], ["mortality growth rate", "TEST", 425, 446], ["med", "ANATOMY", 99, 102]]], ["This offset serves as a proxy for the time between infection and fatality.(which was not certified by peer review)The time offset that yielded the highest correlation between ( ) and mortality growth rate was 25.75 days on average across countries (average Pearson , all except for Iceland, Latvia, and Slovakia, which had only several death incidents; Supplementary Table S6 and Supplementary Fig. S3 ).", [["infection", "DISEASE", 51, 60], ["death", "DISEASE", 336, 341], ["infection", "PROBLEM", 51, 60], ["fatality", "PROBLEM", 65, 73], ["mortality growth rate", "TEST", 183, 204], ["Supplementary Fig", "TREATMENT", 380, 397], ["infection", "OBSERVATION", 51, 60]]], ["This result highly resembles previous estimations of the time from infection to fatality 9,10 , although here it was derived from entirely different data and analysis.", [["infection", "DISEASE", 67, 76], ["infection", "PROBLEM", 67, 76], ["analysis", "TEST", 158, 166], ["infection", "OBSERVATION", 67, 76]]], ["Interestingly, this offset highly varied among the countries ( days), with exceptionally low offset in the United Kingdom (eight days) and exceptionally high offset in Finland, Hungary, and Estonia (38-39 days).", [["exceptionally low offset", "PROBLEM", 75, 99], ["low offset", "OBSERVATION_MODIFIER", 89, 99], ["high offset", "OBSERVATION", 153, 164]]], ["There was a mild correlation between the offset and COVID-19 Mortality Probability ( ), namely, the time between exposure and fatality shortens as the mortality rate grows.DiscussionIn this study, we modeled the mobility dynamics across time during the COVID-19 pandemic.DiscussionUsing this model we computed explanatory features that characterize a lockdown, and in turn, these features provided a quantitative measure for comparing the lockdown dynamics and outcome across countries.", [["a mild correlation", "PROBLEM", 10, 28], ["COVID", "TEST", 52, 57], ["the mortality rate", "TEST", 147, 165], ["this study", "TEST", 185, 195], ["the COVID", "TEST", 249, 258], ["pandemic", "PROBLEM", 262, 270], ["mild", "OBSERVATION_MODIFIER", 12, 16]]], ["We found high correlation between the response time of a country and its mortality rate.", [["its mortality rate", "TEST", 69, 87], ["high", "OBSERVATION_MODIFIER", 9, 13]]], ["In contrast, neither the lockdown duration nor the lockdown strictness were significantly associated with mortality rates (Supplementary Table S5 ).", [["the lockdown strictness", "PROBLEM", 47, 70]]], ["These results imply that a tight lockdown could have been unnecessary.DiscussionOfficial governmental regulations are possible resources for extracting features regarding the lockdown.", [["a tight lockdown", "TREATMENT", 25, 41]]], ["Such features were examined for their association with infection rates in previous studies 5, 11 .", [["infection", "DISEASE", 55, 64], ["infection rates", "PROBLEM", 55, 70], ["previous studies", "TEST", 74, 90], ["infection", "OBSERVATION", 55, 64]]], ["For example, Italy announced regional lockdowns in three phases.", [["regional", "OBSERVATION_MODIFIER", 29, 37]]], ["Initially, a lockdown was applied in Lombardy and Veneto regions on February 20.", [["a lockdown", "TREATMENT", 11, 21]]], ["However, the mobility data show that even though the initial lockdown was declared on Lombardy, mobility volumes across Italy kept .", [["the mobility data", "TEST", 9, 26]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.11.20128520 doi: medRxiv preprint elevating and started to decrease only a week later.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["medRxiv", "TREATMENT", 320, 327], ["med", "ANATOMY", 99, 102]]], ["In contrast, when the lockdowns on Northern Italy and later, on the entire country, were declared, a large drop in mobility usage had already taken place (Supplementary Fig. S4 ).(which was not certified by peer review)Most of the examined OECD countries complied well to the regression analysis in this study.(which was not certified by peer review)Small deviations could be explained by modest variations between countries, such as the conditions for defining a patient as a SARS-CoV-2 carrier, or by differences in mobile usage across areas.", [["SARS", "DISEASE", 477, 481], ["patient", "ORGANISM", 464, 471], ["patient", "SPECIES", 464, 471], ["a large drop in mobility usage", "PROBLEM", 99, 129], ["the regression analysis", "TEST", 272, 295], ["this study", "TEST", 299, 309], ["Small deviations", "PROBLEM", 350, 366], ["large", "OBSERVATION_MODIFIER", 101, 106], ["drop", "OBSERVATION_MODIFIER", 107, 111], ["deviations", "OBSERVATION", 356, 366], ["could be explained", "UNCERTAINTY", 367, 385], ["modest", "OBSERVATION_MODIFIER", 389, 395], ["variations", "OBSERVATION", 396, 406]]], ["Notably, different geographical areas also differ in numerous other attributes that may affect the coronavirus spread and induced mortality rates, e.g., humidity, wind speed, ethnicity, viral genotypic variation, and cultural habits.", [["coronavirus", "DISEASE", 99, 110], ["coronavirus", "ORGANISM", 99, 110], ["the coronavirus spread", "PROBLEM", 95, 117], ["viral genotypic variation", "PROBLEM", 186, 211], ["different", "OBSERVATION_MODIFIER", 9, 18], ["geographical", "OBSERVATION_MODIFIER", 19, 31], ["areas", "OBSERVATION_MODIFIER", 32, 37]]], ["One eminent example emerging from our analysis is Japan, where a relatively low mortality rate occurred even though mobility reduction took place relatively late.", [["our analysis", "TEST", 34, 46], ["a relatively low mortality rate", "PROBLEM", 63, 94], ["mobility reduction", "PROBLEM", 116, 134]]], ["The low mortality rate in Japan has previously been discussed 6 , and it should be beneficial to better understand the different trajectory of the pandemic in Japan, with respect to the Japanese governmental regulations and customs as a possible alternative to a strict lockdown.", [["The low mortality rate", "PROBLEM", 0, 22], ["a strict lockdown", "TREATMENT", 261, 278], ["low", "OBSERVATION_MODIFIER", 4, 7]]], ["Combining these features with the proposed mobility model may increase its overall accuracy.(which was not certified by peer review)The inferred high association between mobility and mortality rate led to crucial implications.(which was not certified by peer review)First, we found that the number of death incidents would double if action was taken in a delay of approximately one week.", [["death", "DISEASE", 301, 306], ["mortality rate", "TEST", 183, 197], ["high", "OBSERVATION_MODIFIER", 145, 149]]], ["Second, we inferred that the time offset from exposure to fatality is roughly 26 days, with some countries exhibiting extremely shorter time offsets and others much longer.", [["fatality", "DISEASE", 58, 66]]], ["We also observed that the correlation between this time offset and COVID-19 Mortality Probability results in .", [["COVID", "TEST", 67, 72]]], ["We hypothesize that the inverse correlation between the two may be explained by the load of high mortality on the health system, which might hamper the treatment and shorten survival time.", [["the treatment", "TREATMENT", 148, 161]]], ["The remaining variation may be explained by different treatment protocols, COVID-19 test policies, or other characteristics, and requires additional study.(which was not certified by peer review)We focused our analysis on 37 OECD countries, to concentrate on a representative group of relatively reliable reports.", [["different treatment protocols", "TREATMENT", 44, 73], ["COVID", "TEST", 75, 80], ["additional study", "TEST", 138, 154], ["our analysis", "TEST", 206, 218], ["may be explained", "UNCERTAINTY", 24, 40]]], ["Nevertheless, our results sustain when including additional non-OECD countries or when concentrating on sub regions for which sufficient data exist: the Pearson between and the log COVID-19 Mortality Probability for 58 countries was ( ; Supplementary Fig. S5) .", [["S5", "GENE_OR_GENE_PRODUCT", 256, 258], ["S5", "PROTEIN", 256, 258], ["the log COVID", "TREATMENT", 173, 186]]], ["A significant correlation ( ) was also observed when .", [["significant", "OBSERVATION_MODIFIER", 2, 13]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.11.20128520 doi: medRxiv preprint analyzing states within the United States ( ; Supplementary Fig. S6 ).", [["CC", "CHEMICAL", 0, 2], ["S6", "GENE_OR_GENE_PRODUCT", 402, 404], ["S6", "PROTEIN", 402, 404], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["Finally, while in this study we investigated the association of lockdown and mortality, the number of confirmed cases or hospital-committed patients can also be examined.", [["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148], ["this study", "TEST", 18, 28]]], ["We opted to use mortality as the outcome since it is less dependent on the number of COVID-19 tests, which widely varies among different countries.", [["mortality", "TREATMENT", 16, 25], ["COVID", "TEST", 85, 90], ["less dependent", "OBSERVATION_MODIFIER", 53, 67]]], ["Nevertheless, significant Pearson of 0.47 between and the log COVID-19 Infection Probability in OECD countries was also observed ( ; Supplementary Fig. S7 ).(which was not certified by peer review)The results of our analysis show that social distancing is a major factor in controlling COVID-19(which was not certified by peer review)spread.", [["the log COVID", "TEST", 54, 67], ["Infection", "PROBLEM", 71, 80], ["our analysis", "TEST", 212, 224], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["Infection", "OBSERVATION", 71, 80]]], ["Similar to previous studies 2, 8 , our analysis shows that if social distancing is not adopted, death incidents are doubled every 7.49 days.", [["death", "DISEASE", 96, 101], ["previous studies", "TEST", 11, 27], ["our analysis", "TEST", 35, 47]]], ["However, it also shows that a strict lockdown policy is not required.", [["a strict lockdown policy", "TREATMENT", 28, 52]]], ["Therefore, to avoid major infection outbreaks, we suggest undertaking a moderate form of a lockdown that can be tolerated by the society for longer time periods, with minimal socio-economic damage.Mobility dataMobility data, ( ), with one data point per day, , were downloaded from Apple repository on May 11, 2020 7 .", [["infection", "DISEASE", 26, 35], ["major infection outbreaks", "PROBLEM", 20, 45], ["a lockdown", "TREATMENT", 89, 99], ["minimal socio-economic damage", "PROBLEM", 167, 196], ["Mobility dataMobility data", "TEST", 197, 223], ["infection", "OBSERVATION", 26, 35]]], ["Due to the high similarity between \"walking\" and \"driving\" data (average Pearson correlation across countries , , all ) and since the \"transit\" data are incomplete, all analyses were applied using the \"driving\" data only.Mobility dataTo fit \u0302( ) to the mobility data, ( ), and receive the values of the parameters for every country, we used the Levenberg-Marquardt optimization algorithm from the SciPy module [12] [13] [14] .Mobility dataAccording to the parameters inferred from \u0302( ), we computed seven features to characterize the mobility trend in a country.", [["the mobility data", "TEST", 249, 266], ["the Levenberg", "TREATMENT", 341, 354]]], ["(1) , Social distancing start time; and (2) , Minimal mobility time point, corresponding to the times before and after the mobility drop.", [["the mobility drop", "PROBLEM", 119, 136]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020.Mortality dataThe Probability, the expected mortality ( ) was normalized by the population size for each country.Mortality dataData of population size were obtained from the World Population Review website 17 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["Mortality data", "TEST", 268, 282], ["med", "ANATOMY", 99, 102], ["size", "OBSERVATION_MODIFIER", 359, 363], ["size", "OBSERVATION_MODIFIER", 414, 418]]], ["Of note, our goal in this work was not to predict mortality rates, but rather, to find correlates with large changes in mortality patterns across countries.", [["large changes in mortality patterns", "PROBLEM", 103, 138], ["large", "OBSERVATION_MODIFIER", 103, 108]]], ["Since we correlate with the logarithm of the mortality rates, we expect that small deviations in mortality estimates will not affect our conclusions.Mortality data.", [["small deviations in mortality estimates", "PROBLEM", 77, 116], ["Mortality data", "TEST", 149, 163], ["small", "OBSERVATION_MODIFIER", 77, 82], ["deviations", "OBSERVATION", 83, 93]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.11.20128520 doi: medRxiv preprintAssociation between mortality and response timeWe define a response time, , as the difference between two time points: the social distancing start time (as inferred from \u0302( )) and the day in which ten first COVID-19 related deaths were recorded (according to ( ), see Fig. 3 ).", [["CC", "CHEMICAL", 0, 2], ["deaths", "DISEASE", 560, 566], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["medRxiv preprintAssociation", "TREATMENT", 320, 347], ["med", "ANATOMY", 99, 102]]], ["The ten deaths threshold was set to avoid incidental fluctuations that do not reflect the mortality trend of a certain country.", [["deaths", "DISEASE", 8, 14], ["The ten deaths threshold", "PROBLEM", 0, 24], ["incidental fluctuations", "PROBLEM", 42, 65]]], ["Thresholds of five and 20 deaths led to similar results.", [["deaths", "DISEASE", 26, 32]]], ["We chose an absolute threshold rather than a relative threshold (i.e., number of death incidents normalized to population size) because the very initial dynamics of the disease is not expected to be strongly coupled with the population size.", [["death", "DISEASE", 81, 86], ["the disease", "PROBLEM", 165, 176], ["size", "OBSERVATION_MODIFIER", 122, 126], ["disease", "OBSERVATION", 169, 176], ["size", "OBSERVATION_MODIFIER", 236, 240]]], ["Furthermore, setting a relative threshold of one death per 1 million (or more) citizens is problematic for countries such as Iceland because its population size is smaller than 10 6 .", [["death", "DISEASE", 49, 54], ["size", "OBSERVATION_MODIFIER", 156, 160], ["smaller", "OBSERVATION_MODIFIER", 164, 171]]], ["However, setting a threshold of one death per 10 5 citizens is problematic for countries such as Australia because such countries would never reach the starting threshold (at the date the data were collected, Australia had a mortality rate of death cases per population size).Association between mortality and response timeWe fitted a linear regression model to these data ( Fig. 4 ; excluding Japan), i.e., between and the log COVID-19 Mortality Probability (denoted as ( )).", [["death", "DISEASE", 36, 41], ["death", "DISEASE", 243, 248], ["one death", "PROBLEM", 32, 41], ["a linear regression model", "TREATMENT", 333, 358], ["size", "OBSERVATION_MODIFIER", 270, 274]]], ["This fitting resulted in the inferredThe offset between mortality growth rate and mobility dataThe mortality growth rate measures the relative daily increase of fatalities and is defined byThe offset between mortality growth rate and mobility data) .", [["fatalities", "DISEASE", 161, 171], ["mobility data", "TEST", 82, 95], ["The mortality growth rate", "PROBLEM", 95, 120], ["mortality growth rate", "TEST", 208, 229]]], ["The optimal time offset, namely, the offset that yields the highest correlation between the declining trends of mobility ( ) and mortality growth rate ( ), is Supplementary Fig. S3 ).The offset between mortality growth rate and mobility data.", [["mortality growth rate", "TEST", 129, 150], ["mortality growth rate", "TEST", 202, 223], ["mobility data", "TEST", 228, 241]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The offset between mortality growth rate and mobility dataThe copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.11.20128520 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["mortality growth rate", "TEST", 215, 236], ["mobility data", "TEST", 241, 254], ["The copyright holder", "TREATMENT", 254, 274], ["medRxiv", "TREATMENT", 379, 386], ["med", "ANATOMY", 99, 102]]]], "99f11f6e7dcf626abe3290b0cdc98d91e291517a": [["The firefly luciferase reporter plasmid, pABM2 (pGAL4-M2-Luc), with five GAL4-binding sites 36 base pairs upstream of the adenovirus major late TATA box and with a downstream region taken from the retinoic acid receptor \uf062 2 promoter [3] [4] , was a gift from Dr. Mark S. Ptashne.", [["retinoic acid", "CHEMICAL", 197, 210], ["retinoic acid", "CHEMICAL", 197, 210], ["luciferase", "GENE_OR_GENE_PRODUCT", 12, 22], ["pABM2", "GENE_OR_GENE_PRODUCT", 41, 46], ["pGAL4-M2-Luc", "GENE_OR_GENE_PRODUCT", 48, 60], ["GAL4", "GENE_OR_GENE_PRODUCT", 73, 77], ["adenovirus", "ORGANISM", 122, 132], ["retinoic acid receptor \uf062 2", "GENE_OR_GENE_PRODUCT", 197, 223], ["firefly luciferase reporter plasmid", "DNA", 4, 39], ["pABM2", "DNA", 41, 46], ["pGAL4", "DNA", 48, 53], ["M2", "DNA", 54, 56], ["Luc", "DNA", 57, 60], ["GAL4-binding sites", "DNA", 73, 91], ["adenovirus major late TATA box", "DNA", 122, 152], ["downstream region", "DNA", 164, 181], ["retinoic acid receptor \uf062 2 promoter", "DNA", 197, 232], ["The firefly luciferase reporter plasmid", "TEST", 0, 39], ["pABM2", "TEST", 41, 46], ["pGAL4", "TEST", 48, 53], ["five GAL4-binding sites", "TREATMENT", 68, 91], ["a downstream region", "TREATMENT", 162, 181], ["the retinoic acid receptor", "TREATMENT", 193, 219]]], ["The plasmid constitutively expressing the Renilla luciferase pHRL-TK (GenBank Acc.", [["plasmid", "ANATOMY", 4, 11], ["luciferase", "GENE_OR_GENE_PRODUCT", 50, 60], ["plasmid", "DNA", 4, 11], ["Renilla luciferase pHRL-TK (GenBank Acc", "DNA", 42, 81], ["the Renilla luciferase pHRL", "TEST", 38, 65], ["Renilla luciferase", "OBSERVATION", 42, 60]]], ["AF362549.1) from Promega (Madison, WI, USA) was used to normalize the level of the transfection in the experiments that used the firefly luciferase as a reporter gene.", [["AF362549.1", "CHEMICAL", 0, 10], ["luciferase", "GENE_OR_GENE_PRODUCT", 137, 147], ["firefly luciferase", "DNA", 129, 147], ["reporter gene", "DNA", 153, 166]]]], "PMC7123785": [["Factors that Influence Evaluation ::: IntroductionPreparation of quality lung tissue samples is important for histopathologic examination to optimize preservation of fine pulmonary architecture and, in the case of immunostaining, antigenicity of target epitopes [11\u201313].", [["lung tissue samples", "ANATOMY", 73, 92], ["pulmonary", "ANATOMY", 171, 180], ["lung tissue samples", "TISSUE", 73, 92], ["pulmonary", "ORGAN", 171, 180], ["histopathologic examination", "TEST", 110, 137], ["immunostaining", "TEST", 214, 228], ["target epitopes", "TEST", 246, 261], ["lung", "ANATOMY", 73, 77], ["tissue", "OBSERVATION", 78, 84], ["pulmonary architecture", "ANATOMY", 171, 193]]], ["A study by Engel and Moore identified more than 60 variables in this time frame, beginning with proper sample collection and handling and including multiple aspects of tissue collection, fixation, processing, embedding, slide drying, and storage [14].", [["tissue", "ANATOMY", 168, 174], ["tissue", "TISSUE", 168, 174], ["A study", "TEST", 0, 7], ["proper sample collection", "PROBLEM", 96, 120], ["tissue collection", "PROBLEM", 168, 185], ["fixation", "TREATMENT", 187, 195], ["multiple", "OBSERVATION_MODIFIER", 148, 156], ["tissue", "ANATOMY", 168, 174], ["collection", "OBSERVATION", 175, 185], ["fixation", "OBSERVATION", 187, 195]]], ["Thus, attention to details and quality early will greatly aid the subsequent evaluation, interpretation, and impact of tissue examination.Factors that Influence Evaluation ::: IntroductionTo collect lungs for histology, samples should be harvested as soon as possible following death to minimize autolysis [11].", [["tissue", "ANATOMY", 119, 125], ["lungs", "ANATOMY", 199, 204], ["samples", "ANATOMY", 220, 227], ["death", "DISEASE", 278, 283], ["tissue", "TISSUE", 119, 125], ["lungs", "ORGAN", 199, 204], ["the subsequent evaluation", "TEST", 62, 87], ["tissue examination", "TEST", 119, 137], ["histology", "TEST", 209, 218], ["autolysis", "PROBLEM", 296, 305], ["lungs", "ANATOMY", 199, 204]]], ["Autolysis (\u201cself-digestion\u201d) is a postmortem change characterized by degradation of cellular constituents (DNA, RNA, protein) and dissolution of the tissue [15].", [["cellular", "ANATOMY", 84, 92], ["tissue", "ANATOMY", 149, 155], ["Autolysis", "DISEASE", 0, 9], ["cellular", "CELL", 84, 92], ["DNA", "CELLULAR_COMPONENT", 107, 110], ["tissue", "TISSUE", 149, 155], ["Autolysis", "TEST", 0, 9], ["a postmortem change", "PROBLEM", 32, 51], ["cellular constituents", "TEST", 84, 105], ["tissue", "ANATOMY", 149, 155]]], ["Not only can this cause degradation of epitopes and increased nonspecific staining with immunohistochemistry, autolytic regions can be morphologically confused with foci of necrosis and edema [15\u201317].", [["foci", "ANATOMY", 165, 169], ["edema", "ANATOMY", 186, 191], ["necrosis", "DISEASE", 173, 181], ["edema", "DISEASE", 186, 191], ["edema", "PATHOLOGICAL_FORMATION", 186, 191], ["epitopes", "PROTEIN", 39, 47], ["epitopes", "PROBLEM", 39, 47], ["increased nonspecific staining with immunohistochemistry", "PROBLEM", 52, 108], ["autolytic regions", "PROBLEM", 110, 127], ["necrosis", "PROBLEM", 173, 181], ["edema", "PROBLEM", 186, 191], ["increased", "OBSERVATION_MODIFIER", 52, 61], ["nonspecific", "OBSERVATION_MODIFIER", 62, 73], ["foci", "OBSERVATION_MODIFIER", 165, 169], ["necrosis", "OBSERVATION", 173, 181], ["edema", "OBSERVATION", 186, 191]]], ["If animals will be euthanized, it is preferable to select a method that does not target the lungs such as an intravenous agent.", [["lungs", "ANATOMY", 92, 97], ["intravenous", "ANATOMY", 109, 120], ["animals", "ORGANISM", 3, 10], ["lungs", "ORGAN", 92, 97], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 109, 120], ["a method", "TREATMENT", 58, 66], ["an intravenous agent", "TREATMENT", 106, 126], ["lungs", "ANATOMY", 92, 97]]], ["Even use of inhalational overdose of carbon dioxide, as is commonly used in rodents, can potentially cause minor edema/hemorrhage [11, 18, 19].", [["edema", "ANATOMY", 113, 118], ["overdose", "DISEASE", 25, 33], ["carbon dioxide", "CHEMICAL", 37, 51], ["edema", "DISEASE", 113, 118], ["hemorrhage", "DISEASE", 119, 129], ["carbon dioxide", "CHEMICAL", 37, 51], ["carbon dioxide", "SIMPLE_CHEMICAL", 37, 51], ["edema", "PATHOLOGICAL_FORMATION", 113, 118], ["carbon dioxide", "TREATMENT", 37, 51], ["minor edema", "PROBLEM", 107, 118], ["hemorrhage", "PROBLEM", 119, 129], ["edema", "OBSERVATION", 113, 118], ["hemorrhage", "OBSERVATION", 119, 129]]], ["Evaluation of controls should be standard to evaluate for antemortem or euthanasia-related variables affecting lung evaluation.", [["lung", "ANATOMY", 111, 115], ["lung", "ORGAN", 111, 115], ["Evaluation of controls", "TEST", 0, 22], ["antemortem", "PROBLEM", 58, 68], ["euthanasia", "PROBLEM", 72, 82], ["lung evaluation", "TEST", 111, 126], ["euthanasia", "OBSERVATION", 72, 82], ["lung", "ANATOMY", 111, 115]]], ["When examining rodents versus lungs from larger animals or humans, sampling becomes a relevant variable.", [["lungs", "ANATOMY", 30, 35], ["lungs", "ORGAN", 30, 35], ["humans", "ORGANISM", 59, 65], ["humans", "SPECIES", 59, 65], ["humans", "SPECIES", 59, 65], ["lungs", "ANATOMY", 30, 35], ["larger", "OBSERVATION_MODIFIER", 41, 47], ["animals", "OBSERVATION", 48, 55]]], ["For instance, mice have small lungs that can be sectioned onto one glass slide for widespread evaluation.", [["lungs", "ANATOMY", 30, 35], ["mice", "ORGANISM", 14, 18], ["lungs", "ORGAN", 30, 35], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 14, 18], ["small lungs", "PROBLEM", 24, 35], ["widespread evaluation", "TEST", 83, 104], ["small", "OBSERVATION_MODIFIER", 24, 29], ["lungs", "ANATOMY", 30, 35]]], ["Larger sized lungs cannot be sampled adequately using only one slide without introducing sampling bias.", [["lungs", "ANATOMY", 13, 18], ["lungs", "ORGAN", 13, 18], ["Larger sized lungs", "PROBLEM", 0, 18], ["introducing sampling bias", "TEST", 77, 102], ["sized", "OBSERVATION_MODIFIER", 7, 12], ["lungs", "ANATOMY", 13, 18], ["cannot be", "UNCERTAINTY", 19, 28]]], ["Therefore, several samples will need to be collected in larger lungs.", [["samples", "ANATOMY", 19, 26], ["lungs", "ANATOMY", 63, 68], ["lungs", "ORGAN", 63, 68], ["several samples", "TEST", 11, 26], ["lungs", "ANATOMY", 63, 68]]], ["The collection method will need to be defined in the methods of publications and should include collection site (standardized vs. lesions sites) and total number, the latter of which depends on the size of the lungs, distribution of lung lesions, and overarching goals of the study.Factors that Influence Evaluation ::: IntroductionProper and adequate fixation of the tissues is essential to retain optimal tissue morphology and cellular antigenicity for immunostaining techniques [11, 20].", [["lesions sites", "ANATOMY", 130, 143], ["lungs", "ANATOMY", 210, 215], ["lung lesions", "ANATOMY", 233, 245], ["tissues", "ANATOMY", 368, 375], ["tissue", "ANATOMY", 407, 413], ["cellular", "ANATOMY", 429, 437], ["lung lesions", "DISEASE", 233, 245], ["lesions sites", "MULTI-TISSUE_STRUCTURE", 130, 143], ["lungs", "ORGAN", 210, 215], ["lung lesions", "CANCER", 233, 245], ["tissues", "TISSUE", 368, 375], ["tissue", "TISSUE", 407, 413], ["cellular", "CELL", 429, 437], ["The collection method", "TREATMENT", 0, 21], ["collection site", "PROBLEM", 96, 111], ["lesions sites", "PROBLEM", 130, 143], ["lung lesions", "PROBLEM", 233, 245], ["the study", "TEST", 272, 281], ["IntroductionProper", "TREATMENT", 320, 338], ["adequate fixation of the tissues", "TREATMENT", 343, 375], ["immunostaining techniques", "TEST", 455, 480], ["total", "OBSERVATION_MODIFIER", 149, 154], ["number", "OBSERVATION_MODIFIER", 155, 161], ["size", "OBSERVATION_MODIFIER", 198, 202], ["lungs", "ANATOMY", 210, 215], ["distribution", "OBSERVATION_MODIFIER", 217, 229], ["lung", "ANATOMY", 233, 237], ["lesions", "OBSERVATION", 238, 245], ["adequate", "OBSERVATION_MODIFIER", 343, 351], ["fixation", "OBSERVATION", 352, 360], ["tissues", "ANATOMY", 368, 375], ["optimal tissue", "OBSERVATION_MODIFIER", 399, 413]]], ["However, it is important to remember that if lungs are to be assessed or scored for macroscopic (gross) indicators of disease (such as color, surface texture, and consistency), this must be done prior to fixation, which will affect all of these parameters.", [["lungs", "ANATOMY", 45, 50], ["surface", "ANATOMY", 142, 149], ["lungs", "ORGAN", 45, 50], ["macroscopic (gross) indicators of disease", "PROBLEM", 84, 125], ["color, surface texture", "TEST", 135, 157], ["fixation", "TREATMENT", 204, 212], ["lungs", "ANATOMY", 45, 50], ["disease", "OBSERVATION", 118, 125]]], ["Macroscopic evaluation and scoring can be a nice tool to complement histopathology lesions [21, 22].", [["histopathology lesions", "ANATOMY", 68, 90], ["Macroscopic evaluation", "TEST", 0, 22], ["complement histopathology lesions", "PROBLEM", 57, 90]]], ["For tissues that will be paraffin embedded, sections are typically fixed in 10% neutral buffered formalin or 4% paraformaldehyde, though other fixatives may be employed based on the desired analysis endpoints.", [["tissues", "ANATOMY", 4, 11], ["sections", "ANATOMY", 44, 52], ["formalin", "CHEMICAL", 97, 105], ["paraffin", "CHEMICAL", 25, 33], ["formalin", "CHEMICAL", 97, 105], ["paraformaldehyde", "CHEMICAL", 112, 128], ["tissues", "TISSUE", 4, 11], ["sections", "MULTI-TISSUE_STRUCTURE", 44, 52], ["formalin", "SIMPLE_CHEMICAL", 97, 105], ["paraformaldehyde", "SIMPLE_CHEMICAL", 112, 128], ["neutral buffered formalin", "TREATMENT", 80, 105], ["4% paraformaldehyde", "TREATMENT", 109, 128], ["other fixatives", "TREATMENT", 137, 152]]], ["Collected lung samples can be placed in a minimum of 20:1 volume of fixative:tissue with a maximal thickness of tissue of no more than ~5 mm in at least one dimension to be consistently fixed [20].", [["lung samples", "ANATOMY", 10, 22], ["tissue", "ANATOMY", 77, 83], ["tissue", "ANATOMY", 112, 118], ["lung samples", "CANCER", 10, 22], ["tissue", "TISSUE", 77, 83], ["tissue", "TISSUE", 112, 118], ["Collected lung samples", "TEST", 0, 22], ["a maximal thickness of tissue", "TEST", 89, 118], ["lung", "ANATOMY", 10, 14], ["fixative", "OBSERVATION", 68, 76], ["maximal thickness", "OBSERVATION_MODIFIER", 91, 108], ["tissue", "OBSERVATION", 112, 118], ["no", "UNCERTAINTY", 122, 124], ["more than ~5 mm", "OBSERVATION_MODIFIER", 125, 140], ["consistently", "OBSERVATION_MODIFIER", 173, 185], ["fixed", "OBSERVATION", 186, 191]]], ["For rodents, inflation of the lungs via intratracheal instillation of fixative is recommended to best preserve lung morphology and reduce artifactual atelectasis [15].", [["lungs", "ANATOMY", 30, 35], ["intratracheal", "ANATOMY", 40, 53], ["lung", "ANATOMY", 111, 115], ["atelectasis", "DISEASE", 150, 161], ["lungs", "ORGAN", 30, 35], ["intratracheal", "IMMATERIAL_ANATOMICAL_ENTITY", 40, 53], ["lung", "ORGAN", 111, 115], ["inflation of the lungs via intratracheal instillation of fixative", "TREATMENT", 13, 78], ["artifactual atelectasis", "PROBLEM", 138, 161], ["inflation", "OBSERVATION", 13, 22], ["lungs", "ANATOMY", 30, 35], ["intratracheal", "ANATOMY", 40, 53], ["lung", "ANATOMY", 111, 115], ["artifactual", "OBSERVATION_MODIFIER", 138, 149], ["atelectasis", "OBSERVATION", 150, 161]]], ["However, this approach is contraindicated for lung infection as this can alter the anatomic location of inflammation and cellular debris [22].", [["lung", "ANATOMY", 46, 50], ["cellular", "ANATOMY", 121, 129], ["lung infection", "DISEASE", 46, 60], ["inflammation", "DISEASE", 104, 116], ["lung", "ORGAN", 46, 50], ["cellular", "CELL", 121, 129], ["lung infection", "PROBLEM", 46, 60], ["inflammation", "PROBLEM", 104, 116], ["cellular debris", "PROBLEM", 121, 136], ["lung", "ANATOMY", 46, 50], ["infection", "OBSERVATION", 51, 60], ["inflammation", "OBSERVATION", 104, 116], ["cellular debris", "OBSERVATION", 121, 136]]], ["The lungs and heart of rodents can be removed en bloc for fixation.", [["lungs", "ANATOMY", 4, 9], ["heart", "ANATOMY", 14, 19], ["en bloc", "ANATOMY", 46, 53], ["lungs", "ORGAN", 4, 9], ["heart", "ORGAN", 14, 19], ["rodents", "ORGANISM", 23, 30], ["en bloc", "TREATMENT", 46, 53], ["fixation", "TREATMENT", 58, 66], ["lungs", "ANATOMY", 4, 9], ["heart", "ANATOMY", 14, 19]]], ["Freezing of tissue may be an alternative approach to preserve specific antigens, but this process typically results in suboptimal retention of cellular and tissue architectural detail [11].Factors that Influence Evaluation ::: IntroductionAfter processing to dehydrate the fixed lungs, samples must be embedded and sectioned in a consistent manner.", [["tissue", "ANATOMY", 12, 18], ["cellular", "ANATOMY", 143, 151], ["tissue", "ANATOMY", 156, 162], ["lungs", "ANATOMY", 279, 284], ["samples", "ANATOMY", 286, 293], ["tissue", "TISSUE", 12, 18], ["cellular", "CELL", 143, 151], ["tissue", "TISSUE", 156, 162], ["lungs", "ORGAN", 279, 284], ["Freezing of tissue", "PROBLEM", 0, 18], ["dehydrate the fixed lungs", "PROBLEM", 259, 284], ["tissue", "ANATOMY", 12, 18], ["suboptimal", "OBSERVATION_MODIFIER", 119, 129], ["retention", "OBSERVATION_MODIFIER", 130, 139], ["cellular", "OBSERVATION_MODIFIER", 143, 151], ["lungs", "ANATOMY", 279, 284]]], ["Due to the relatively small size of mice, all lung lobes can be embedded en bloc with the ventral lobar surfaces oriented down in the cassette, which results in sections showing longitudinal views of major conducting airways.", [["lung lobes", "ANATOMY", 46, 56], ["ventral lobar surfaces", "ANATOMY", 90, 112], ["sections", "ANATOMY", 161, 169], ["airways", "ANATOMY", 217, 224], ["mice", "ORGANISM", 36, 40], ["lung lobes", "MULTI-TISSUE_STRUCTURE", 46, 56], ["airways", "MULTI-TISSUE_STRUCTURE", 217, 224], ["mice", "SPECIES", 36, 40], ["mice", "SPECIES", 36, 40], ["en bloc", "TREATMENT", 73, 80], ["the ventral lobar surfaces", "TREATMENT", 86, 112], ["longitudinal views", "TEST", 178, 196], ["relatively", "OBSERVATION_MODIFIER", 11, 21], ["small", "OBSERVATION_MODIFIER", 22, 27], ["size", "OBSERVATION_MODIFIER", 28, 32], ["mice", "OBSERVATION", 36, 40], ["lung", "ANATOMY", 46, 50], ["lobes", "ANATOMY_MODIFIER", 51, 56], ["bloc", "OBSERVATION", 76, 80], ["ventral", "ANATOMY_MODIFIER", 90, 97], ["lobar", "ANATOMY_MODIFIER", 98, 103], ["surfaces", "OBSERVATION_MODIFIER", 104, 112], ["airways", "ANATOMY", 217, 224]]], ["An alternative approach for mice, or standard approach for larger species, lung lobes can be collected as multiple sections that fit into a cassette, with each sample embedded separately [11].", [["lung lobes", "ANATOMY", 75, 85], ["sections", "ANATOMY", 115, 123], ["sample", "ANATOMY", 160, 166], ["mice", "ORGANISM", 28, 32], ["lung lobes", "MULTI-TISSUE_STRUCTURE", 75, 85], ["mice", "SPECIES", 28, 32], ["mice", "SPECIES", 28, 32], ["larger species, lung lobes", "PROBLEM", 59, 85], ["lung", "ANATOMY", 75, 79], ["lobes", "ANATOMY_MODIFIER", 80, 85]]], ["Slides are typically stained with hematoxylin and eosin (HE) for routine histologic evaluation.", [["hematoxylin", "CHEMICAL", 34, 45], ["eosin", "CHEMICAL", 50, 55], ["hematoxylin", "SIMPLE_CHEMICAL", 34, 45], ["eosin", "SIMPLE_CHEMICAL", 50, 55], ["hematoxylin", "TREATMENT", 34, 45], ["routine histologic evaluation", "TEST", 65, 94]]], ["If immunostaining is desired, it is essential to optimize and validate each new antibody utilizing appropriate positive and negative controls to ensure accurate staining results [20, 23].", [["immunostaining", "PROBLEM", 3, 17], ["new antibody", "TEST", 76, 88]]], ["Similarly, if special histochemical stains will be employed, appropriate control slides and tissues should also be utilized for each batch.Factors that Influence Evaluation ::: IntroductionAwareness of normal anatomy and morphology is necessary to recognize any type of change and when utilizing animal models of human disease, this includes knowing differences between the species [24, 25].", [["tissues", "ANATOMY", 92, 99], ["human disease", "DISEASE", 313, 326], ["tissues", "TISSUE", 92, 99], ["human", "ORGANISM", 313, 318], ["human", "SPECIES", 313, 318], ["human", "SPECIES", 313, 318], ["special histochemical stains", "TEST", 14, 42], ["human disease", "PROBLEM", 313, 326], ["normal anatomy", "OBSERVATION", 202, 216]]], ["For example, there are a number of morphologic differences between the respiratory tract structures of mice and humans.", [["respiratory tract structures", "ANATOMY", 71, 99], ["respiratory tract", "ORGANISM_SUBDIVISION", 71, 88], ["mice", "ORGANISM", 103, 107], ["humans", "ORGANISM", 112, 118], ["mice", "SPECIES", 103, 107], ["humans", "SPECIES", 112, 118], ["mice", "SPECIES", 103, 107], ["humans", "SPECIES", 112, 118], ["number", "OBSERVATION_MODIFIER", 25, 31], ["morphologic", "OBSERVATION_MODIFIER", 35, 46], ["differences", "OBSERVATION_MODIFIER", 47, 58], ["respiratory tract", "ANATOMY", 71, 88]]], ["Lobation is distinct, in that mice have four right lung lobes (cranial, middle, caudal, and accessory) and only one left lobe, while humans have three right lung lobes (upper, middle, and lower) and two left lobes (upper and lower) [15, 22].", [["right lung lobes", "ANATOMY", 45, 61], ["cranial", "ANATOMY", 63, 70], ["caudal", "ANATOMY", 80, 86], ["left lobe", "ANATOMY", 116, 125], ["right lung lobes", "ANATOMY", 151, 167], ["left lobes", "ANATOMY", 203, 213], ["mice", "ORGANISM", 30, 34], ["lung lobes", "MULTI-TISSUE_STRUCTURE", 51, 61], ["cranial", "ORGAN", 63, 70], ["caudal", "MULTI-TISSUE_STRUCTURE", 80, 86], ["lobe", "ORGAN", 121, 125], ["humans", "ORGANISM", 133, 139], ["lung lobes", "MULTI-TISSUE_STRUCTURE", 157, 167], ["upper", "ORGANISM_SUBDIVISION", 169, 174], ["left lobes", "MULTI-TISSUE_STRUCTURE", 203, 213], ["upper", "ORGANISM_SUBDIVISION", 215, 220], ["mice", "SPECIES", 30, 34], ["humans", "SPECIES", 133, 139], ["mice", "SPECIES", 30, 34], ["humans", "SPECIES", 133, 139], ["distinct", "OBSERVATION_MODIFIER", 12, 20], ["right", "ANATOMY_MODIFIER", 45, 50], ["lung", "ANATOMY", 51, 55], ["lobes", "ANATOMY_MODIFIER", 56, 61], ["cranial", "ANATOMY_MODIFIER", 63, 70], ["middle", "ANATOMY_MODIFIER", 72, 78], ["caudal", "ANATOMY_MODIFIER", 80, 86], ["accessory", "ANATOMY_MODIFIER", 92, 101], ["left lobe", "ANATOMY", 116, 125], ["right", "ANATOMY_MODIFIER", 151, 156], ["lung", "ANATOMY", 157, 161], ["lobes", "ANATOMY_MODIFIER", 162, 167], ["upper", "ANATOMY_MODIFIER", 169, 174], ["middle", "ANATOMY_MODIFIER", 176, 182], ["lower", "ANATOMY_MODIFIER", 188, 193], ["two", "ANATOMY_MODIFIER", 199, 202], ["left lobes", "ANATOMY", 203, 213], ["upper", "ANATOMY_MODIFIER", 215, 220], ["lower", "ANATOMY_MODIFIER", 225, 230]]], ["Rats and mice lack intralobular septa, intrapulmonary bronchi, intrapulmonary submucosal glands, and respiratory bronchioles.", [["intralobular septa", "ANATOMY", 19, 37], ["intrapulmonary bronchi", "ANATOMY", 39, 61], ["intrapulmonary submucosal glands", "ANATOMY", 63, 95], ["respiratory bronchioles", "ANATOMY", 101, 124], ["Rats", "ORGANISM", 0, 4], ["mice", "ORGANISM", 9, 13], ["intralobular septa", "MULTI-TISSUE_STRUCTURE", 19, 37], ["intrapulmonary bronchi", "MULTI-TISSUE_STRUCTURE", 39, 61], ["intrapulmonary submucosal glands", "ORGAN", 63, 95], ["respiratory bronchioles", "MULTI-TISSUE_STRUCTURE", 101, 124], ["Rats", "SPECIES", 0, 4], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 9, 13], ["mice lack intralobular septa, intrapulmonary bronchi, intrapulmonary submucosal glands, and respiratory bronchioles", "PROBLEM", 9, 124], ["intralobular", "ANATOMY_MODIFIER", 19, 31], ["septa", "ANATOMY_MODIFIER", 32, 37], ["intrapulmonary", "ANATOMY_MODIFIER", 39, 53], ["bronchi", "ANATOMY", 54, 61], ["intrapulmonary", "ANATOMY_MODIFIER", 63, 77], ["submucosal glands", "ANATOMY", 78, 95], ["respiratory", "ANATOMY_MODIFIER", 101, 112], ["bronchioles", "ANATOMY", 113, 124]]], ["Mice also have more club cells extending to the trachea, a thinner blood-gas barrier, and a smaller alveolar diameter than humans [11, 26].", [["cells", "ANATOMY", 25, 30], ["trachea", "ANATOMY", 48, 55], ["blood", "ANATOMY", 67, 72], ["alveolar", "ANATOMY", 100, 108], ["Mice", "ORGANISM", 0, 4], ["club cells", "CELL", 20, 30], ["trachea", "ORGAN", 48, 55], ["blood", "ORGANISM_SUBSTANCE", 67, 72], ["alveolar", "TISSUE", 100, 108], ["humans", "ORGANISM", 123, 129], ["club cells", "CELL_TYPE", 20, 30], ["Mice", "SPECIES", 0, 4], ["humans", "SPECIES", 123, 129], ["humans", "SPECIES", 123, 129], ["a thinner blood-gas barrier", "PROBLEM", 57, 84], ["more", "OBSERVATION_MODIFIER", 15, 19], ["club cells", "OBSERVATION", 20, 30], ["trachea", "ANATOMY", 48, 55], ["thinner", "OBSERVATION_MODIFIER", 59, 66], ["gas barrier", "OBSERVATION", 73, 84], ["smaller", "OBSERVATION_MODIFIER", 92, 99], ["alveolar", "ANATOMY_MODIFIER", 100, 108], ["diameter", "OBSERVATION_MODIFIER", 109, 117]]], ["These anatomic variations do not mean that rodents cannot be very valuable models of lung disease; rather they are highlighted here as an example of the type of knowledge necessary for correct interpretation of experimental models.Factors that Influence Evaluation ::: IntroductionInclusion of experienced board-certified pathologists, who are specially trained to examine and interpret tissues changes, as part of the multidisciplinary team can greatly enhance the quality of tissue evaluation [22, 27].", [["lung", "ANATOMY", 85, 89], ["tissues", "ANATOMY", 387, 394], ["tissue", "ANATOMY", 477, 483], ["lung disease", "DISEASE", 85, 97], ["lung", "ORGAN", 85, 89], ["tissues", "TISSUE", 387, 394], ["tissue", "TISSUE", 477, 483], ["lung disease", "PROBLEM", 85, 97], ["tissue evaluation", "TEST", 477, 494], ["lung", "ANATOMY", 85, 89], ["disease", "OBSERVATION", 90, 97]]], ["By histopathology, a skilled eye (ideally a pathologist familiar with the model) can not only define the types of inflammatory processes, but also corroborate these findings to clinical signs and/or data from other analyses [22, 27\u201330].", [["eye", "ANATOMY", 29, 32], ["eye", "ORGAN", 29, 32], ["inflammatory processes", "PROBLEM", 114, 136], ["clinical signs", "TEST", 177, 191], ["other analyses", "TEST", 209, 223], ["eye", "ANATOMY", 29, 32], ["inflammatory", "OBSERVATION", 114, 126]]], ["In addition, pathologists have knowledge of correct lesion nomenclature, as well as potential effects of such variables as strain-related background lesions, husbandry, the microbiome, and diet on the interpretation of results [25].", [["lesion", "ANATOMY", 52, 58], ["lesions", "ANATOMY", 149, 156], ["lesions", "PATHOLOGICAL_FORMATION", 149, 156], ["correct lesion nomenclature", "PROBLEM", 44, 71], ["such variables", "PROBLEM", 105, 119], ["background lesions", "PROBLEM", 138, 156], ["lesion", "OBSERVATION", 52, 58], ["lesions", "OBSERVATION", 149, 156]]], ["If pathologists are not involved in designing translational experiments and interpreting lesions in animal models, bias may be introduced and the accuracy of the data and conclusions may be questionable.", [["lesions", "ANATOMY", 89, 96], ["lesions", "PATHOLOGICAL_FORMATION", 89, 96], ["interpreting lesions", "PROBLEM", 76, 96], ["the data", "TEST", 158, 166], ["lesions", "OBSERVATION", 89, 96]]], ["This approach, which lacks the expertise of a pathologist trained in tissue interpretation, has been labeled as \u201cdo-it-yourself pathology\u201d and is linked to multiple publications containing erroneous interpretations [22, 25, 31, 32].", [["tissue", "ANATOMY", 69, 75], ["tissue", "TISSUE", 69, 75]]], ["While observations made by biomedical personnel may be biologically accurate in some cases, it is important to note that tissue examination by non-pathologists (even those who are \u201cscientific experts\u201d for a particular disease) is prone to false-positive and false-negative errors and not recommended [33].", [["tissue", "ANATOMY", 121, 127], ["tissue", "TISSUE", 121, 127], ["tissue examination", "TEST", 121, 139], ["a particular disease", "PROBLEM", 205, 225]]], ["Ideally, tissues should be examined by a pathologist familiar with histopathology of the model (seeNote 1).", [["tissues", "ANATOMY", 9, 16], ["tissues", "TISSUE", 9, 16]]], ["It is recognized that not all labs have access to pathologists for this role and in many situations a member of the investigational team is assigned to the role.", [["all labs", "TEST", 26, 34]]], ["In these situations, if possible, it helps to have a pathologist review the study findings prior to publication or have the examiner meet with a pathologist to screen the slides and data for accuracy.Factors that Influence Evaluation ::: IntroductionLungs have unique features compared to other organs that are important for consideration in designing experiments or when making interpretations.", [["organs", "ANATOMY", 295, 301], ["organs", "ORGAN", 295, 301], ["the study", "TEST", 72, 81], ["the slides", "TEST", 167, 177], ["accuracy", "TEST", 191, 199]]], ["For study of infectious diseases, distribution and histologic appearance of lung lesions depends on a variety of factors including the viral inoculate concentration, route of exposure, regional deposition, cellular uptake, chronicity, and host immune response.", [["lung lesions", "ANATOMY", 76, 88], ["cellular", "ANATOMY", 206, 214], ["infectious diseases", "DISEASE", 13, 32], ["lung lesions", "DISEASE", 76, 88], ["lung lesions", "PATHOLOGICAL_FORMATION", 76, 88], ["cellular", "CELL", 206, 214], ["infectious diseases", "PROBLEM", 13, 32], ["lung lesions", "PROBLEM", 76, 88], ["the viral inoculate concentration", "PROBLEM", 131, 164], ["regional deposition", "PROBLEM", 185, 204], ["cellular uptake", "PROBLEM", 206, 221], ["chronicity", "PROBLEM", 223, 233], ["infectious", "OBSERVATION", 13, 23], ["histologic", "OBSERVATION_MODIFIER", 51, 61], ["lung", "ANATOMY", 76, 80], ["lesions", "OBSERVATION", 81, 88], ["regional deposition", "OBSERVATION", 185, 204], ["cellular uptake", "OBSERVATION", 206, 221], ["host immune response", "OBSERVATION", 239, 259]]], ["For instance, inbred mouse strains can have variably sized airways that may affect viral droplet delivery or clinical disease manifestations such as airway obstruction [34].", [["airways", "ANATOMY", 59, 66], ["airway", "ANATOMY", 149, 155], ["airway obstruction", "DISEASE", 149, 167], ["mouse", "ORGANISM", 21, 26], ["airways", "MULTI-TISSUE_STRUCTURE", 59, 66], ["airway", "PATHOLOGICAL_FORMATION", 149, 155], ["mouse", "SPECIES", 21, 26], ["mouse", "SPECIES", 21, 26], ["inbred mouse strains", "PROBLEM", 14, 34], ["variably sized airways", "PROBLEM", 44, 66], ["viral droplet delivery", "TREATMENT", 83, 105], ["clinical disease manifestations", "PROBLEM", 109, 140], ["airway obstruction", "PROBLEM", 149, 167], ["airways", "ANATOMY", 59, 66], ["airway", "ANATOMY", 149, 155], ["obstruction", "OBSERVATION", 156, 167]]], ["Inbred mouse strains can also exhibit biased (e.g., Th1 vs. Th2 immune responses) or deficient immune signaling pathways that might influence infection susceptibility or severity [35, 36].", [["infection", "DISEASE", 142, 151], ["Inbred", "ORGANISM", 0, 6], ["mouse", "ORGANISM", 7, 12], ["mouse", "SPECIES", 7, 12], ["mouse", "SPECIES", 7, 12], ["Inbred mouse strains", "PROBLEM", 0, 20], ["biased (e.g., Th1 vs", "PROBLEM", 38, 58], ["deficient immune signaling pathways", "PROBLEM", 85, 120], ["influence infection susceptibility", "PROBLEM", 132, 166]]], ["Sex can also be an influencing factor for infection and needs to be considered in the experimental design [37].", [["infection", "DISEASE", 42, 51], ["infection", "PROBLEM", 42, 51], ["infection", "OBSERVATION", 42, 51]]], ["Even actions as simple as laying an animal in lateral recumbency to recover from anesthesia following viral inoculation may lead to more prominent lesions in certain lobe(s) [22].", [["lesions", "ANATOMY", 147, 154], ["lesions", "PATHOLOGICAL_FORMATION", 147, 154], ["anesthesia", "TREATMENT", 81, 91], ["viral inoculation", "PROBLEM", 102, 119], ["more prominent lesions", "PROBLEM", 132, 154], ["prominent", "OBSERVATION_MODIFIER", 137, 146], ["lesions", "OBSERVATION", 147, 154], ["lobe", "ANATOMY_MODIFIER", 166, 170]]], ["For many of these features, inclusion of appropriate control animals (i.e., strain-, age-, and sex-matched, housed under identical husbandry conditions and free from confounding pathogens) is necessary and important to tease out any lesions unrelated to the treatments.", [["lesions", "ANATOMY", 233, 240], ["lesions", "PATHOLOGICAL_FORMATION", 233, 240], ["confounding pathogens", "PROBLEM", 166, 187], ["any lesions", "PROBLEM", 229, 240], ["the treatments", "TREATMENT", 254, 268], ["lesions", "OBSERVATION", 233, 240]]], ["Unlike the other organs in which the size is relatively static, the lung has dynamic size changes during normal respiration.", [["organs", "ANATOMY", 17, 23], ["lung", "ANATOMY", 68, 72], ["organs", "ORGAN", 17, 23], ["lung", "ORGAN", 68, 72], ["dynamic size changes", "PROBLEM", 77, 97], ["size", "OBSERVATION_MODIFIER", 37, 41], ["relatively", "OBSERVATION_MODIFIER", 45, 55], ["static", "OBSERVATION", 56, 62], ["lung", "ANATOMY", 68, 72], ["dynamic", "OBSERVATION_MODIFIER", 77, 84], ["size", "OBSERVATION_MODIFIER", 85, 89], ["normal respiration", "OBSERVATION", 105, 123]]], ["Handing of the postmortem lung in a standardized manner is useful to prevent postmortem atelectasis or variable inter-animal insufflation.", [["postmortem lung", "ANATOMY", 15, 30], ["atelectasis", "DISEASE", 88, 99], ["lung", "ORGAN", 26, 30], ["postmortem atelectasis", "PROBLEM", 77, 99], ["variable inter-animal insufflation", "PROBLEM", 103, 137], ["lung", "ANATOMY", 26, 30], ["atelectasis", "OBSERVATION", 88, 99], ["variable", "OBSERVATION_MODIFIER", 103, 111], ["inter-animal insufflation", "OBSERVATION", 112, 137]]], ["Right ventricular perfusion of fixative into the lungs prior to extraction can help with fixation as well as insufflate the airspaces without dislodging inflammation or mucocellular debris [22].Histopathology ::: IntroductionHistopathology is the microscopic examination of tissues for morphologic or structural changes that differ from normal and these changes are called lesions.", [["Right ventricular", "ANATOMY", 0, 17], ["lungs", "ANATOMY", 49, 54], ["airspaces", "ANATOMY", 124, 133], ["tissues", "ANATOMY", 274, 281], ["lesions", "ANATOMY", 373, 380], ["inflammation", "DISEASE", 153, 165], ["Right ventricular", "MULTI-TISSUE_STRUCTURE", 0, 17], ["lungs", "ORGAN", 49, 54], ["airspaces", "MULTI-TISSUE_STRUCTURE", 124, 133], ["tissues", "TISSUE", 274, 281], ["lesions", "PATHOLOGICAL_FORMATION", 373, 380], ["extraction", "TREATMENT", 64, 74], ["fixation", "TREATMENT", 89, 97], ["dislodging inflammation", "PROBLEM", 142, 165], ["mucocellular debris", "PROBLEM", 169, 188], ["IntroductionHistopathology", "TEST", 213, 239], ["the microscopic examination", "TEST", 243, 270], ["structural changes", "PROBLEM", 301, 319], ["lesions", "PROBLEM", 373, 380], ["ventricular", "ANATOMY", 6, 17], ["perfusion", "OBSERVATION", 18, 27], ["fixative", "OBSERVATION", 31, 39], ["lungs", "ANATOMY", 49, 54], ["airspaces", "ANATOMY", 124, 133], ["without", "UNCERTAINTY", 134, 141], ["dislodging", "OBSERVATION_MODIFIER", 142, 152], ["inflammation", "OBSERVATION", 153, 165], ["mucocellular debris", "OBSERVATION", 169, 188], ["normal", "OBSERVATION", 337, 343], ["lesions", "OBSERVATION", 373, 380]]], ["Histopathology of coronavirus-infected lung in humans and animal models can be a useful tool to help define affected cells, illuminate the structural cause(s) of clinical signs, and clarify potential therapies.", [["lung", "ANATOMY", 39, 43], ["cells", "ANATOMY", 117, 122], ["coronavirus-infected", "DISEASE", 18, 38], ["coronavirus", "ORGANISM", 18, 29], ["lung", "ORGAN", 39, 43], ["humans", "ORGANISM", 47, 53], ["cells", "CELL", 117, 122], ["coronavirus", "SPECIES", 18, 29], ["humans", "SPECIES", 47, 53], ["humans", "SPECIES", 47, 53], ["Histopathology", "TEST", 0, 14], ["coronavirus", "PROBLEM", 18, 29], ["infected lung in humans", "PROBLEM", 30, 53], ["affected cells", "PROBLEM", 108, 122], ["clinical signs", "TEST", 162, 176], ["potential therapies", "TREATMENT", 190, 209], ["coronavirus", "OBSERVATION", 18, 29], ["infected", "OBSERVATION", 30, 38], ["lung", "ANATOMY", 39, 43]]], ["During disease outbreaks, clinical data including autopsy cases can be studied in parallel with animal model investigations to better define lung disease pathogenesis and therapies.", [["lung", "ANATOMY", 141, 145], ["lung disease", "DISEASE", 141, 153], ["lung", "ORGAN", 141, 145], ["clinical data", "TEST", 26, 39], ["autopsy cases", "TEST", 50, 63], ["animal model investigations", "TEST", 96, 123], ["lung disease pathogenesis", "PROBLEM", 141, 166], ["therapies", "TREATMENT", 171, 180], ["lung", "ANATOMY", 141, 145], ["disease", "OBSERVATION", 146, 153]]], ["For instance, in 2012 the novel human coronavirus known as MERS-CoV was first isolated from a patient dying in Saudi Arabia [2, 38].", [["coronavirus", "DISEASE", 38, 49], ["human", "ORGANISM", 32, 37], ["coronavirus", "ORGANISM", 38, 49], ["MERS-CoV", "ORGANISM", 59, 67], ["patient", "ORGANISM", 94, 101], ["human", "SPECIES", 32, 37], ["coronavirus", "SPECIES", 38, 49], ["patient", "SPECIES", 94, 101], ["human coronavirus", "SPECIES", 32, 49], ["MERS-CoV", "SPECIES", 59, 67], ["the novel human coronavirus", "PROBLEM", 22, 49]]], ["In the region of the outbreak, local burial rituals along with the requirement for high biosecurity constrained autopsy studies from being performed until the first report in early 2016 [4].", [["local burial rituals", "TREATMENT", 31, 51], ["autopsy studies", "TEST", 112, 127], ["outbreak", "OBSERVATION_MODIFIER", 21, 29], ["local", "OBSERVATION_MODIFIER", 31, 36], ["burial rituals", "OBSERVATION", 37, 51]]], ["Within a few years of the first reported MERS-CoV case in humans in 2012, several animal models were being studied and these models provided much of the initial critically important lung pathology data [39\u201344].Histopathology ::: IntroductionHistopathologic examination of viral lung infection requires awareness of any anticipated lesions from clinical or published data, as it is available.", [["lung", "ANATOMY", 182, 186], ["lung", "ANATOMY", 278, 282], ["lesions", "ANATOMY", 331, 338], ["viral lung infection", "DISEASE", 272, 292], ["MERS-CoV", "ORGANISM", 41, 49], ["humans", "ORGANISM", 58, 64], ["lung", "ORGAN", 182, 186], ["lung", "ORGAN", 278, 282], ["lesions", "PATHOLOGICAL_FORMATION", 331, 338], ["humans", "SPECIES", 58, 64], ["humans", "SPECIES", 58, 64], ["Histopathologic examination", "TEST", 241, 268], ["viral lung infection", "PROBLEM", 272, 292], ["any anticipated lesions", "PROBLEM", 315, 338], ["lung", "ANATOMY", 182, 186], ["viral", "OBSERVATION_MODIFIER", 272, 277], ["lung", "ANATOMY", 278, 282], ["infection", "OBSERVATION", 283, 292], ["lesions", "OBSERVATION", 331, 338]]], ["Examples of MERS-CoV lesions are listed in Table 1.", [["MERS-CoV lesions", "ANATOMY", 12, 28], ["MERS-CoV lesions", "CANCER", 12, 28], ["MERS-CoV", "SPECIES", 12, 20], ["CoV lesions", "PROBLEM", 17, 28], ["CoV", "OBSERVATION_MODIFIER", 17, 20], ["lesions", "OBSERVATION", 21, 28]]], ["For instance, acute diffuse alveolar damage (DAD) is a common feature of MERS-CoV lung lesions and it is composed of lesions such as edema, inflammation, and alveolar septal injury [4, 48\u201350].", [["alveolar", "ANATOMY", 28, 36], ["MERS-CoV lung lesions", "ANATOMY", 73, 94], ["lesions", "ANATOMY", 117, 124], ["edema", "ANATOMY", 133, 138], ["alveolar septal", "ANATOMY", 158, 173], ["alveolar damage", "DISEASE", 28, 43], ["DAD", "DISEASE", 45, 48], ["MERS-CoV lung lesions", "DISEASE", 73, 94], ["edema", "DISEASE", 133, 138], ["inflammation", "DISEASE", 140, 152], ["alveolar septal injury", "DISEASE", 158, 180], ["alveolar", "TISSUE", 28, 36], ["MERS-CoV lung lesions", "CANCER", 73, 94], ["lesions", "PATHOLOGICAL_FORMATION", 117, 124], ["edema", "PATHOLOGICAL_FORMATION", 133, 138], ["alveolar septal", "MULTI-TISSUE_STRUCTURE", 158, 173], ["MERS-CoV", "SPECIES", 73, 81], ["acute diffuse alveolar damage (DAD", "PROBLEM", 14, 48], ["MERS", "PROBLEM", 73, 77], ["CoV lung lesions", "PROBLEM", 78, 94], ["lesions", "PROBLEM", 117, 124], ["edema", "PROBLEM", 133, 138], ["inflammation", "PROBLEM", 140, 152], ["alveolar septal injury", "PROBLEM", 158, 180], ["acute", "OBSERVATION_MODIFIER", 14, 19], ["diffuse", "OBSERVATION_MODIFIER", 20, 27], ["alveolar", "ANATOMY_MODIFIER", 28, 36], ["damage", "OBSERVATION", 37, 43], ["MERS", "OBSERVATION", 73, 77], ["CoV", "OBSERVATION_MODIFIER", 78, 81], ["lung", "ANATOMY", 82, 86], ["lesions", "OBSERVATION", 87, 94], ["lesions", "OBSERVATION", 117, 124], ["edema", "OBSERVATION", 133, 138], ["inflammation", "OBSERVATION", 140, 152], ["alveolar", "ANATOMY_MODIFIER", 158, 166], ["septal", "ANATOMY_MODIFIER", 167, 173], ["injury", "OBSERVATION", 174, 180]]], ["While awareness of reported lesions can help guide the pathologist in examination, it is also useful to have a consistent method for examination of experimental tissues to avoid unintentional bias that might cause a failure to detection of unexpected lesions[51].", [["lesions", "ANATOMY", 28, 35], ["tissues", "ANATOMY", 161, 168], ["lesions", "ANATOMY", 251, 258], ["lesions", "PATHOLOGICAL_FORMATION", 28, 35], ["tissues", "TISSUE", 161, 168], ["lesions", "PATHOLOGICAL_FORMATION", 251, 258], ["reported lesions", "PROBLEM", 19, 35], ["the pathologist in examination", "TEST", 51, 81], ["examination", "TEST", 133, 144], ["experimental tissues", "PROBLEM", 148, 168], ["unintentional bias", "PROBLEM", 178, 196], ["a failure", "PROBLEM", 214, 223], ["unexpected lesions", "PROBLEM", 240, 258], ["lesions", "OBSERVATION", 28, 35], ["lesions", "OBSERVATION", 251, 258]]], ["Consistent examination of all tissues from control and treatment groups can reduce the chances of mistakenly diagnosing nonspecific model background phenotype as a MERS-CoV-specific lesion [22, 25, 29].", [["tissues", "ANATOMY", 30, 37], ["tissues", "TISSUE", 30, 37], ["Consistent examination", "TEST", 0, 22], ["treatment groups", "TREATMENT", 55, 71], ["nonspecific model background phenotype", "PROBLEM", 120, 158], ["a MERS", "TEST", 162, 168], ["specific lesion", "PROBLEM", 173, 188], ["all tissues", "OBSERVATION_MODIFIER", 26, 37], ["lesion", "OBSERVATION", 182, 188]]], ["For instance, a lesion that is present in the controls and treatment groups can be defined as a background model/technique phenotype and should not be reported as a MERS-CoV specific lesion.", [["lesion", "ANATOMY", 16, 22], ["lesion", "CANCER", 16, 22], ["a lesion", "PROBLEM", 14, 22], ["a background model/technique phenotype", "PROBLEM", 94, 132], ["a MERS-CoV specific lesion", "PROBLEM", 163, 189], ["lesion", "OBSERVATION", 16, 22], ["lesion", "OBSERVATION", 183, 189]]], ["Masking of the pathologist to the group assignments is useful to avoid observer bias and each type of masking method has certain advantages and limitations (Table 2, seeNote 2) [22].", [["masking method", "PROBLEM", 102, 116]]], ["A common approach for histopathologic examination is to start at low magnification to screen for any obvious lesions and assess quality of the tissue section (seeNote 3).", [["lesions", "ANATOMY", 109, 116], ["tissue section", "ANATOMY", 143, 157], ["lesions", "CANCER", 109, 116], ["tissue", "TISSUE", 143, 149], ["histopathologic examination", "TEST", 22, 49], ["any obvious lesions", "PROBLEM", 97, 116], ["the tissue section", "TEST", 139, 157], ["lesions", "OBSERVATION", 109, 116]]], ["This allows examination of microscopic structures such as airways, alveoli, alveolar septa, air spaces, vessels, and pleura.", [["airways", "ANATOMY", 58, 65], ["alveoli", "ANATOMY", 67, 74], ["alveolar septa", "ANATOMY", 76, 90], ["air spaces", "ANATOMY", 92, 102], ["vessels", "ANATOMY", 104, 111], ["pleura", "ANATOMY", 117, 123], ["airways", "MULTI-TISSUE_STRUCTURE", 58, 65], ["alveoli", "MULTI-TISSUE_STRUCTURE", 67, 74], ["alveolar septa", "MULTI-TISSUE_STRUCTURE", 76, 90], ["air spaces", "MULTI-TISSUE_STRUCTURE", 92, 102], ["vessels", "MULTI-TISSUE_STRUCTURE", 104, 111], ["pleura", "ORGAN", 117, 123], ["examination of microscopic structures", "TEST", 12, 49], ["airways, alveoli, alveolar septa, air spaces, vessels, and pleura", "PROBLEM", 58, 123], ["airways", "ANATOMY", 58, 65], ["alveoli", "ANATOMY_MODIFIER", 67, 74], ["alveolar", "ANATOMY_MODIFIER", 76, 84], ["septa", "ANATOMY_MODIFIER", 85, 90], ["air spaces", "OBSERVATION", 92, 102], ["vessels", "ANATOMY", 104, 111], ["pleura", "ANATOMY", 117, 123]]], ["Examination at high magnification allows for screening of cellular and interstitial components of each structure for lesions (e.g., injury, inflammation, necrosis).", [["cellular", "ANATOMY", 58, 66], ["interstitial components", "ANATOMY", 71, 94], ["lesions", "ANATOMY", 117, 124], ["inflammation", "DISEASE", 140, 152], ["necrosis", "DISEASE", 154, 162], ["cellular", "CELL", 58, 66], ["interstitial components", "IMMATERIAL_ANATOMICAL_ENTITY", 71, 94], ["lesions", "PATHOLOGICAL_FORMATION", 117, 124], ["Examination", "TEST", 0, 11], ["screening", "TEST", 45, 54], ["cellular and interstitial components", "PROBLEM", 58, 94], ["lesions", "PROBLEM", 117, 124], ["injury", "PROBLEM", 132, 138], ["inflammation", "PROBLEM", 140, 152], ["necrosis", "PROBLEM", 154, 162], ["interstitial", "ANATOMY_MODIFIER", 71, 83], ["lesions", "OBSERVATION", 117, 124], ["inflammation", "OBSERVATION", 140, 152], ["necrosis", "OBSERVATION", 154, 162]]], ["Most slides will be examined using HE, but additional stains can be used on serial sections to further define any changes.", [["sections", "ANATOMY", 83, 91], ["additional stains", "TEST", 43, 60], ["serial sections", "TEST", 76, 91]]], ["For instance, mucus in goblet cells or secreted into air spaces can be highlighted by special stains like Periodic acid Schiff in glycogen-depleted tissues or Alcian blue [55, 56].Histopathology ::: IntroductionAfter the slides and stains have been examined for all groups, the results will need to be prepared for publication.", [["mucus", "ANATOMY", 14, 19], ["goblet cells", "ANATOMY", 23, 35], ["tissues", "ANATOMY", 148, 155], ["glycogen", "CHEMICAL", 130, 138], ["Alcian blue", "CHEMICAL", 159, 170], ["Periodic acid Schiff", "CHEMICAL", 106, 126], ["Alcian blue", "CHEMICAL", 159, 170], ["mucus", "ORGANISM_SUBSTANCE", 14, 19], ["goblet cells", "CELL", 23, 35], ["Periodic acid Schiff", "SIMPLE_CHEMICAL", 106, 126], ["glycogen", "SIMPLE_CHEMICAL", 130, 138], ["tissues", "TISSUE", 148, 155], ["Alcian blue", "SIMPLE_CHEMICAL", 159, 170], ["goblet cells", "CELL_TYPE", 23, 35], ["mucus in goblet cells", "PROBLEM", 14, 35], ["secreted into air spaces", "PROBLEM", 39, 63], ["special stains", "TEST", 86, 100], ["Periodic acid Schiff", "TEST", 106, 126], ["Alcian blue", "TEST", 159, 170], ["the slides and stains", "TEST", 217, 238], ["mucus", "OBSERVATION", 14, 19], ["goblet cells", "OBSERVATION", 23, 35], ["air spaces", "OBSERVATION", 53, 63], ["acid Schiff", "OBSERVATION", 115, 126], ["depleted tissues", "OBSERVATION", 139, 155]]], ["Qualitative characterization of the findings is very important to understand features of the disease including cellular tropism, anatomic predisposition, and nature of lesions leading to clinical signs (seeNote 4) [10, 21].", [["cellular", "ANATOMY", 111, 119], ["lesions", "ANATOMY", 168, 175], ["cellular", "CELL", 111, 119], ["lesions", "PATHOLOGICAL_FORMATION", 168, 175], ["the disease", "PROBLEM", 89, 100], ["cellular tropism", "PROBLEM", 111, 127], ["anatomic predisposition", "PROBLEM", 129, 152], ["lesions", "PROBLEM", 168, 175], ["clinical signs", "TEST", 187, 201], ["disease", "OBSERVATION", 93, 100], ["cellular tropism", "OBSERVATION", 111, 127], ["lesions", "OBSERVATION", 168, 175]]], ["Qualitative descriptions of lesions include type (e.g., epithelial sloughing/ necrosis), location (e.g., alveoli), distribution (e.g., locally extensive), inflammation (e.g., neutrophilic), and cell types involved (e.g., type I pneumocytes).", [["lesions", "ANATOMY", 28, 35], ["epithelial", "ANATOMY", 56, 66], ["alveoli", "ANATOMY", 105, 112], ["neutrophilic", "ANATOMY", 175, 187], ["cell", "ANATOMY", 194, 198], ["type I pneumocytes", "ANATOMY", 221, 239], ["necrosis", "DISEASE", 78, 86], ["inflammation", "DISEASE", 155, 167], ["lesions", "PATHOLOGICAL_FORMATION", 28, 35], ["epithelial", "TISSUE", 56, 66], ["alveoli", "MULTI-TISSUE_STRUCTURE", 105, 112], ["cell", "CELL", 194, 198], ["type I pneumocytes", "GENE_OR_GENE_PRODUCT", 221, 239], ["type I pneumocytes", "CELL_TYPE", 221, 239], ["lesions", "PROBLEM", 28, 35], ["type (e.g.", "PROBLEM", 44, 54], ["epithelial sloughing/ necrosis", "PROBLEM", 56, 86], ["location (e.g., alveoli), distribution (e.g., locally extensive)", "PROBLEM", 89, 153], ["inflammation (e.g., neutrophilic)", "PROBLEM", 155, 188], ["cell types", "PROBLEM", 194, 204], ["type I pneumocytes)", "PROBLEM", 221, 240], ["lesions", "OBSERVATION", 28, 35], ["epithelial", "ANATOMY", 56, 66], ["sloughing", "OBSERVATION", 67, 76], ["necrosis", "OBSERVATION", 78, 86], ["alveoli", "ANATOMY", 105, 112], ["inflammation", "OBSERVATION", 155, 167], ["neutrophilic", "OBSERVATION_MODIFIER", 175, 187], ["cell types", "OBSERVATION", 194, 204]]], ["Use of arrows and other forms of annotation are valuable in figures to clarify and guide readers through the images.", [["the images", "TEST", 105, 115]]], ["High-quality descriptions will help the reader (including reviewers) better understand what was seen and allow for others to reproduce the study.Immunostaining ::: IntroductionImmunostaining ( immunohistochemistry) is a valuable tool in viral lung disease investigations as it can be used to study cellular localization of receptors and viral targets.", [["lung", "ANATOMY", 243, 247], ["cellular", "ANATOMY", 298, 306], ["viral lung disease", "DISEASE", 237, 255], ["lung", "ORGAN", 243, 247], ["cellular", "CELL", 298, 306], ["the study", "TEST", 135, 144], ["viral lung disease investigations", "PROBLEM", 237, 270], ["viral", "OBSERVATION_MODIFIER", 237, 242], ["lung", "ANATOMY", 243, 247], ["disease", "OBSERVATION", 248, 255], ["viral targets", "OBSERVATION", 337, 350]]], ["For instance, detection of the MERS-CoV receptor dipeptidyl peptidase 4 (DPP4) virus receptor can give insights to cell tropism to help explain disease pathogenesis [4, 6, 21, 42, 57\u201359].Immunostaining ::: IntroductionThere are several tissue handling (preanalytical) factors that can significantly affect the quality and specificity of immunostaining and its analysis.", [["cell", "ANATOMY", 115, 119], ["tissue", "ANATOMY", 236, 242], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 31, 39], ["dipeptidyl peptidase 4", "GENE_OR_GENE_PRODUCT", 49, 71], ["DPP4", "GENE_OR_GENE_PRODUCT", 73, 77], ["cell", "CELL", 115, 119], ["tissue", "TISSUE", 236, 242], ["MERS-CoV receptor dipeptidyl peptidase 4 (DPP4) virus receptor", "PROTEIN", 31, 93], ["MERS-CoV", "SPECIES", 31, 39], ["the MERS", "PROBLEM", 27, 35], ["CoV receptor dipeptidyl peptidase 4 (DPP4) virus receptor", "TREATMENT", 36, 93], ["cell tropism", "PROBLEM", 115, 127], ["disease pathogenesis", "PROBLEM", 144, 164], ["several tissue handling (preanalytical) factors", "PROBLEM", 228, 275], ["immunostaining", "TEST", 337, 351], ["its analysis", "TEST", 356, 368], ["several tissue", "OBSERVATION_MODIFIER", 228, 242]]], ["Similarly, there are many factors during the staining procedure that itself can also influence the results.", [["the staining procedure", "TREATMENT", 41, 63], ["many", "OBSERVATION_MODIFIER", 21, 25]]], ["Deparaffinization, lack of control tissues, optimization/validation techniques, species, batch effects, and chromogens can all influence the final quality and assessment of immunostaining methods.", [["tissues", "ANATOMY", 35, 42], ["tissues", "TISSUE", 35, 42], ["chromogens", "SIMPLE_CHEMICAL", 108, 118], ["Deparaffinization", "TREATMENT", 0, 17], ["lack of control tissues", "PROBLEM", 19, 42], ["optimization/validation techniques", "TEST", 44, 78], ["chromogens", "TREATMENT", 108, 118], ["immunostaining methods", "TEST", 173, 195]]], ["Standard operating procedures for each of the technical steps, if used by all biomedical staff, can significantly mitigate many of these issues.", [["Standard operating procedures", "TREATMENT", 0, 29]]], ["Use of positive and negative control tissues for each batch of immunostained tissues can help in validating appropriate staining and also making clear any potential nonspecific immunostaining.", [["tissues", "ANATOMY", 37, 44], ["tissues", "ANATOMY", 77, 84], ["tissues", "TISSUE", 37, 44], ["tissues", "TISSUE", 77, 84], ["immunostained tissues", "PROBLEM", 63, 84], ["positive", "OBSERVATION", 7, 15], ["nonspecific", "OBSERVATION_MODIFIER", 165, 176], ["immunostaining", "OBSERVATION", 177, 191]]], ["After the stained slides have been examined for all groups, qualitative statements about the immunostaining can be made and prepared for publication text and images.", [["the stained slides", "TEST", 6, 24], ["the immunostaining", "TEST", 89, 107], ["images", "TEST", 158, 164]]], ["Descriptive text of immunostaining (receptor or virus) could include cell types (e.g., type I pneumocytes), cell integrity (necrotic vs. intact cells), and subcellular location (e.g., diffuse cytoplasmic).", [["cell", "ANATOMY", 69, 73], ["type I pneumocytes", "ANATOMY", 87, 105], ["cell", "ANATOMY", 108, 112], ["cells", "ANATOMY", 144, 149], ["subcellular", "ANATOMY", 156, 167], ["cytoplasmic", "ANATOMY", 192, 203], ["necrotic", "DISEASE", 124, 132], ["cell", "CELL", 69, 73], ["type I pneumocytes", "GENE_OR_GENE_PRODUCT", 87, 105], ["cell", "CELL", 108, 112], ["cells", "CELL", 144, 149], ["cytoplasmic", "ORGANISM_SUBSTANCE", 192, 203], ["type I pneumocytes", "CELL_TYPE", 87, 105], ["necrotic vs. intact cells", "CELL_TYPE", 124, 149], ["immunostaining (receptor or virus", "PROBLEM", 20, 53], ["cell types", "PROBLEM", 69, 79], ["type I pneumocytes)", "PROBLEM", 87, 106], ["cell integrity (necrotic vs. intact cells", "PROBLEM", 108, 149], ["diffuse cytoplasmic)", "PROBLEM", 184, 204], ["cell types", "OBSERVATION", 69, 79], ["cell integrity", "OBSERVATION", 108, 122], ["necrotic", "OBSERVATION_MODIFIER", 124, 132], ["intact cells", "OBSERVATION", 137, 149], ["subcellular location", "OBSERVATION", 156, 176], ["diffuse", "OBSERVATION_MODIFIER", 184, 191], ["cytoplasmic", "OBSERVATION_MODIFIER", 192, 203]]], ["Demonstration of immunostaining using annotated images can strengthen the qualitative data.Nominal Approaches ::: Scoring ::: IntroductionNominal approaches do not score or make quantitative measurements on tissue samples, but rather each sample is assigned to well-defined categories [52, 54].", [["tissue samples", "ANATOMY", 207, 221], ["tissue samples", "TISSUE", 207, 221], ["immunostaining", "TEST", 17, 31], ["annotated images", "TEST", 38, 54], ["IntroductionNominal approaches", "TREATMENT", 126, 156], ["tissue samples", "TEST", 207, 221]]], ["The numbers of samples assigned to each category are recorded and evaluated with appropriate statistical tests.", [["samples", "ANATOMY", 15, 22], ["appropriate statistical tests", "TEST", 81, 110]]], ["As a simple mock example, consider examining the lungs of wild-type (WT) or mutated mice for the presence or absence of edema, a common feature of DAD.", [["lungs", "ANATOMY", 49, 54], ["edema", "ANATOMY", 120, 125], ["edema", "DISEASE", 120, 125], ["DAD", "DISEASE", 147, 150], ["lungs", "ORGAN", 49, 54], ["wild-type (WT)", "ORGANISM", 58, 72], ["mice", "ORGANISM", 84, 88], ["edema", "PATHOLOGICAL_FORMATION", 120, 125], ["mice", "SPECIES", 84, 88], ["mice", "SPECIES", 84, 88], ["edema", "PROBLEM", 120, 125], ["lungs", "ANATOMY", 49, 54], ["edema", "OBSERVATION", 120, 125]]], ["Each mouse would be assigned to either \u201cno edema\u201d (Fig. 1a) or \u201cedema\u201d (Fig. 1b, c) categories.", [["edema", "ANATOMY", 43, 48], ["edema", "ANATOMY", 64, 69], ["edema", "DISEASE", 43, 48], ["edema", "DISEASE", 64, 69], ["mouse", "ORGANISM", 5, 10], ["edema", "PATHOLOGICAL_FORMATION", 43, 48], ["edema", "PATHOLOGICAL_FORMATION", 64, 69], ["mouse", "SPECIES", 5, 10], ["mouse", "SPECIES", 5, 10], ["edema", "PROBLEM", 43, 48], ["\u201cedema", "PROBLEM", 63, 69], ["edema", "OBSERVATION", 43, 48], ["edema", "OBSERVATION", 64, 69]]], ["If 10 mice per group were evaluated, the WT group might have nine with edema and one without, while the mutated group has three with edema and seven without.", [["edema", "ANATOMY", 71, 76], ["edema", "DISEASE", 71, 76], ["edema", "DISEASE", 133, 138], ["mice", "ORGANISM", 6, 10], ["edema", "PATHOLOGICAL_FORMATION", 71, 76], ["edema", "PATHOLOGICAL_FORMATION", 133, 138], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 6, 10], ["edema", "PROBLEM", 71, 76], ["edema", "PROBLEM", 133, 138], ["edema", "OBSERVATION", 71, 76], ["edema", "OBSERVATION", 133, 138]]], ["Evaluating these data using a Fisher exact test results in a significant difference (P = 0.02) between WT and mutated mice.", [["mice", "ORGANISM", 118, 122], ["mice", "SPECIES", 118, 122], ["mice", "SPECIES", 118, 122], ["a Fisher exact test", "TEST", 28, 47]]], ["The presence of any lesion or immunostaining can be similarly assessed in this manner, but it is important to have clear guidelines or thresholds to distinguish the categories.Semiquantitative Approaches ::: Scoring ::: IntroductionSemiquantitative approaches are used to transform qualitative tissue changes into numerical scores using specific morphologic criteria [52, 53].", [["lesion", "ANATOMY", 20, 26], ["tissue", "ANATOMY", 294, 300], ["tissue", "TISSUE", 294, 300], ["any lesion", "PROBLEM", 16, 26], ["immunostaining", "PROBLEM", 30, 44], ["IntroductionSemiquantitative approaches", "TREATMENT", 220, 259], ["lesion", "OBSERVATION", 20, 26], ["immunostaining", "OBSERVATION", 30, 44]]], ["Semiquantitative methods have several advantages in that they can be done with minimal technical resources, quickly at the microscope for small to medium studies, provide guidance for future quantitative studies, and provide complementary data for publication [52\u201354].", [["Semiquantitative methods", "TREATMENT", 0, 24], ["medium studies", "TEST", 147, 161], ["future quantitative studies", "TEST", 184, 211]]], ["Ordinal implies there is an order or progression of severity in the assigned grades that define each score, with typically four to five grades being optimal (e.g., 0, 1, 2, 3, 4).", [["severity", "PROBLEM", 52, 60]]], ["Each grade should be well defined so there is minimal ambiguity in assigning samples.", [["samples", "ANATOMY", 77, 84], ["samples", "CANCER", 77, 84], ["minimal ambiguity", "PROBLEM", 46, 63], ["should be", "UNCERTAINTY", 11, 20], ["well defined", "OBSERVATION_MODIFIER", 21, 33], ["minimal", "OBSERVATION_MODIFIER", 46, 53], ["ambiguity", "OBSERVATION", 54, 63]]], ["Use of simple descriptive modifiers such as normal, rare, mild, moderate, and severe is discouraged as these have different meanings for each observer and thus limit reproducibility of the scoring.", [["simple descriptive modifiers", "TREATMENT", 7, 35], ["mild, moderate, and severe is discouraged", "PROBLEM", 58, 99], ["normal", "OBSERVATION", 44, 50], ["mild", "OBSERVATION_MODIFIER", 58, 62], ["moderate", "OBSERVATION_MODIFIER", 64, 72], ["severe", "OBSERVATION_MODIFIER", 78, 84]]], ["As a mock example of ordinal scoring, WT and mutated mice might be evaluated for the extent of hyaline membranes lining alveolar walls.", [["hyaline membranes", "ANATOMY", 95, 112], ["alveolar walls", "ANATOMY", 120, 134], ["mice", "ORGANISM", 53, 57], ["hyaline membranes", "CELLULAR_COMPONENT", 95, 112], ["alveolar walls", "MULTI-TISSUE_STRUCTURE", 120, 134], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 53, 57], ["ordinal scoring", "TEST", 21, 36], ["hyaline membranes lining alveolar walls", "PROBLEM", 95, 134], ["hyaline", "OBSERVATION", 95, 102], ["membranes", "ANATOMY_MODIFIER", 103, 112], ["lining", "ANATOMY_MODIFIER", 113, 119], ["alveolar", "ANATOMY_MODIFIER", 120, 128], ["walls", "ANATOMY_MODIFIER", 129, 134]]], ["The scoring grades might look like: \u201c0\u201d\u2014none, \u201c1\u201d\u2014 <25% (see Fig. 1d), \u201c2\u201d\u201426\u201350% (see Fig. 1e), \u201c3\u201d\u201451\u201375%, and \u201c4\u201d >75% of alveolar walls in the lung section.", [["alveolar walls", "ANATOMY", 125, 139], ["lung section", "ANATOMY", 147, 159], ["alveolar walls", "MULTI-TISSUE_STRUCTURE", 125, 139], ["lung", "ORGAN", 147, 151], ["\u201c", "TEST", 71, 72], ["\u201d\u2014", "TEST", 73, 75], ["\u201c", "TEST", 97, 98], ["\u201d\u2014", "TEST", 99, 101], ["\u2013", "TEST", 103, 104], ["%", "TEST", 106, 107], ["\u201c", "TEST", 113, 114], ["\u201d", "TEST", 115, 116], ["alveolar walls in the lung section", "PROBLEM", 125, 159], ["alveolar", "ANATOMY_MODIFIER", 125, 133], ["walls", "ANATOMY_MODIFIER", 134, 139], ["lung", "ANATOMY", 147, 151]]], ["If the ordinal scoring for seven mice per group produced the following results for WT (3, 3, 2, 3, 4, 3, 4) and mutated mice (1, 2, 1, 1, 1, 1, 2), then the data can be statistically analyzed.", [["mice", "ORGANISM", 33, 37], ["mice", "ORGANISM", 120, 124], ["mice", "SPECIES", 33, 37], ["mice", "SPECIES", 120, 124], ["mice", "SPECIES", 33, 37], ["mice", "SPECIES", 120, 124], ["the ordinal scoring", "TEST", 3, 22], ["WT", "TEST", 83, 85]]], ["Importantly, ordinal scores do not meet the assumptions required for parametric tests; thus nonparametric tests should be used [33].", [["parametric tests", "TEST", 69, 85], ["nonparametric tests", "TEST", 92, 111]]], ["For the mock example, the difference between groups using a Mann-Whitney U-test was significant (P = 0.002).Quantitative Approaches ::: Scoring ::: IntroductionQuantitative methods are tissue techniques that measure specific tissue components (length, area, volume, number, percentage, etc.) [52].", [["tissue", "ANATOMY", 185, 191], ["tissue", "ANATOMY", 225, 231], ["tissue", "TISSUE", 185, 191], ["tissue", "TISSUE", 225, 231], ["a Mann-Whitney U-test", "TEST", 58, 79], ["IntroductionQuantitative methods", "TREATMENT", 148, 180], ["tissue techniques", "TREATMENT", 185, 202], ["volume", "TEST", 258, 264], ["specific tissue", "OBSERVATION_MODIFIER", 216, 231], ["components", "OBSERVATION_MODIFIER", 232, 242], ["length", "OBSERVATION_MODIFIER", 244, 250], ["volume", "OBSERVATION_MODIFIER", 258, 264]]], ["Quantitative methods tend to have greater precision and sensitivity than semiquantitative methods.", [["Quantitative methods", "PROBLEM", 0, 20], ["semiquantitative methods", "TEST", 73, 97]]], ["These methods often require high-quality images and specialized software to properly analyze the tissues, which can make the methods costlier for some labs than semiquantitative techniques.", [["tissues", "ANATOMY", 97, 104], ["tissues", "TISSUE", 97, 104], ["some labs", "TEST", 146, 155], ["semiquantitative techniques", "TEST", 161, 188], ["tissues", "ANATOMY", 97, 104]]], ["The growing interest in automation and artificial intelligence may increase future efficiency and cost-effectiveness of quantification of tissue parameters, especially for large projects [64\u201367].Quantitative Approaches ::: Scoring ::: IntroductionQuantification of viral lesions and immunostaining in tissues is an option; however, quantification is not commonly performed in tissue sections due to potential confounding factors such as random distribution of viral inoculum and difficulty in objectively quantifying lesions.", [["tissue", "ANATOMY", 138, 144], ["lesions", "ANATOMY", 271, 278], ["tissues", "ANATOMY", 301, 308], ["tissue sections", "ANATOMY", 376, 391], ["lesions", "ANATOMY", 517, 524], ["tissue", "TISSUE", 138, 144], ["viral lesions", "PATHOLOGICAL_FORMATION", 265, 278], ["tissues", "TISSUE", 301, 308], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 376, 391], ["lesions", "PATHOLOGICAL_FORMATION", 517, 524], ["artificial intelligence", "PROBLEM", 39, 62], ["tissue parameters", "TEST", 138, 155], ["viral lesions", "PROBLEM", 265, 278], ["immunostaining in tissues", "PROBLEM", 283, 308], ["potential confounding factors", "PROBLEM", 399, 428], ["viral inoculum", "PROBLEM", 460, 474], ["difficulty in objectively quantifying lesions", "PROBLEM", 479, 524], ["growing", "OBSERVATION_MODIFIER", 4, 11], ["interest", "OBSERVATION_MODIFIER", 12, 20], ["viral", "OBSERVATION_MODIFIER", 265, 270], ["lesions", "OBSERVATION", 271, 278], ["viral inoculum", "OBSERVATION", 460, 474], ["lesions", "OBSERVATION", 517, 524]]], ["If choosing to perform quantitative scoring, evaluation of clinically relevant anatomic compartments (airways or alveoli) can help standardize the assessment.", [["anatomic compartments", "ANATOMY", 79, 100], ["airways", "ANATOMY", 102, 109], ["alveoli", "ANATOMY", 113, 120], ["airways", "MULTI-TISSUE_STRUCTURE", 102, 109], ["alveoli", "MULTI-TISSUE_STRUCTURE", 113, 120], ["quantitative scoring", "TEST", 23, 43], ["evaluation", "TEST", 45, 55], ["the assessment", "TEST", 143, 157], ["airways", "ANATOMY", 102, 109], ["alveoli", "ANATOMY", 113, 120]]], ["As a mock example, viral immunostaining could be evaluated as a percent of cell number in mouse bronchioles (Fig. 2a\u2013c; 0%, 12.5%, and 43.8%, respectively) or as an alternative one could also assess the area of immunostaining as a percent of the bronchiolar epithelium area.", [["cell", "ANATOMY", 75, 79], ["bronchioles", "ANATOMY", 96, 107], ["bronchiolar epithelium area", "ANATOMY", 246, 273], ["cell", "CELL", 75, 79], ["mouse", "ORGANISM", 90, 95], ["bronchioles", "MULTI-TISSUE_STRUCTURE", 96, 107], ["bronchiolar epithelium area", "TISSUE", 246, 273], ["mouse", "SPECIES", 90, 95], ["mouse", "SPECIES", 90, 95], ["a mock example", "TEST", 3, 17], ["viral immunostaining", "TEST", 19, 39], ["immunostaining", "PROBLEM", 211, 225], ["bronchioles", "ANATOMY", 96, 107], ["immunostaining", "OBSERVATION", 211, 225], ["percent", "OBSERVATION_MODIFIER", 231, 238], ["bronchiolar", "ANATOMY", 246, 257], ["epithelium", "ANATOMY_MODIFIER", 258, 268]]], ["In contrast, the alveolar compartment can be more difficult to assess than airways because of their thin walls, which makes evidence of necrosis/sloughing or immunostaining a challenge.", [["alveolar compartment", "ANATOMY", 17, 37], ["airways", "ANATOMY", 75, 82], ["necrosis", "DISEASE", 136, 144], ["alveolar compartment", "MULTI-TISSUE_STRUCTURE", 17, 37], ["airways", "MULTI-TISSUE_STRUCTURE", 75, 82], ["necrosis", "PROBLEM", 136, 144], ["sloughing", "PROBLEM", 145, 154], ["immunostaining a challenge", "TREATMENT", 158, 184], ["alveolar", "ANATOMY_MODIFIER", 17, 25], ["thin", "OBSERVATION_MODIFIER", 100, 104], ["walls", "OBSERVATION_MODIFIER", 105, 110], ["makes evidence of", "UNCERTAINTY", 118, 135], ["necrosis", "OBSERVATION", 136, 144], ["sloughing", "OBSERVATION", 145, 154]]], ["To normalize analysis, one could assess the percent of alveoli with immunostaining (Fig. 2d\u2013e).", [["alveoli", "ANATOMY", 55, 62], ["alveoli", "MULTI-TISSUE_STRUCTURE", 55, 62], ["analysis", "TEST", 13, 21], ["alveoli", "ANATOMY", 55, 62]]], ["If quantitation is not feasible but is an important variable, one could revert to semiquantitative scoring to assess immunostaining as a percentage of affected alveolar walls.", [["alveolar walls", "ANATOMY", 160, 174], ["alveolar walls", "MULTI-TISSUE_STRUCTURE", 160, 174], ["semiquantitative scoring", "TEST", 82, 106], ["immunostaining", "TEST", 117, 131], ["affected alveolar walls", "PROBLEM", 151, 174], ["alveolar", "ANATOMY_MODIFIER", 160, 168], ["walls", "ANATOMY_MODIFIER", 169, 174]]], ["Using the distribution scoring system defined for Fig. 1, one could score the samples in Fig. 2d\u2013e, as ordinal scores of 1 and 4, respectively.", [["samples", "ANATOMY", 78, 85], ["ordinal scores", "TEST", 103, 117]]], ["While the mock example is simple, reality often paints a more complex portrait of lesion or immunostaining distribution (Fig. 2f).Quantitative Approaches ::: Scoring ::: IntroductionWhen it comes to tissue scoring, each project is unique.", [["lesion", "ANATOMY", 82, 88], ["tissue", "ANATOMY", 199, 205], ["lesion", "CANCER", 82, 88], ["tissue", "TISSUE", 199, 205], ["lesion", "PROBLEM", 82, 88], ["lesion", "OBSERVATION", 82, 88]]], ["Investigators will have to evaluate the lung samples to determine the best scoring approaches in relation to the breadth of lesions and goals of the project.", [["lung samples", "ANATOMY", 40, 52], ["lesions", "ANATOMY", 124, 131], ["lung samples", "CANCER", 40, 52], ["lesions", "PATHOLOGICAL_FORMATION", 124, 131], ["the lung samples", "TEST", 36, 52], ["lesions", "PROBLEM", 124, 131], ["lung", "ANATOMY", 40, 44], ["lesions", "OBSERVATION", 124, 131]]], ["For instance, if group A has more immunostaining than group B, this could be validated by ELISA or Western blots of whole lung homogenates.", [["lung homogenates", "ANATOMY", 122, 138], ["lung homogenates", "TISSUE", 122, 138], ["whole lung homogenates", "PROBLEM", 116, 138], ["lung", "ANATOMY", 122, 126]]], ["Alternatively, lesion severity could be corroborated to measurements of clinical data (seeNote 6).", [["lesion", "ANATOMY", 15, 21], ["lesion severity", "PROBLEM", 15, 30], ["clinical data", "TEST", 72, 85], ["lesion", "OBSERVATION", 15, 21]]], ["Validation can help give more confidence in the data rigor and reproducibility.Statistical Analyses ::: Scoring ::: IntroductionInappropriate use of paired t-tests and shopping for significance are two issues that have slipped into the published literature and potentially compromise the interpretation and reproducibility of studies [33].", [["studies", "TEST", 326, 333]]], ["For the various scoring methods, statistical analyses of the data should involve the collaborative expertise of a statistician to be able to identify the most relevant tests to confidently evaluate for group differences [22, 33, 52, 53].SummaryExamination of infected lung tissues for histopathology and immunostaining are common and needed approaches to study viral lung infection, especially in emergent coronaviruses like MERS-CoV.", [["lung tissues", "ANATOMY", 268, 280], ["lung", "ANATOMY", 367, 371], ["viral lung infection", "DISEASE", 361, 381], ["lung tissues", "TISSUE", 268, 280], ["lung", "ORGAN", 367, 371], ["coronaviruses", "ORGANISM", 406, 419], ["MERS-CoV", "ORGANISM", 425, 433], ["MERS-CoV", "SPECIES", 425, 433], ["infected lung tissues", "PROBLEM", 259, 280], ["histopathology", "TEST", 285, 299], ["immunostaining", "TEST", 304, 318], ["viral lung infection", "PROBLEM", 361, 381], ["infected", "OBSERVATION", 259, 267], ["lung", "ANATOMY", 268, 272], ["lung", "ANATOMY", 367, 371], ["infection", "OBSERVATION", 372, 381]]], ["Following the principles and concepts above will help guide and lead studies to more valid and reproducible data.Notes", [["lead studies", "TEST", 64, 76]]]]}